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ABSTRACT 
Siying Li: Methods in Randomization Based ANCOVA for Novel Crossover Designs and 
Sensitivity Analysis for Missing Data 
(Under the direction of Gary G. Koch) 
 In clinical trials, statistical inference is preferably conducted with less stringent 
assumptions. This dissertation proposes a non-parametric method for dichotomous and ordinal 
missing data, and it proposes a structure for the hypothesis testing and estimation for innovative 
crossover designs.  
            When data missing not at random (MNAR) arise from randomized multi-visit, multi-
center clinical trials, sensitivity analyses to address possibly informative missing are needed. We 
propose a closed form point and variance matrix estimation for dichotomized missing data by 
probabilistically redistributing missing counts, adjusting for a stratification factor and/or baseline 
covariables. The parameter estimates are computed via weighted least squares asymptotic 
regression through randomization based methods. We further extend the methods to sensitivity 
analyses for ordinal endpoints.  
A novel crossover design, the sequential parallel comparison design (SPCD), where 
information from placebo responders in the second period are excluded, serves as a design for 
studies with high placebo response. Estimators for sources of comparison in the traditional SPCD 
design, as well as other sources of information that are available, are constructed with methods 
based on the randomization distribution of the observed population using the nonparametric 
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mean and variance estimates under the null hypothesis, which control Type I error well in 
hypothesis testing. Baseline imbalance is adjusted by randomization-based ANCOVA. 
Simulations are performed to study the statistical properties of the proposed methods, which are 
compared to those of a repeated measures model proposed by Doros et al. (2013).  
Point and confidence interval estimation is also addressed by assuming the study 
population comes from a simple random sample of an almost infinite population. A consistent 
covariance matrix estimator is constructed and properties of the proposed estimators are studied 
with simulations, particularly for coverage of confidence intervals. The nominal coverage level is 
achieved with a t distribution for the approximation to the asymptotic distribution when the 
sample size is not sufficiently large.  
The methodologies are extended to the two-way enrichment design (TED) introduced by 
Ivanova and Tamura (2011), and to a related bilateral design that applies the four sequence group 
design to two sides of the same subject instead of two periods.
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 CHAPTER 1 INTRODUCTION 
 In clinical trials, statistical inference is preferably conducted with less model 
assumptions. This dissertation proposes a nonparametric method to handle dichotomous and 
ordinal missing data, and proposes a structure for hypothesis testing and estimation in innovative 
crossover designs.  
 Handling Random Imbalance of Baseline Covariables 
In the statistical analysis plan of a clinical trial, the statistical methods to determine if there 
is a significant treatment effect need to be stated in an a priori way before the clinical trials are 
actually carried out. Oftentimes, assumptions have to be made for certain statistical models to be 
valid, and they are difficult to test before data analysis. Therefore, methods requiring fewer 
assumptions are more desirable than those complicated ones, especially in the regulatory setting. 
This consideration led to the development of nonparametric randomization based analysis 
of covariance (ANCOVA). In randomized clinical trials, the covariable imbalances (if any) 
between treatment and control groups are due to random chance, since the treatment assignment 
is random. 
The details about nonparametric randomization based ANCOVA for analyzing 
randomized clinical trials can be found in (Koch et al., 1998b; LaVange, Durham and Koch, 
2005). Briefly, differences between treatment groups with respect to outcome variables and 
covariables are analyzed simultaneously using weighted least squares (WLS), restricting the 
covariables differences to be zero. As mentioned before, in a randomized clinical trial, the 
expected value of such differences for covariables would in fact be equal to zero. 
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Let 𝑦𝑔𝑖 be the outcome of subject 𝑖 in group 𝑔, and let 𝒙𝑔𝑖 = (𝑥𝑔𝑖1, … , 𝑥𝑔𝑖𝑚)
′
 be the pre-
specified vector of m covariables, and let 𝒇𝑔𝑖 be the response-covariable (m+1) dimensional 
vector (𝑦𝑔𝑖, 𝒙𝑔𝑖
′ )′. Then the sample mean of the outcome and covariables of treatment 𝑔 is ?̅?𝑔 =
1
𝑛𝑔
∑ 𝑦𝑔𝑖
𝑛𝑔
𝑖=1  and  ?̅?𝑔 =
1
𝑛𝑔
∑ 𝒙𝑔𝑖
𝑛𝑔
𝑖=1 . And ?̅?𝑔 =
1
𝑛𝑔
∑ 𝒇𝑔𝑖 = (?̅?𝑔,
𝑛𝑔
𝑖=1 ?̅?𝑔
′ )′  is the sample mean of the 
response-covariables of subjects in group 𝑔 and ?̅? =
1
𝑛
∑ ∑ 𝒇𝑔𝑖
𝑛𝑔
𝑖=1
2
𝑔=1  is the sample mean of all 
subjects in the trial. Let 𝒅 = (𝑑𝑦, 𝒅𝒙
′ )′ be the vector of differences in means, where 𝑑𝑦 = (?̅?1 −
?̅?2) and 𝑑𝑥 = (?̅?1 − ?̅?2). 
There are two ways to estimate the variance of the difference 𝒅. One is through the 
randomization distribution of 𝒅 for the finite population selected for the clinical trial assuming 
the strong null hypothesis 𝐻0: 𝑦1𝑖 = 𝑦2𝑖 = 𝑦∗𝑖 that each patient would have the same outcome 
regardless of the assigned treatment. Under this null hypothesis, the covariance matrix for the 
difference  𝒅 is expressed as 
𝑽𝟎 =
𝑛
𝑛1𝑛2(𝑛 − 1)
∑ ∑[𝒇𝑔𝑖 − ?̅?][𝒇𝑔𝑖 − ?̅?]
′
𝑛𝑔
𝑖=1
2
𝑔=1
                 (1.1). 
Since 𝑽𝟎  is the covariance matrix for  the randomization distribution of 𝒅, permuting all 
possible randomized assignments to the two treatments for the patients in the clinical trial, it is a 
matrix of known constant values (rather than random variables), with a conditional nature that 
the response of this finite population is known.  
Alternatively, under the assumption that the patients in the clinical trial are a simple 
random sample of a very large population, and thus are representative of this large population, an 
unbiased estimator for the unconditional covariance matrix of the difference 𝒅 as  shown in (1.2). 
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𝑽𝑺 = ∑
1
𝑛𝑖(𝑛𝑖 − 1)
∑[𝒇𝑔𝑖 − ?̅?𝑔][𝒇𝑔𝑖 − ?̅?𝑔]
′
𝑛𝑔
𝑖=1
                  (1.2).
2
𝑔=1
 
In this case, the covariance matrix 𝑽𝑺 is a random matrix instead of a constant matrix, in 
a sense that the randomness comes from the variability of the simple random sample of patients 
and the random assignment of treatment groups, regardless of 𝐻0.  
Applying the non-parametric analysis of covariance to 𝒅, it has the form of a linear 
regression as below, 
𝒅 = [
𝑑𝑦
𝒅𝒙
] ≜ 𝒁𝑏 = [
1 
 𝟎𝑝
] 𝑏                                             (1.3) 
where ≜ denotes “is estimated by”, 𝟎𝑝 denotes a 𝑝 dimensional vector, 𝒁 = [1 𝟎𝑝
′ ]′, and 𝑏 is the 
adjusted mean difference for the response, i.e., the adjusted version of 𝑑𝑦. 
Applying WLS, determination of 𝑏 can be obtained by, 
𝑏 = (𝒁′𝑽−𝟏𝒁)−𝟏𝒁′𝑽−𝟏𝒇 = 𝑑𝑦 − 𝑽𝒚𝒙
′ 𝑽𝒙𝒙
−𝟏𝒅𝒙           (1.4) 
where 𝑽 = [
𝑽𝒚𝒚 𝑽𝒚𝒙
′  
𝑽𝒚𝒙 𝑽𝒙𝒙
]   and V can be either  𝑽0 or 𝑽𝑆 defined above. 
An estimator for the covariance of 𝑏 is expressed as, 
𝑉𝑏 = (𝒁
′𝑽−1𝒁)−1 = 𝑉𝑦𝑦 − 𝑽𝒚𝒙
′ 𝑽𝒙𝒙
−1𝑽𝒚𝒙       (1.5) 
When 𝑽𝟎 is used in place of 𝑽, 𝑽𝒃 is an exact variance of the randomization distribution 
of the adjusted treatment difference b; and when 𝑽𝑆 is used, 𝑉𝑏 is a random matrix and a 
consistent estimator of the covariance matrix of b. 
Since the variance 𝑉𝑏 of the adjusted mean difference 𝑏 is smaller than its counterpart 𝑉𝑦𝑦 
of the variance of the unadjusted mean difference 𝑑𝑦, the test based on the adjusted difference 𝑏 
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is more powerful than that based on 𝑑𝑦, and the confidence interval of 𝑏 is narrower than that of 
𝑑𝑦. The variance reduction of 𝑏 relative to 𝑑𝑦 is based on the correlation between the response 
and the covariable, and the stronger this correlation, the more variance reduction produced (Koch 
et al., 1998). 
The nonparametric ANCOVA can be extended to multivariate response variables, and 
other types of data including dichotomized, ordinal, and time to event data (Tangen and Koch, 
1999). 
 Handling Missing Data 
In public health studies, repeated measurements of the same subject over time are useful in 
a number of different contexts, including, but not limited to, reliable estimation by several 
measurements close in time, testing for a change over time in an experimental study, or 
comparisons for a difference between treatment groups over time.  
In a clinical trial, missing data were planned to be collected but are not present in the 
database. No matter how well designed and conducted a trial is, some missing data is almost 
always unavoidable. The consequences of missing data can be wide-ranging in that they might 
lead to a perceived or real reduction in trial quality and validity, and a reduction in the statistical 
power of the study.  
When missing data are unavoidable and exist in the collected data, assumptions about the 
missing data can be made. Often, dropout is due to some specific reasons, related (i.e. adverse 
events, or lack of efficacy) or unrelated (i.e., move out of the neighborhood) to the treatment. 
Investigators are urged to collect as much information about the reasons of withdrawal as 
possible when missing data are unpreventable.  
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 The validity of many statistical models that can handle missing data relies heavily on the 
assumptions for the missing data. For example, generalized estimating equations (GEE) must be 
carried out along with the missing completely at random (MCAR) assumption and the mixed 
models for repeated measures with a missing at random (MAR) assumption. These assumptions 
might not be realistic in real life, and possibly not even verifiable.  
 With the withdrawal reasons, assumptions of missingness could be checked; or when the 
assumptions could not be verified, sensitivity analyses could be performed under different 
scenarios to test against the robustness of a study result. 
 Besides the assumptions of the missingness, the handling of missing data is complicated 
by the form of the study outcome, for example, non-normality of data, such as dichotomous data, 
ordinal data, or skewed continuous data. 
1.2.1 Missing Data Mechanism 
We now review the mechanisms that lead to missing data, and in particular the question 
of whether the variables that are missing are related to the underlying values of variables that are 
observed or not observed in the dataset. It is crucial to understand the missing data mechanism 
before any analyses are carried out since the properties of missing data methods rely heavily on 
the nature of the dependencies in these mechanisms. 
The role of these mechanisms was largely ignored in the analysis of missing values until 
these concepts were formalized in the theory of Rubin (1976), through treating the missing data 
indicators as random variables and constructing a joint distribution among values of interest and 
the missing indicators. The following notation and terminology is based on the standard missing 
data framework of Carpenter and Kenward (2012), which is developed from the original paper of 
Rubin (1976) but is modified to fit the modern statistics literature on missing data. 
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Notation 
In the context of a longitudinal trial, we assume that measurements are obtained at J visits 
at times 𝑗 = 1,⋯ , 𝐽 for independent subjects 𝑖, 𝑖 = 1,⋯ , 𝑛. 
Let 𝒀 = (𝑦𝑖𝑗) denote an (𝑛 × 𝐽) rectangular data matrix of the measurements without 
missing values, with the 𝑖-th row 𝒚𝑖 = (𝑦𝑖1, ⋯ , 𝑦𝑖𝐽) being the complete data vector of outcomes 
for subject 𝑖. 
Additionally, let 𝑿𝑖 be the design matrix of covariates for subject 𝑖. 
Let 𝒓𝑖 = (𝑟𝑖1, ⋯ , 𝑟𝑖𝐽) be the missing data indicator vector. Specifically, let 𝑟𝑖𝑗=1 if 𝑦𝑖𝑗 is 
observed and 𝑟𝑖𝑗=0 otherwise. 
Given the missing data indicator 𝒓𝑖, we can partition 𝒚𝑖 into (𝒚𝑖
𝑂, 𝒚𝑖
𝑀), with 𝒚𝑖
𝑂 being the 
observed measurements in 𝒚𝑖 and 𝒚𝑖
𝑀 being the missing measurements. 
The joint distribution of the data and the missing indicator can be formulated as follows 
and factored into two parts: 
𝑓(𝒚𝑖
𝑂 , 𝒚𝑖
𝑀, 𝒓𝑖|𝑿𝑖, 𝜽, 𝝍) = 𝑓(𝒚𝑖
𝑂, 𝒚𝑖
𝑀|𝑿𝑖, 𝜽)𝑓(𝒓𝑖|𝒚𝑖
𝑂 , 𝒚𝑖
𝑀, 𝑿𝑖 , 𝝍)               (1.6) 
where 𝜽 denotes the parameter vectors for the data and 𝝍 denote the parameter vectors for the 
missing data mechanism. The first factor on the right-side is the marginal density of the 
measurements, and the second factor is the conditional density of the missingness on the 
measurements.  
Missing Completely at Random (MCAR) 
Under MCAR, the missingness is assumed to be unrelated to either the observed 
information or the missing, i.e., 
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 𝑓(𝒓𝑖|𝒚𝑖
𝑂 , 𝒚𝑖
𝑀, 𝑿𝑖 , 𝝍) = 𝑓(𝒓𝑖|𝝍) (1.7) 
Note that this assumption doesn’t mean that the missingness itself is random, but rather 
that this distribution does not depend on the data values. 
Therefore, the joint distribution simplifies to  
 𝑓(𝒚𝑖
𝑂 , 𝒚𝑖
𝑀, 𝒓𝑖|𝑿𝑖 , 𝜽, 𝝍) = 𝑓(𝒚𝑖
𝑂 , 𝒚𝑖
𝑀|𝑿𝑖 , 𝜽)𝑓(𝒓𝑖|𝝍) (1.8) 
which indicates the measurement and the missingness are independent. 
The missing data 𝒚𝑖
𝑀 can be now integrated out from the joint distribution, and so the 
joint distribution of the observed measurement and the missing indicator becomes 
𝑓(𝒚𝑖
𝑂, 𝒓𝑖|𝑿𝑖, 𝜽, 𝝍) = 𝑓(𝒚𝑖
𝑂|𝑿𝑖, 𝜽)𝑓(𝒓𝑖|𝝍)                  (1.9) 
And thus estimation of 𝜽 can be solely based on the observed information 𝒚𝑖
𝑂 and does 
not depend on the nuisance parameter 𝝍. 
Missing at Random (MAR) 
An assumption less restrictive than MCAR is that missingness depends only on the 
components that are observed, i.e., 𝒚𝑖
𝑂, and not on the components that are missing, i.e., 𝒚𝑖
𝑀. 
Under MAR, conditional on the observed data, the missingness is independent of the 
missing measurements, which is, 
𝑓(𝒓𝑖|𝒚𝑖
𝑂 , 𝒚𝑖
𝑀, 𝑿𝑖 , 𝝍) = 𝑓(𝒓𝑖|𝒚𝑖
𝑂, 𝑿𝑖, 𝝍)      (1.10) 
Therefore, the full data density becomes 
𝑓(𝒚𝑖
𝑂 , 𝒚𝑖
𝑀, 𝒓𝑖|𝑿𝑖, 𝜽, 𝝍) = 𝑓(𝒚𝑖
𝑂 , 𝒚𝑖
𝑀|𝑿𝑖, 𝜽)𝑓(𝒓𝑖|𝒚𝑖
𝑂 , 𝑿𝑖 , 𝝍)                (1.11) 
The joint distribution of the observed measurements and the missing indicators can again 
integrate out the missing data and become 
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𝑓(𝒚𝑖
𝑂 , 𝒓𝑖|𝑿𝑖 , 𝜽, 𝝍) = 𝑓(𝒚𝑖
𝑂|𝑿𝑖, 𝜽)𝑓(𝒓𝑖|𝒚𝑖
𝑂 , 𝑿𝑖 , 𝝍)                               (1.12) 
With MAR assumption, the model 𝑓(𝒓𝑖|𝒚𝑖
𝑂 , 𝑿𝑖 , 𝝍)  does not need to be specified to 
obtain valid likelihood based inferences, and only the model 𝑓(𝒚𝑖
𝑂 , 𝒚𝑖
𝑀|𝑿𝑖 , 𝜽) is needed.  
MCAR and MAR are often referred to as ignorable missing. The ignorability refers to the 
fact that once 𝑓(𝒓𝑖|𝒚𝑖, 𝑿𝑖) not depending on 𝒚𝑖
𝑀 can be established,  𝑓(𝒓𝑖|𝒚𝑖, 𝑿𝑖) can be ignored 
and a valid likelihood based inference can be obtained given that we model 𝑓(𝒚𝑖
𝑂 , 𝒚𝑖
𝑀|𝑿𝑖, 𝜽) 
correctly.  
Not Missing at Random (NMAR) 
If the measurements are NMAR, which means 𝒓𝑖 depends on 𝒚𝑖
𝑀, the joint distribution 
can no longer have 𝒚𝑖
𝑀 integrated out. No simplification of the joint distribution is possible.  
Under the MNAR assumption, the probability of an observation being missing depends 
on the underlying missing value, and the joint distribution has to be written as in (1.13), 
𝑓(𝒚𝒊
𝑶, 𝒓𝒊|𝑿𝒊, 𝜽, 𝝍) = ∫ 𝑓(𝒚𝒊
𝑶, 𝒚𝒊
𝑴|𝑿𝒊, 𝜽)𝑓(𝒓𝒊|𝒚𝒊
𝑶, 𝒚𝒊
𝑴, 𝑿𝒊, 𝝍)𝑑𝒚𝒊
𝑴        (1.13) 
and inferences could only be made by making further assumptions (Molenberghs and Kenward, 
2007). 
Monotone versus Non-Monotone Missingness 
If the data are arranged as one record per subject, with each record containing outcomes 
of all visits of a subject, the monotone missing pattern applies when variables can be arranged so 
that missing values are always occurring as one block at the end of data records; in the case of a 
non-monotone missing pattern, missing values cannot to be arranged in this way and may happen 
anywhere in a study record.  
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In the clinical trials setting, monotone missingness happens when a study subject 
withdraws from the trial prematurely and doesn’t come back to the study, which is commonly 
referred to as dropout or loss to follow up in longitudinal studies; while non-monotone missing is 
the case when a subject misses one or more intermediate visits but does come back to provide 
subsequent measurements (O’Kelly and Ratitch, 2014). A dataset is considered as monotone 
missing only when all the subjects in the study have a monotone pattern, but it is considered as 
non-monotone missing if there is intermediate missingness in at least one subject. 
1.2.2 Approaches for Handling Dropouts by Parametric Model 
Complete Case Analysis 
One approach to handling missing data is to have analyses that exclude all data from any 
subject who drops out. This method is referred to as a complete-case analysis, which is 
performed by excluding any subjects that missed any intended measurement. It is emphasized 
that this method is very problematic and is rarely an acceptable approach in most occasions 
(Fitzmaurice, Laird and Ware, 2012). It will yield unbiased estimates of the mean response 
trends only when the dropout can be assumed as MCAR. When dropout is MCAR, the study 
completers are a random subsample of the original sample from the population. However, even 
in occasions where the MCAR assumptions might hold, a complete-case analysis is not an 
appealing one since it leads to reduction in the number of subjects and hence results in reduction 
in statistical power.  
Generalizing Estimating Equations (GEE) 
GEE is a semiparametric method that models a known function of the marginal 
expectation of a clustered dependent variable via a linear or non-linear link function for a linear 
function of one or more explanatory variables (Liang and Zeger, 1986). It is based on the concept 
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of estimating equations and the use of a non-linear link function for the marginal model of the 
correlated response can facilitate the analyses of continuous or discrete responses.  
The correlation of the clustered dependent variable can be specified via a working 
correlation matrix and the consistency of parameter estimates do not rely on correct specification 
of the correlation. The dependent variable doesn’t need to have the same number of elements 
across clusters and thus in the longitudinal data context, missing data is allowed. However, if the 
data is MAR, as GEE methods only require a model for the mean response but do not specify the 
multivariate joint distribution for the response vector, the standard GEE methods do not provide 
valid estimates of the regression parameters (Fitzmaurice et al., 2012). 
An adaption of GEE methods for the MAR assumption is to model the missingness  
𝑓(𝒓𝑖|𝒚𝑖, 𝑿𝑖) and weighting the analysis by including it in the estimating equations accordingly 
(Robins, Rotnitzky and Zhao, 1995).  
Mixed Model for Repeated Measures (MMRM) 
MMRM is a likelihood based method that assumes a multivariate normal distribution for 
the repeated measurements. The mean structure can take into account the time effect and thus the 
time effect within subjects at different measurements can be modeled. The correlation within 
subjects can also be modeled by the covariance structure of the repeated measurements through 
assumptions of dependence among the different measurements. This approach includes all 
subjects with at least one observed measurement, and the missing measurements are assumed to 
have the same distribution as the observed. Since MMRM is likelihood based, it provides valid 
inference on the model if the data are MAR when the joint distribution of the responses is 
correctly specified (O’Kelly and Ratitch, 2014). 
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1.2.3 Approaches for Handling Dropouts by Imputation 
Ad-hoc Single Imputation 
 Imputation replaces the missing values with plausible ones. There are many approaches 
to do single imputation. The missing values could be filled in from an individual imputation, 
where these values are coming from the same individual with the actual missing values, or from 
a group imputation, in which information from the entire sample or a portion of the sample is 
used to fill in for the missing value of an individual (Fitzmaurice et al., 2012).  
Two of the most commonly used individual imputations are, baseline observation carried 
forward (BOCF) and last observation carried forward (LOCF), where either the baseline value or 
the last observed value is substituted for the missing values of the study subject. For example, in 
the LOCF case, if an individual was supposed to have five measurements but only the first three 
measurements were observed, the last two missing measurements would be filled in with the 
third value as it was the last observed value before the loss to follow up. The assumption of 
BOCF or LOCF is conservative in estimating the missing outcome if a subject does benefit from 
the trial. The imputation using BOCF or LOCF would underestimate the variability of the 
estimation and result in smaller standard errors estimate. Other single imputation includes the 
individual mean substitution, the group mean substitution, the individual worst case substitution, 
or the interpolation of last and next observed values if the missingness is not monotonic.  
Multiple Imputation (MI) 
Multiple imputation was first introduced by Rubin (1987) to handle missing data in sample 
surveys, and has been developed to spread to other areas including observational studies and 
randomized clinical trials. The application of multiple imputation has become very popular in 
recent years as many analysts become familiar with it, and as many software packages such as 
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SAS, R, and Stata have included procedures or packages to deal with it, which reduces the 
computational burden and complexity. Multiple imputation is a more flexible and powerful tool 
to handle incomplete data than the other parametric methods such as GEE and MMRM, in that it 
has both an imputation model and an analysis model and these two don’t have to be the same, 
and it is more acceptable in most settings than the single imputation.  
Multiple imputation adopts a three-step approach to fill in the incomplete data and 
analyze the resulting data structure. First, an imputation model is assumed for the missing 
outcomes, and plausible values for missing observations are imputed with a draw from the 
imputation model, usually as a posterior distribution of the missing values conditioning on the 
imputation model covariates and any previous visits is assumed. This process is repeated to 
reflect uncertainty about the missing values, resulting in the creation of a number of complete 
datasets. The number of needed imputations depends on the fraction of missing data, and usually 
a number of K>5 would be sufficient for most applications to obtain acceptable properties (that 
is, correct confidence interval coverage) (Carpenter and Kenward, 2012). Second, each of these 
K complete datasets is analyzed with an analysis model, which need not be the same as the 
imputation model. Finally, the results are combined for overall inference using Rubin’s 
combination rule (Rubin, 1987). 
Rubin’s combination rule is as follows. Assume the parameter of interest of the complete 
data analysis is 𝜃 and denote  𝜃𝑘 and ?̂?𝑘 as the point estimate and variance estimate of 𝜃 from the 
k-th imputed dataset, 𝑘 = 1,… , 𝐾. Then the MI estimate of 𝜃 can be expressed as the average of 
the estimates from the  𝐾 complete datasets, 
𝜃𝑀𝐼 =
1
𝐾
∑ 𝜃𝑘
𝐾
𝑘=1
         (1.14) 
13 
  
The measure of precision for 𝜃𝑀𝐼 consists of two parts, the between imputation variance 
and the within imputation variance. Define  
?̂? =
1
𝐾
∑ ?̂?𝑘
𝐾
𝑘=1
        (1.15) 
to be the average within imputation variance, and 
?̂? =
1
𝐾
∑(𝜃𝑘 − 𝜃𝑀𝐼)
2
𝐾
𝑘=1
        (1.16) 
to be the between imputation variance. Then an estimate of the variance of 𝜃𝑀𝐼 is given by  
?̂?𝑀𝐼 = ?̂? + (1 +
1
𝐾
) ?̂?        (1.17) 
 A few practical considerations occur in the first step of multiple imputation. Imputation 
can be performed in a variety of different ways, depending on the type of the missing data 
pattern (monotone or non-monotone), and depending on the type of missing variables (i.e. 
continuous or categorical). One of the common practical considerations is to impute the non-
monotone missing data to monotone. When all response variables are continuous for data with 
non-monotone missingness, imputation can be done by drawing from a Bayesian posterior for 
the multivariate normal distribution, with a Markov Chain Monte Carlo (MCMC) simulation. 
MCMC will impute data partially, filling in only those missing values that have a non-monotone 
pattern (O’Kelly and Ratitch, 2014). This method is most suitable when all variables included in 
the imputation model are continuous, however, this approach has also been applied when some 
variables are categorical; and it is usually the case that the covariates in a model include both 
continuous and categorical variables. To apply MCMC imputation, nominal categorical values 
can be dummy-coded as a set of binary variables, while ordinal variables can sometimes be 
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treated as continuous in this partial imputation step. However, in the clinical trial setting, when 
multiple clinical centers need to be adjusted for, and when the number of centers is large (>10), 
the center variable might have to be removed from the multivariate normal model for the partial 
imputation. This assumption could be reasonable if the non-monotone missingness doesn’t vary 
by center, otherwise the imputed values would not have taken into account the variability 
introduced by study center. 
1.2.4 Sensitivity Analyses 
Sensitivity analysis in missing data situations is usually carried out through stressing the 
assumption of MAR. It is important to examine the sensitivity of statistical inferences when 
departures from the MAR assumption are in question, because this assumption cannot be verified 
using the data (O’Kelly and Ratitch, 2014). In this regard, the primary purpose of a sensitivity 
analysis in a clinical trial is to seek to answer the question that if plausible unfavorable outcomes 
happen to the withdrawal in the experimental treatment, does the significant results drawn from 
the primary analysis remain credible or not? 
 For example, the loss to follow up outcomes that are suspected to be different from what 
would have happened if remaining in the study, could be made worse by a clinically significant 
value, if the outcome is continuous, or by an odds ratio if the outcome is categorical. This is 
often known as the delta adjustment method (National Research Council Panel, 2010), where 
delta is the clinically important difference, or odds ratio. Delta adjustment could be applied to all 
the treatment groups, or it might be of more interest to be used to penalize the withdrawals in the 
experimental treatment (O’Kelly and Ratitch, 2014). Tipping point analysis is the application of 
a sequence of delta adjustments, by positing a wide range of assumptions from less pessimistic to 
more pessimistic to explore the influence of missingness on the study conclusion (National 
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Research Council Panel, 2010). The tipping point in this range of assumptions is the value that 
overturns the conclusion from being favorable to the experimental treatment, to being not 
different from the reference group. In terms of hypothesis testing of a treatment effect, the 
tipping point is the value at which the p value of the test changes from significant to non-
significant. 
 Crossover Studies 
Crossover studies are experimental designs for which each subject is randomly assigned 
to receive a sequence of treatments during consecutive periods for some response variables. 
There are many possible designs of crossover studies, depending on the number of treatments to 
compare, the number of periods of each treatment, and the aim of the trials (Jones and Kenward, 
2014). 
1.3.1 Traditional Crossover Designs 
One of the most well-known crossover designs is the one with two sequence groups for 
two treatments in two periods. This is also the simplest crossover design, which is known as the 
2×2 design, or the two-period two-treatment design. The main advantage of the crossover study 
is that treatments are compared within subjects, where every subject provides two periods of 
different treatments and thus removal of the subject effect is enabled by direct comparison within 
subject (Jones and Kenward, 2014).  
Secondly, since every subject provides two response measurements in the two periods, at 
a fixed sample size, the power of the treatment comparison is improved. In addition, since all the 
patients would receive the experimental treatment in one period or another, the dropout rate in 
this design could be minimized, at least for the first study period. For example, Pincus et al. 
(2001) performed a randomized crossover trial of an experimental drug versus active control in 
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ambulatory patients with osteoarthritis of the hip or knee and achieved a low dropout rate. Of the 
227 enrolled patients, 218 (96.0%) patients completed the first treatment period and 181 (79.7%) 
completed both treatment periods.   
 However, the feature of repeated measurements in crossover designs brings 
disadvantages along with its advantages; for example, the possibility that the effect of an earlier 
period would be carried into the later period, and the potential risk of more dropouts due to 
longer study duration compared to a single period trial. 
Statistical Methods for 2×2 Design 
 Tudor and Koch (1994) review nonparametric methods for analyzing the traditional 
crossover studies comparing two treatments with small sample sizes and the parametric 
counterparts when sample sizes are sufficiently large. The methods apply to various types of 
outcome including continuous, dichotomous, ordinal, and censored time-to-event response. 
 In particular, for a 2x2 crossover design with a univariate continuous outcome, the 
structure for the inference is as shown in Table 1.1. 
Table 1.1 2×2 Design Parameters 
Group Period 1 Period 2 
AB 𝜇 + 𝜋1 + 𝜏𝐴 𝜇 + 𝜋2 + 𝜏𝐵 + 𝜆𝐴 
BA 𝜇 + 𝜋1 + 𝜏𝐵 𝜇 + 𝜋2 + 𝜏𝐴 + 𝜆𝐵 
 
𝜏𝐴 and 𝜏𝐵 are direct treatment effects of treatment A and treatment B, and 𝜋1 and 𝜋2 are 
period effects of periods 1 and 2, and 𝜆𝐴 and 𝜆𝐵 are carryover effects of treatment A and 
treatment B respectively. 
With small sample sizes, observed statistics are compared to permutation distributions to 
provide 𝑝 values for the hypothesis testing of similarity of treatment effects 𝐻0𝜏: 𝜏𝐴 = 𝜏𝐵 using 
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data from both periods in a few steps. In the first step, one would test 𝐻0, where 
𝐻0: 2(𝜏𝐵 − 𝜏𝐴) − (𝜆𝐵 − 𝜆𝐴) = 0. If the 𝐻0 is contradicted, one moves on to test the equality of 
carryover effects 𝐻0𝜆: 𝜆𝐴 = 𝜆𝐵; and if this similarity is not contradicted, one could have 
confidence that the contradiction of 𝐻0 is mainly due to the difference in treatment effects 𝜏𝐴 and 
𝜏𝐵 and the equivalence of testing 𝐻0 and 𝐻0𝜏; or if this equality of carryover effects 𝐻0𝜆 is 
contradicted, meaning there are different carryover effects by the two treatments, which may 
partly account for the contradiction of 𝐻0, one would have to move on to compare the difference 
between treatments only using data from Period 1,  which does not depend on the carryover 
effects.  
 The above tests in each step could be replaced by the asymptotic tests with approximate 
distributions when the sample size is sufficiently large (sample size per sequence ≥15).  
A more comprehensive review of analyses in the traditional 2x2 design and other higher 
order designs is provided in Jones and Kenward (2014). 
1.3.2 Innovative Two-Period Crossover Designs 
Innovative crossover designs can have multiple designs embedded within them, which 
are also in the general class of re-randomization designs. Instead of re-randomization at the 
beginning of the second period, randomization before the trial could be performed to get the 
randomized sequences. Without loss of generality, this literature review limits the scope of the 
discussion to the design with fixed randomization sequences at the initiation of the study without 
re-randomization later.  
 With a two-period design comparing test treatment (T) to placebo treatment (P), four 
sequence groups P:P, P:T, T:P, and T:T could be of interest. Designs with some combination of 
those sequence groups have provided useful features for the studies of different patient 
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populations. Other advances of crossover designs with this structure could be made use of with 
other added design features, such as enrichment. 
Enriched Two-Sequence Design 
 Common crossover designs that use two of four sequence groups are the T:P, and P:T 
design (the 2×2 design), the T:P and T:T design, and the P:P and P:T design. The latter two-
sequence designs are usually used with enrichment features. 
The randomized withdrawal design, with the T:P and T:T sequence groups, makes use of 
only the patients who respond to the drug in the first period for continuation to the second period. 
This design is helpful when there is heterogeneity in the patient population itself to respond to a 
treatment. For example, Temple (1994) discusses situations where the gold standard randomized, 
double-blind, placebo-controlled study design with continuous treatment might not be able to 
provide an optimal study when certain diseases are treated, such as irritable bowel syndrome 
(IBS), a gastrointestinal disorder, which he suggested might be due to IBS being a “common 
response to a diverse group of abnormality”. The FDA has proposed to conduct clinical trials to 
include only IBS patients identified by their clinicians as responders to the study treatment 
(Dunger-Baldauf, Racine, and Koch 2006).  
The P:P and P:T design, usually known as the placebo lead-in design, has the other two 
sequence groups of the four as compared to randomized withdrawal design. In this design, only 
the patient who doesn’t respond to placebo in the first period remains in the study. This design is 
practical in studies such as drugs to treat disease in the central nerve system, where there are 
many placebo responders. The placebo response rate in antidepressant and antipsychotic trials is 
reported to increase overtime in meta analyses of trials between 1985 and 2000 (Khan et al., 
2005). With only the placebo nonresponders identified in the first period continuing in the 
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second period to receive either experimental treatment or placebo, the treatment effect is 
maximized since patients who do not respond to the first period are not expected to become 
placebo-responders in the second period (Fava et al., 2003).  
 
 
Figure 1.1 Randomized Withdrawal Design 
  
 
Figure 1.2 Placebo Lead-In Design 
Three-Sequence Design 
 Designs with three or more sequence groups could provide additional benefits to the two-
sequence designs mentioned above.  
One design in this class to improve completeness of data with this crossover structure 
was proposed by Koch, Davis, and Anderson (1998). This design has three of the four sequence 
groups, P:T, T:P, and T:T; as shown in Figure 1.3, it provides T during the second period to 
patients with P during the first period, and provides continued treatment of T to some fraction of 
the patients who received T during the first period. This design embeds the comparison that is 
capable in the 2×2 design and the randomized withdrawal design.  
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Figure 1.3 P:T, T:P, and T:T Sequence Design 
 Another design with attractive features also has three sequence groups as P:P, P:T, and 
T:T, and it is commonly known as the randomized delayed-start design . In this design, patients 
are initially randomized to placebo or test drug in the first period, and patients who are in the 
placebo group in the first period would receive either placebo or test drug in the second period, 
while patients who receive test drug in the first period remain on the same treatment. This design 
is suitable to evaluate treatments for disease with long term progression to distinguish the 
symptomatic improvement from the true disease modifying effect. The effect of the active 
treatment in the first period compared to placebo could be due to either the symptomatic 
improvement or the true effect on modifying the disease, but in the second period when the 
delayed-start P:T sequence patients receive the active treatment, if the early-start T:T sequence 
patients show benefits from being in the trial longer than the P:T sequence, it indicates a disease 
modifying effect of the active treatment. If these two sequence groups are showing similar 
improvement from baseline, then the active treatment might only reflect a symptomatic relief in 
the course (Dunger-Baldauf, Racine and Koch, 2006) (Clinical Trial Design in Parkinson's 
Disease 2013 p3). 
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Figure 1.4 Randomized Delayed-Start Design 
 These two three-sequence designs both have an advantage over the two-sequence 
randomized withdrawal design in that there is a higher chance in receiving the better treatment in 
the second period, which might provide a favorable impact on the patient retention and reduce 
non-compliance with the protocol, at least at the end of the first period (Dunger-Baldauf, 2007). 
Enriched Multiple-Sequence Design 
 Another study design that has the same sequence groups as the randomized delayed-start 
design is the sequential parallel comparison design (SPCD). SPCD design was proposed by Fava 
et al. (2013), and it is different from the delayed-start design in that only the placebo non-
responders of the first period in the P:P and P:T groups continue into the second period. SPCD 
serves similar purposes as the two-sequence placebo lead-in design in psychiatric clinical trials 
with a high placebo response rate, except that it has an additional T:T sequence. And thus 
besides sharing the high compliance benefit of the three sequence design mentioned above, it 
also eliminates the potential risk brought by the placebo lead-in design that it is more difficult to 
identify placebo-responders when it is hard to hide from the clinicians that only placebo is given 
in the first period (Fava et al., 2003; Ivanova, Qaqish and Schoenfeld, 2011; Doros et al., 2013). 
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Figure 1.5 SPCD Design 
The original paper of Fava et al. (2003) focused on the study outcome as dichotomized 
data. Other methods have been proposed for the analyses of binary outcomes in the context of 
SPCD designs by Huang and Tamura (2010), Ivanova, Qaqish and Schoenfeld (2011), and 
Huang, Tamura, and Boos (2011).  
Recent uses of the SPCD design have been extended to continuous or ordinal outcome as 
it arises more naturally than the dichotomizing of a continuous measurement. Huang and Tamura 
(2010) considered seemingly unrelated regression (SUR) to account for the correlation between 
subjects in the two periods of the trial. Chen et al (2011) proposed an ordinary least squares 
approach and Doros et al. (2013) proposed a repeated measures model that includes all possible 
outcome data collected in the trial. 
The two-way enrichment design (TED), introduced by Ivanova and Tamura (2011), has all four 
sequence groups, P:P, P:T, T:P, and T:T, but in the second period, only the non-responders to the 
placebo in the first period of the P:P and P:T sequences, and the responders to the active 
treatment in the first period of the T:P and T:T sequences remain in the study. And thus the TED 
design has the advantage of both the placebo lead-in design and the randomized withdrawal 
designs. This design is suitable to study the maintenance of efficacy of an active treatment 
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(through the randomized withdrawal design) for a disease with a high placebo response rate. For 
example, for generalized anxiety disorder (GAD), which is a central nerve system disease with a 
high placebo response rate, and a chronic disease for which worsening would quickly occur after 
discontinuation from an active treatment, a trial to evaluate an active treatment versus placebo 
would benefit from the TED design.  
 
Figure 1.6 TED Design 
Bilateral Design 
 Besides the studies mentioned above, the four sequence group design could also be 
applied to two sides of the same subject, instead of two periods. For example, Kawaguchi and 
Koch (2009) studied the two eyes of the same patients with four sequence group, with the 
treatments assigned to the two eyes instead of the two periods respectively. 
 Summary 
This literature review covers many aspects of clinical trials. The existing methodology for 
handling missing data in different missing data scenarios is reviewed and different designs and 
usage of crossover studies is discussed. Also, this chapter discusses a nonparametric way to 
handle the random imbalance in covariables, as well as its usefulness in reducing the variability 
of estimation. 
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The following chapters are organized as follows. In Chapter 2, we discuss a method for 
sensitivity analyses of estimation in favorable proportion for missing dichotomous data. Chapter 
3 extends the method in Chapter 2 to outcome data with an ordinal nature. Chapter 4 presents a 
method for statistical inference under the null for SPCD trials and Chapter 5 further studies the 
point and confidence interval estimation under the alternative of this design. And Chapters 6 and 
7 provides an outline and statistical planning for topic in hypothesis testing for TED trials and 
bilateral design.  
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 CHAPTER 2: SENSITIVITY ANALYSIS OF FAVORABLE PROPORTION FOR 
MISSING DICHOTOMOUS DATA IN MULTI-VISIT RANDOMIZED CLINICAL 
TRIAL 
 Introduction 
 In clinical trials, the dichotomous endpoint only has two possible outcomes for an 
observation, either directly or via categorization of an ordinal or continuous observation. 
However, missing data often occur for one or more visits during a multi-visit study. No matter 
how well designed and conducted a trial is, some missing data can almost always be expected 
(O’Kelly and Ratitch, 2014). Oftentimes, missing data are due to some specific reasons, and they 
can be related to the treatment for a patient (e.g., adverse events, or lack of efficacy) or unrelated 
(e.g., move from the community for treatment).  
 When loss to follow-up occurs, investigators are urged to collect as much information as 
possible for the withdrawal reasons. Given the withdrawal reasons, sensitivity analyses could be 
performed under different scenarios. In the regulatory setting, a tipping point analysis is usually 
needed to assess what conditions would overturn the statistical significance of the claimed 
treatment difference and whether such pivotal conditions are potentially possible in the real trial 
(National Research Council Panel, 2010). 
 In the situations for missing data in a clinical trial, the two quantities of primary interest 
are the treatment comparison estimate under different assumptions and its corresponding 
variance. They can be obtained through imputation for missing data, or with statistical models 
with some assumptions for the missingness and covariance structure for the data. In the statistical 
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analysis plan of the clinical trial, the statistical methods need to be stated a priori for the 
assessment of the treatment comparison before the clinical trials are actually conducted. 
Oftentimes, possibly unrealistic assumptions are required for the validity of certain statistical 
models, and they are difficult to evaluate before data analysis. Therefore, methods requiring 
fewer assumptions are desired rather than those with complex assumptions, especially in the 
regulatory setting. 
 In this paper, we propose a method that mathematically redistributes the missing counts 
as favorable or unfavorable under different specifications for the missing data, so as to provide 
resulting estimates for the treatment comparisons in a multi-visit clinical trial and a 
corresponding covariance matrix. Also, adjustment for covariates is possible through 
randomization-based analysis of covariance (ANCOVA) so as to provide variance reduction and 
offset random imbalances. Section 2.2 introduces the data set up and the methodology, and the 
methods are illustrated with an example in Section 2.3. Chapter 3 provides an extension to an 
ordinal categorical outcome. 
 Methods 
 Consider a study comparing a test treatment and a control treatment for a favorable 
outcome or not through assessments at each of several visits. For the dichotomous outcome with 
possibly missing data, there are three possible responses, favorable, unfavorable, or missing, 
although the outcome for missing could be expanded to include the applicable reason. While 
outcome and response are often interchangeable in the literature, here we make a distinction 
between outcome categories and response categories, where the former could only have two 
outcomes and the latter includes missing as a category. 
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2.2.1 Notation 
 Let 𝑦𝑔ℎ𝑖𝑗𝑘 be the indicator variable for the response of subject 𝑖 in group g and stratum ℎ 
at visit 𝑗 being 𝑘, where group 𝑔 = 1, 2 index the test treatment and control treatment 
respectively; stratum ℎ = 1, 2,⋯ ,𝐻 index the stratum for the subject; subject 𝑖 = 1, 2,⋯ , 𝑛𝑔ℎ; 
visit 𝑗 = 1, 2,⋯ , 𝐽, and response 𝑘 = 1, 2, 3, where 1, 2 and 3 index favorable, unfavorable, and 
missing response respectively. If there were 3 potential reasons for missing such as lack of 
efficacy, unacceptable tolerability, and other, then 𝑘 = 1, 2, 3, 4, 5 could apply; but throughout 
this paper, only one missing category is mainly considered. We define a three-dimensional 
vector 𝒀𝑔ℎ𝑖𝑗∗ = (𝑦𝑔ℎ𝑖𝑗1, 𝑦𝑔ℎ𝑖𝑗2, 𝑦𝑔ℎ𝑖𝑗3)
′ to combine the three indicators. For example, 𝑌1111∗ =
(0,1,0) means Subject 1 for the test treatment and Stratum 1 at time point 1 has unfavorable 
outcome. Accordingly, we further define a data vector that includes all visits as 𝒀𝑔ℎ𝑖∗∗ =
(𝒀𝑔ℎ𝑖1∗
′ , ⋯ , 𝒀𝑔ℎ𝑖𝐽∗
′ )
′
= (𝑦𝑔ℎ𝑖11, 𝑦𝑔ℎ𝑖12, 𝑦𝑔ℎ𝑖13, … , 𝑦𝑔ℎ𝐽11, 𝑦𝑔ℎ𝐽12, 𝑦𝑔ℎ𝐽13)
′
. 
2.2.2 Data Structure 
For subjects in treatment group 𝑔 and stratum ℎ, the observed data can be arranged in a 
contingency table format as in Table 2.1. After including missing as a category, the number of 
Table 2.1 Data Structure 
            Response 
Time 
Fav UnFav Missing Total 
1 𝑛𝑔ℎ11(𝑝𝑔ℎ11) 𝑛𝑔ℎ12(𝑝𝑔ℎ12) 𝑛𝑔ℎ13(𝑝𝑔ℎ13) 𝑛𝑔ℎ 
⋮ ⋮ ⋮ ⋮ 𝑛𝑔ℎ 
𝐽 𝑛𝑔ℎ𝐽1(𝑝𝑔ℎ𝐽1) 𝑛𝑔ℎ𝐽2(𝑝𝑔ℎ𝐽2) 𝑛𝑔ℎ𝐽3(𝑝𝑔ℎ𝐽3) 𝑛𝑔ℎ 
 
subjects at each visit is fixed as 𝑛𝑔ℎ. The cell count 𝑛𝑔ℎ𝑗𝑘 is 𝑛𝑔ℎ𝑗𝑘 = ∑ 𝑦𝑔ℎ𝑖𝑗𝑘
𝑛𝑔ℎ
𝑖=1 , and cell 
proportion 𝑝𝑔ℎ𝑗𝑘 is 𝑝𝑔ℎ𝑗𝑘 =
𝑛𝑔ℎ𝑗𝑘
𝑛𝑔ℎ
. The counts vector at row 𝑗 of the table is expressed as  
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𝑛𝑔ℎ𝑗 = (𝑛𝑔ℎ𝑗1, 𝑛𝑔ℎ𝑗2, 𝑛𝑔ℎ𝑗3), which follows a multinomial distribution, 
𝒏𝑔ℎ𝑗~𝑀𝑢𝑙𝑡𝑖𝑛𝑜𝑚𝑖𝑛𝑎𝑙(𝑛𝑔ℎ, 𝝅𝑔ℎ𝑗), where 𝝅𝑔ℎ𝑗 = (𝜋𝑔ℎ𝑗1, 𝜋𝑔ℎ𝑗2, 𝜋𝑔ℎ𝑗3)
′
 is the marginal 
multinomial probability vector of response for the 𝑗-th visit. From the properties of multinomial 
distributions, the unbiased estimator of the multinomial probability 𝝅𝑔ℎ𝑗, is the proportion vector 
at row 𝑗, 𝒑𝑔ℎ𝑗 = (𝑝𝑔ℎ𝑗1, 𝑝𝑔ℎ𝑗2, 𝑝𝑔ℎ𝑗3)
′
. Combining across all time points, 𝒑𝑔ℎ =
(𝒑𝑔ℎ1
′ , … , 𝒑𝑔ℎ𝐽
′ )
′
 and 𝝅𝑔ℎ = (𝝅𝑔ℎ1
′ , … , 𝝅𝑔ℎ𝐽
′ )′ apply to the correlated multinomial distributions 
for the 𝒏𝑔ℎ𝑗 for the 𝐽 visits. The estimated covariance matrix of 𝒑𝑔ℎ as the mean of the 𝒀𝑔ℎ𝑖∗∗ is 
shown in (2.1). 
𝑽𝑝𝑔ℎ =
1
𝑛𝑔ℎ(𝑛𝑔ℎ − 1)
∑(𝒀𝑔ℎ𝑖∗∗ − 𝒑𝑔ℎ)(𝒀𝑔ℎ𝑖∗∗ − 𝒑𝑔ℎ)
′
𝑛𝑔ℎ
𝑖=1
    (2.1) 
2.2.3 Favorable Probability Estimation 
 Now the estimation of interest is for the probability of favorable outcome. For this 
purpose, the missing response category is redistributed to the favorable and unfavorable 
outcomes according to a missing outcome specification.  
 Let 𝑞𝑔ℎ𝑗 be the probability estimator that a subject in group g and stratum h would have a 
favorable outcome at visit 𝑗. The redistributed favorable outcome proportion under a missing 
completely at random (MCAR) specification is shown in (2.2). 
𝑞𝑔ℎ𝑗 = 𝑝𝑔ℎ𝑗1 +
𝑝𝑔ℎ𝑗1
𝑝𝑔ℎ𝑗1 + 𝑝𝑔ℎ𝑗2
𝑝𝑔ℎ𝑗3      (2.2) 
 It is also an “observed case” estimate which has the assumption that patients with missing 
status have the same probability of favorable outcome as those with observed status as shown in 
(2.3). 
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𝑞𝑔ℎ𝑗 =
𝑝𝑔ℎ𝑗1
𝑝𝑔ℎ𝑗1 + 𝑝𝑔ℎ𝑗2
                             (2.3) 
2.2.4 Sensitivity Analysis 
 So far we have assumed the missing responses are MCAR-like. However, in clinical 
trials, the discontinued patients could have withdrawn from the study due to reasons related to 
the unobserved outcome, which renders the data non-ignorable missing (NMAR); see Little and 
Rubin (2014). 
 For the subsequent discussion in this section, we omit the notation for group 𝑔 and 
stratum ℎ for simplicity of presentation, although they can always be included without loss of 
generality. Now let 𝑛𝑗1, 𝑛𝑗2, and 𝑛𝑗3 represent the counts of the favorable, unfavorable, and 
missing responses at visit 𝑗, and 𝑛𝑗1 + 𝑛𝑗2 + 𝑛𝑗3 = 𝑛𝑗. We further divide the missing counts 𝑛𝑗3 
into 𝑛𝑗31 and 𝑛𝑗32, where 𝑛𝑗31 and 𝑛𝑗32 represent the unobserved counts with a favorable and 
unfavorable outcome if missing responses were actually observed. Also, 𝑝𝑗1, 𝑝𝑗2, and 𝑝𝑗3 are the 
corresponding proportion estimators.  Thus, we have the data structure shown in Table 2.2. Also, 
Table 2.2 could be expanded to account for counts for two or more reasons for missing 
responses. 
Table 2.2 Data Structure for Missing Counts Redistribution 
Visit Fav UnFav Missing Total 
j 𝑛𝑗1 𝑛𝑗2 𝑛𝑗3 = 𝑛𝑗31 + 𝑛𝑗32 𝑛𝑗  
 
 The odds ratio ratio 𝜃𝑗  comparing the favorable to the unfavorable outcome in the 
patients with missing status versus observed patients is shown in (2.4); and the solution it implies 
for 𝑛𝑗31 is shown in (2.5). 
𝜃𝑗 =
𝑛𝑗31
𝑛𝑗32
 /  
𝑛𝑗1
𝑛𝑗2
                        (2.4) 
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𝑛𝑗31 =
𝜃𝑗𝑛𝑗1𝑛𝑗3
𝜃𝑗𝑛𝑗1 + 𝑛𝑗2
                   (2.5) 
Thus, there can be determination of total favorable outcome counts through an assumed 
specification of the odds ratio 𝜃𝑗 . Also, separate 𝜃𝑗’s could address two or more reasons for 
missing responses.  
 If 𝜃𝑗 = 1, the missing responses are assumed to be MCAR-like; if 𝜃𝑗 > 1 the missing 
responses are regarded as more likely to have better outcome than those observed; if 𝜃𝑗 < 1, the 
missing responses are regarded as more likely to have worse outcome, as is often the case for 
patients who discontinue the test treatment. Through adjusting for different 𝜃𝑗 , different 
specifications of the possible outcomes for the missing response can be obtained, and thus we 
call the 𝜃𝑗  the sensitivity parameters for missingness.  
              The adjusted favorable proportion estimator can be expressed in terms of the observed 
proportions for the responses and the 𝜃𝑗  as shown in (2.6). 
𝑞𝑗𝜃 =
𝑛𝑗1 + 𝑛𝑗31
𝑛𝑗
=
1
𝑛𝑗
(𝑛𝑗1 +
𝜃𝑗𝑛𝑗1
𝜃𝑗𝑛𝑗1 + 𝑛𝑗2
𝑛𝑗3) = 𝑝𝑗1 +
𝜃𝑗𝑝𝑗1
𝜃𝑗𝑝𝑗1 + 𝑝𝑗2
𝑝𝑗3      (2.6) 
              By construction, the 𝑞𝑗𝜃 are comparable to what might be expected by random multiple 
imputation of the missing responses via (2.5), but they are alternatively produced from 
mathematical redistribution as in (2.5). From (2.6), it follows that the adjusted odds of favorable 
versus unfavorable outcome at time 𝑗 has the structure shown in (2.7). 
𝑞𝑗𝜃
1 − 𝑞𝑗𝜃
=
𝑛𝑗1(𝜃𝑗𝑛𝑗1 + 𝑛𝑗2 + 𝜃𝑗𝑛𝑗3)
𝑛𝑗2(𝜃𝑗𝑛𝑗1 + 𝑛𝑗2 + 𝑛𝑗3)
 
=
𝑝𝑗1 (𝜃𝑗𝑝𝑗1 + 𝑝𝑗2 + 𝜃𝑗(1 − 𝑝𝑗1 − 𝑝𝑗2))
𝑝𝑗2 (𝜃𝑗𝑝𝑗1 + 𝑝𝑗2 + (1 − 𝑝𝑗1 − 𝑝𝑗2))
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=
𝑝𝑗1 (𝑝𝑗2 + 𝜃𝑗(1 − 𝑝𝑗2))
𝑝𝑗2 (𝜃𝑗𝑝𝑗1 + (1 − 𝑝𝑗1))
                (2.7) 
              If 𝜃𝑗=1, which is the MCAR-like case, 
𝑞𝑗𝜃
1−𝑞𝑗𝜃
=
𝑝𝑗1
𝑝𝑗2
, with this indicating that the adjusted 
odds of favorable outcome versus unfavorable is the same as the odds for the observed outcomes. 
2.2.5 Covariance Matrix Estimation 
 Let 𝒒𝜃 = (𝑞1𝜃, … , 𝑞𝐽𝜃) denote the 𝑗-dimensional vector of adjusted outcome proportion 
estimators. In order to use the linear Taylor series methods discussed in Koch et al. (1977), as 
well as summarized Stokes et al. (2012, Chapter 14), to produce a consistent estimate for the 
covariance matrix of the adjusted proportion vector 𝒒𝜽, we express 𝒒𝜽 in the form of compound 
functions of the unadjusted proportion vector 𝒑 = (𝒑1
′ , … , 𝒑𝐽
′ )
′
 and sensivity parameter 𝜃 as 
shown in (2.8). 
𝒒𝜽 = 𝑨𝟑𝒆𝒙𝒑[𝑨𝟐 𝒍𝒐𝒈(𝑨𝟏𝜽𝒑)]                                  (2.8) 
 In (2.8), log() denotes the element-wise vector operation that transforms a vector to the 
corresponding vector of natural logarithms, and exp [] denotes the element-wise vector operation 
that transforms a vector to the corresponding vector of exponentiated values, and matrices 𝑨𝟏𝜽, 
𝑨𝟐, and 𝑨𝟑 are shown in (2.9) for which 𝒃𝒅𝒊𝒂𝒈𝑱(𝑳𝒋) denotes a diagonal matrix of J blocks, with  
𝑨𝟏𝜽 = 𝒃𝒅𝒊𝒂𝒈𝑱 (
1  0  0 
𝜃𝑗  0  0
𝜃𝑗  1  0
0  0 1
) , 𝑨𝟐 = 𝒃𝒅𝒊𝒂𝒈𝑱 (
1  0  0  0 
 0  1 − 1  1
) , 𝑨𝟑 = 𝒃𝒅𝒊𝒂𝒈𝑱(1  1)         (2.9) 
matrix 𝑳𝒋 on the 𝑗-th diagonal block 𝑗 = 1,… , 𝐽. By applying the linear Taylor series methods in 
Koch et al. (1977), we can obtain a consistent estimator for the covariance matrix of 𝒒𝜽 as shown 
in (2.10).  
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𝑽𝑞𝜃 = 𝑩𝜃𝑽𝒑𝑩𝜃
′          (2.10) 
 For (2.10), 𝑩𝜃 is the elementwise first partial derivative of vector 𝒒𝜽 with respect to 
vector 𝒑 and is obtained by applying the chain rule, as shown in (2.11) for which 𝒂𝟏𝜽 = 𝑨𝟏𝜽𝒑, 
𝑩𝜽 =
𝝏𝒒𝜽
𝝏𝒑
=
𝝏𝒒𝜽
𝝏𝒂𝟑𝜽
 
𝝏𝒂𝟑𝜽
𝝏𝒂𝟐𝜽
  
𝝏𝒂𝟐𝜽
𝝏𝒂𝟏𝜽
 
𝝏𝒂𝟏𝜽
𝝏𝒑
= 𝑨𝟑𝑫𝒂𝟑𝜽𝑨𝟐𝑫𝒂𝟏𝜽
−𝟏 𝑨𝟏𝜽   (2.11) 
𝒂𝟐𝜽 = log (𝒂𝟏𝜽), 𝒂𝟑𝜽 = exp [𝑨𝟐𝒂𝟐𝜽], and 𝒒𝜽 = 𝑨𝟑𝒂𝟑𝜽, and 𝑫𝒂𝟏𝜽
−𝟏   is a diagonal matrix with the 
reciprocals of the elements of the vector 𝑎1𝜃 on the main diagonal and 𝑫𝒂𝟑𝜽 is the diagonal 
matrix with the elements of the vector 𝒂𝟑𝜽 on the main diagonal.  
 Now we reconsider group 𝑔 and stratum ℎ, for which the adjusted favorable proportion 
estimate is shown in (2.12).  
𝑞𝑔ℎ𝑗𝜃 = 𝑝𝑔ℎ𝑗1 +
𝜃𝑗𝑝𝑔ℎ𝑗1
𝜃𝑗𝑝𝑔ℎ𝑗1 + 𝑝𝑔ℎ𝑗2
𝑝𝑔ℎ𝑗3    (2.12)  
The covariance estimate of 𝒒𝒈𝒉𝜽, where 𝒒𝒈𝒉𝜽 = (𝑞𝑔ℎ1𝜃, … , 𝑞𝑔ℎ𝐽𝜃)
′
 is shown in (2.13). 
𝑽𝒒𝒈𝒉𝜽 = 𝑩𝒈𝒉𝜽𝑽𝒑𝒈𝒉𝑩𝒈𝒉𝜽
′                           (2.13) 
The selection of the sensitivity parameter 𝜃𝑔ℎ𝑗 could be based on knowledge for the trial 
being conducted and the nature of disease; see Zhao et al. (2014). In many cases, it can 
correspond to fractions of the reciprocal for a known odds ratio for the effect of a useful 
treatment versus placebo. 
Typically, the 𝜃𝑔ℎ𝑗 are the same for all strata in group 𝑔, i.e., 𝜃𝑔ℎ𝑗 = 𝜃𝑔𝑗 , and they could 
vary at different visits 𝑗 and 𝑗′. In addition, one could expect missing responses for patients in the 
placebo group to have a similar outcome distribution as the observed patients, which corresponds 
to 𝜃2ℎ𝑗 = 1 for any ℎ and any visit 𝑗 in the placebo group. 
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2.2.6 Treatment Comparison 
Treatment Difference 
 The treatment difference Δ = (Δ1,⋯ , Δ𝐽) between test and placebo visits 1 to 𝑗 could be 
estimated using the corresponding adjusted proportion differences, and they can be weighted by 
the Mantel-Haenszel weights 𝑤ℎ = {
𝑛1ℎ𝑛2ℎ (𝑛1ℎ+𝑛2ℎ)⁄
∑ 𝑛1ℎ′𝑛2ℎ′ (𝑛1ℎ′+𝑛2ℎ′)⁄
𝐻
ℎ′=1
} for the combined strata. The 
treatment difference estimator at visit 𝑗 for Δ𝑗 is 𝑑𝑗𝜃 as shown in (2.14). 
𝑑𝑗𝜃 = ∑ 𝑤ℎ(𝑞1ℎ𝑗𝜃 − 𝑞2ℎ𝑗𝜃)
𝐻
ℎ=1
         (2.14) 
 Letting  𝒅𝜽 = (𝑑1𝜃,⋯ , 𝑑𝐽𝜃), the consistent covariance matrix estimator of 𝒅𝜽 can be 
obtained using the covariance matrix estimator 𝑽𝒒𝒈𝒉𝜽  of 𝒒𝒈𝒉𝜽  in (2.13), and it is expressed as 
(2.15).  
𝑽𝒅𝜽 = ∑ 𝑤ℎ
2 (𝑽𝒒𝟏𝒉𝒋𝜽 + 𝑽𝒒𝟐𝒉𝒋𝜽)
𝐻
ℎ=1
          (2.15) 
Adjusted Treatment Difference via Randomzation-Based ANCOVA 
 In a randomized clinical trial, baseline covariables are expected to have the same 
distribution in the randomized groups. Baseline covariables could include the baseline 
measurement of the outcome, demographic variables, or other variables. However, random 
imbalances in the baseline covariables could occur as each treatment group is a finite sample of 
the randomized population, and covariance adjustment for them can offset such imbalances. 
 Covariance adjustment can also provide variance reduction for treatment comparison 
estimation when applied in a randomization-based way (Koch et al., 1998; Tangen and Koch, 
2001; LaVange et al., 2005). The motivation behind the variance reduction is that the parameter 
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estimate that is associated with the imbalance would be corrected to offset the direction of the 
imbalance. The estimation is through randomization-based ANCOVA, which is an approach that 
applies weighted least squares methods to evaluate differences between treatment groups with 
respect to outcome variables and covariables simultaneously (Koch et al., 1998).  
 Here, we introduce some notations for the covariables. Suppose each subject has 𝑀 
baseline covariables 𝒙𝒈𝒉𝒊, 𝒙𝒈𝒉𝒊 = (𝑥𝑔ℎ𝑖1, … , 𝑥𝑔ℎ𝑖𝑀)
′
, and ?̅?𝒈𝒉 =
1
𝑛𝑔ℎ
∑ 𝒙𝒈𝒉𝒊
𝑛𝑔ℎ
𝑖=1  is the mean 
vector of the prespecified covariables. 
 We define 𝒇𝒈𝒉𝒊 = (𝒀𝒈𝒉𝒊∗∗
′ , 𝒙𝒈𝒉𝒊
′ )
′
 as a (3 × 𝐽 + 𝑀) dimensional response-covariable 
vector, and ?̅?𝒈𝒉 =
1
𝑛𝑔ℎ
∑ 𝒇𝒈𝒉𝒊
𝑛𝑔ℎ
𝑖=1 = (𝒑𝒈𝒉
′ , ?̅?𝒈𝒉
′ )
′
 is the mean of the response-covariable vector.  
 Further, we transform ?̅?𝒈𝒉 to 𝑭𝒈𝒉𝜽 = (𝒒𝒈𝒉𝜽
′  , ?̅?𝒈𝒉
′ )
′
, then 𝑭𝒈𝒉𝜽 =
(𝑨𝟑 𝐞𝐱𝐩[𝑨𝟐 𝐥𝐨𝐠(𝑨𝟏𝜽𝒑𝒈𝒉)] , ?̅?𝒈𝒉
′ )
′
.  
 Also, we denote 𝒖 = ∑ 𝑤ℎ(?̅?1ℎ − ?̅?2ℎ)
𝐻
ℎ=1  as the covariable difference weighted across 
the 𝐻 strata and combine the J treatment differences and 𝑀 covariable difference to get 𝑮𝜽 =
(?̂?𝜃
′ , 𝒖′)
′
.  
 The consistent covariance matrix estimator 𝑽?̅?𝒈𝒉 of ?̅?𝒈𝒉 can be obtained as in (2.16).  
𝑽?̅?𝒈𝒉 =
1
𝑛𝑔ℎ(𝑛𝑔ℎ − 1)
∑(𝒇𝒈𝒉𝒊−?̅?𝒈𝒉)(𝒇𝒈𝒉𝒊−?̅?𝒈𝒉)′ 
𝑛𝑔ℎ
𝑖=1
    (2.16) 
 And then the covariance matrix 𝑉𝐹𝑔ℎ𝜃 of 𝐹𝑔ℎ𝜃 and 𝑉𝐺𝜃 of 𝐺𝜃 can be obtained as (2.17) 
and (2.18).  
𝑽𝑭𝒈𝒉𝜽 = [
𝑩𝒈𝒉𝜽 𝟎𝑱,𝑴 
𝟎𝑴,𝟑𝑱 𝑰𝑴
] 𝑽?̅?𝒈𝒉 [
𝑩𝒈𝒉𝜽
′ 𝟎𝟑𝑱,𝑴 
𝟎𝑴,𝑱 𝑰𝑴
]                (2.17) 
38 
  
𝑽𝑮𝜽 = ∑ 𝑤ℎ
2(𝑽𝑭𝟏𝒉𝜽 + 𝑽𝑭𝟐𝒉𝜽)
𝐻
ℎ=1
          (2.18) 
 Then the differences between means for covariables for the two treatment groups are 
restricted to zero, as is expected by randomization of patients to the two treatments; this 
constraint can be expressed as shown in (2.19).  
𝑬(𝒖) = 𝟎𝑴      (2.19) 
 Randomization-based covariable adjustment for the treatment comparison estimator 𝒅𝜃 
with respect to 𝒖 can be invoked by fitting the linear model in (2.20) by weighted least squares  
𝐸(𝑮𝜽) ≜ [
𝐼𝐽
0𝑀,𝐽
] 𝒃𝜽 = 𝒁𝒃𝜽 =
(
 
 
 
𝒃1𝜃
⋮
 𝒃𝐽𝜃
0
⋮
0 )
 
 
 
             (2.20) 
regression with weights based on 𝑉𝐺𝜃
−1 in (2.18) and with “≜” meaning “is estimated by.” 
 The weighted least squares regression for the specification in (2.20) produces the 
estimator for the covariable-adjusted treatment comparisons 𝒃𝜽 in (2.21), with a consistent 
estimator for the covariance matrix of 𝒃𝜽, as in (2.22). 
𝒃𝜽 = (𝒁
′𝑽𝑮𝜽
−𝟏𝒁)
−𝟏
𝒁′𝑽𝑮𝜽
−𝟏𝑮𝜽               (2.21) 
𝑽𝒃𝜽 = (𝒁
′𝑽𝑮𝜽
−𝟏𝒁)
−𝟏
                   (2.22) 
Hypothesis Testing  
 For testing 𝐻0: 𝑪𝚫 = 0, the test statistic in (2.23) is applicable where ?̂? is the  
𝑄𝑪𝚫 = ?̂?
′𝑪′(𝑪𝑽?̂?𝑪
′)−𝟏𝑪?̂?    (2.23) 
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corresponding estimator 𝒅𝜽 or covariable-adjusted estimator 𝒃𝜽, and  𝑪 is the desired full rank 
contrast matrix with rank 𝑟(𝑪). Under 𝐻0,  𝑄𝑪𝚫~𝜒𝑟(𝑪)
2  when the sample size is sufficiently large, 
where 𝜒𝑟(𝑪)
2 is the central Chi-square distribution with 𝒓(𝑪) degrees of freedom.  
 Example 
 The proposed method for sensitivity analysis is illustrated with an example of a double-
blind, randomized, placebo-controlled, parallel-group study to assess the safety and efficacy of a 
test medicine for weight loss in obese patients. The sample data consist of 1000 patients in a 
bootstrap sample from an obesity trial like that discussed in Smith et al. (2010).  
 One of the co-primary endpoints of this weight loss study is the proportion (%) of 
patients who achieve ≥5% weight loss from baseline to week 52. The study participants were 
followed every 4 weeks until the end of the study. The primary assessment was body weight at 
Week 52, and other important assessment visits were at Week 12, Week 24, and Week 36. These 
4 visits are numbered Visits 1 to 4 in chronological order. 
 Substantial numbers of patients withdrew from the study and didn't return for follow up. 
In this bootstrap sample, at Week 52, 45.5% and 53.1% of patients had missing responses for the 
test and placebo group respectively; at all visits, more missingness happened in the placebo 
group than in the test group, as shown in Table 2.3.  
Table 2.3 Missing Percentages of Assessment Visits 
             Visit 
Group 
1 2 3 4 
Test 10.9% 28.8% 38.5% 45.5% 
Placebo 21.8% 34.2% 43.2% 53.1% 
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 Two strata according to gender were considered; and baseline weight, age, and baseline 
body mass index (BMI) were covariables with adjustment through randomization-based 
ANCOVA as discussed in Section 2.2.6.  
 One question of regulatory interest for this example is whether there are 15% or more 
responders for test treatment than placebo. If missing responses cannot be assumed to be 
ignorable, how robust the results are if challenged by a sequence of sensitivity parameters 𝜃 is a 
question of interest.  
 The hypotheses are 𝐻0𝑗: 𝑰𝒋,𝟒𝚫 ≤ 15% versus 𝐻𝐴𝑗: 𝑰𝒋,𝟒𝚫 > 15% for 𝑗 = 1, 2, 3, 4 of the 4 
visits, where 𝑰𝒋,𝟒 denote the 𝑗
𝑡ℎ row of the identity matrix 𝑰𝟒, and it will be addressed with the 
direct treatment difference estimator and the covariables-adjusted treatment difference estimator 
respectively. For sequential testing to address multiplicity, the primary assessment Visit 4 𝐻04 
would be addressed as a first step with two-sided hypothesis testing at the 𝛼 = 0.05 level, and if 
significant, 𝐻03 would be addressed, etc. 
 The methodology can accommodate different sensitivity parameters for different visits, 
strata and treatment groups. But for convenience of illustration, we only consider different 
sensitivity parameters for the test and placebo treatment, and assume 𝜃𝑔ℎ𝑗 = 𝜃𝑔 for 𝑔 = 1,2 for 
test medicine and placebo groups, ℎ = 1, 2 for females and males, 𝑗 = 1, 2, 3, 4 for visits 1 to 4. 
For the placebo group, one would typically use 𝜃2 = 1, which could be a realistic assumption 
since patients would usually experience similar results as if they remained in the placebo group. 
The values of 𝜃1 ≤ 1 for the test medicine group could address the assumptions that the post-
withdrawal experience of a test drug patient was less favorable than for a patient remaining in the 
study. As a tipping point analyses, we use a sequence of 𝜃1 values to see under what assumptions 
the result of rejection of the null hypothesis would remain unchanged (at the two-sided 
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significance level of 0.05), although the attention can additionally be given to the point estimate 
and confidence interval. The estimates of unadjusted and adjusted treatment differences, and 
their standard errors (SE), and the Chi-Square values and corresponding p-values of the testing 
for the hypothesis 𝐻0 above are listed in Table 2.4.  
Table 2.4 Results of Sensitivity Analyses for Treatment Comparison Estimators 
Sensitivity 
parameter 𝜃 
Visit 
Unadjusted Adjusted 
𝑑 SE ChiSq p value 𝑏 SE ChiSq p value 
𝜃1 = 1 1 0.266 0.0309 14.007 0.0002 0.266 0.0306 14.235 0.0002 
 2 0.339 0.0358 27.825 <0.0001 0.341 0.0353 29.354 <0.0001 
 3 0.331 0.0390 21.466 <0.0001 0.333 0.0384 22.611 <0.0001 
 4 0.313 0.0424 14.817 0.0001 0.315 0.0418 15.496 0.0001 
𝜃1 = 0.5 1 0.248 0.0306 10.146 0.0014 0.247 0.0304 10.231 0.0014 
 2 0.294 0.0362 15.880 0.0001 0.296 0.0356 16.797 <0.0001 
 3 0.272 0.0398 9.312 0.0023 0.273 0.0391 9.880 0.0017 
 4 0.241 0.0434 4.387 0.0362 0.242 0.0427 4.634 0.0313 
𝜃1 = 1/3 1 0.239 0.0304 8.547 0.0035 0.238 0.0302 8.571 0.0034 
 2 0.269 0.0361 10.851 0.0010 0.270 0.0355 11.478 0.0007 
 3 0.237 0.0398 4.742 0.0294 0.238 0.0390 5.056 0.0245 
 4 0.198 0.0431 1.255 0.2627 0.199 0.0423 1.342 0.2467 
Note: 𝜃2 = 1 
 
When the missingness is MCAR in either the test group or placebo group with 𝜃1 = 𝜃2 =
1, the conclusion that the test treatment had 15% or more responders than the placebo treatment 
is well supported, at all follow-up visits. As we place more stringent penalties on the missing 
data in the test treatment while keeping the placebo missingness as MCAR, the estimated 
treatment difference becomes smaller, particularly for visits 3 and 4 where missing data are 
much more extensive. At visit 4, when the assumption is made that the test treatment's missing 
response has only (1/3) the odds for favorable outcome as observed responses, the test treatment 
has about 20% more responders than the placebo, with standard error at about 4%, and the 
conclusion of 15% more responders for comparing test to placebo no longer holds. The results of 
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the estimates of the unadjusted difference 𝑑𝜃 and covariable adjusted difference 𝑏𝜃 are similar. 
And the standard errors of the adjusted difference 𝑏𝜃 estimator are only slightly smaller than 
those of the unadjusted 𝑑𝜃. 
 Discussion 
 For situations where MNAR missing dichotomous response data exist for a randomized 
clinical trial, this paper discusses how the mathematical re-distribution of missing responses can 
provide useful sensitivity analyses to address the robustness of treatment comparisons from 
methods with possibly unrealistic assumptions such as MCAR. The tipping point, which is the 
sensitivity parameter that turns a significant result into a nonsignificant one, can be examined to 
see whether it is realistic or not relative to knowledge about the nature of the treatment and 
disorder being studied. Also, the sensitivity analyses are applicable with Mantel-Haenszel 
adjustment for strata and/or covariables through randomization-based ANCOVA. An extension 
of the methods in this paper to an ordered categorical outcome is in Chapter 3.  
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 CHAPTER 3: SENSITIVITY ANALYSIS IN TREATMENT COMPARISON FOR 
MISSING ORDINAL DATA IN MULTIE-VISIT RANDOMIZED CLINICAL TRIAL 
 Introduction 
 The methodology in Chapter 2 is extended to an ordinal outcome with the comparison 
between treatments utilizing the Mann Whitney probability estimator for the ordinal nature of the 
outcome. Section 3.2 will introduce the data set up and the methodology for ordinal data, and 
they will be illustrated with an example in Section 3.3.  
 Methods 
3.2.1 Notation 
 Consider a study comparing a test treatment and a control treatment for an ordinal 
outcome with 𝐾categories and assessments at each of the J visits. For an ordinal outcome with 
missing data, there are (𝐾 + 1) possible responses, with these being the K ordered outcome 
categories plus the missing category. While outcome and response are sometimes 
interchangeable in the literature, here we make a distinction between outcome categories and 
response categories, where the former could only have 𝐾 outcomes and the latter includes 
missing as a category. 
Let 𝑦𝑔𝑖𝑗𝑘 be the indicator variable for the response of subject 𝑖 in group 𝑔 at visit 𝑗 being 
𝑘, where group 𝑔 = 1, 2 index the test treatment and control treatment respectively; subject 𝑖 =
1, 2,⋯ , 𝑛𝑔; visit 𝑗 = 1, 2,⋯ , 𝐽, and response 𝑘 = 1, 2,⋯ , 𝐾, 𝐾 + 1, where 1,… , 𝐾 index the 1 to 
𝐾 outcomes and (𝐾 + 1) indexes missing response respectively. We define a (𝐾 + 1)-
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dimensional vector 𝑌𝑔𝑖𝑗∗ = (𝑦𝑔𝑖11,⋯ , 𝑦𝑔𝑖1𝐾, 𝑦𝑔𝑖1(𝐾+1))′ to combine the (𝐾 + 1) indicators. For 
example, 𝑌111∗ = (0,⋯ ,1,0) means Subject 1 in the test treatment at time point 1 has outcome 
category as 𝐾. Accordingly, we further define a data vector that includes all visits as 𝑌𝑔𝑖∗∗ =
(𝑌𝑔𝑖1∗
′ , ⋯ , 𝑌𝑔𝑖𝐽∗
′ )
′
= (𝑦𝑔𝑖11, ⋯ , 𝑦𝑔𝑖1𝐾, 𝑦𝑔𝑖1(𝐾+1), … , 𝑦𝑔𝑖𝐽1, ⋯ , 𝑦𝑔𝑖𝐽𝐾, 𝑦𝑔𝑖𝐽(𝐾+1))
′
. 
3.2.2 Data Structure 
 For subjects in treatment group 𝑔, the observed data can be arranged in a contingency 
table format as Table 3.1 below. After including missing as a category, the number of subjects at 
each visit is fixed as 𝑛𝑔. 
Table 3.1  Data Structure 
           Response 
Time              
1 ⋯ 𝐾 𝐾 + 1 Total 
1 𝑛𝑔11(𝑝𝑔11) ⋯ 𝑛𝑔1𝐾(𝑝𝑔1𝐾) 𝑛𝑔1(𝐾+1)(𝑝𝑔1(𝐾+1)) 𝑛𝑔 
⋮ ⋮  ⋮ ⋮ 𝑛𝑔 
𝐽 𝑛𝑔𝐽1(𝑝𝑔𝐽1) ⋯ 𝑛𝑔𝐽𝐾(𝑝𝑔𝐽𝐾) 𝑛𝑔𝐽(𝐾+1)(𝑝𝑔𝐽(𝐾+1)) 𝑛𝑔 
 
 The counts vector at row 𝑗 of the table is expressed as 𝒏𝒈𝒋 = (𝑛𝑔𝑗1, ⋯ , 𝑛𝑔ℎ𝑗𝐾 , 𝑛𝑔ℎ𝑗(𝐾+1)), 
which marginally follows a multinomial distribution, 𝒏𝒈𝒋~𝑀𝑢𝑙𝑡𝑖𝑛𝑜𝑚𝑖𝑛𝑎𝑙(𝑛𝑔, 𝝅𝒈𝒋), where 𝝅𝒈𝒋 
is the marginal multinomial probability vector of responses. From the properties of the 
multinomial distribution, the unbiased estimator of the multinomial probability 𝝅𝒈𝒋, is the 
proportion vector at row 𝑗, 𝒑𝑔𝑗 = (𝑝𝑔𝑗1, ⋯ , 𝑝𝑔𝑗𝐾, 𝑝𝑔𝑗(𝐾+1)). Combining across all time points, 
𝒑𝒈 = (𝒑𝒈𝟏
′ , … , 𝒑𝒈𝑱
′ )
′
, and 𝝅𝒈 = (𝝅𝒈𝟏
′ , … , 𝝅𝒈𝑱
′ )
′
. Extensions to allow strata would proceed 
similarly to the methods discussed in Chapter 2 for dichotomous outcomes. An unbiased 
estimator of the covariance matrix of the probability estimator 𝒑𝒈 containing the marginal 
proportions of the correlated multinomial distributions in the rows of Table 3.1 is shown in (3.1). 
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𝑽𝒑𝒈 =
1
𝑛𝑔(𝑛𝑔 − 1)
∑(𝒀𝒈𝒊∗∗ − 𝒑𝒈)(𝒀𝒈𝒊∗∗ − 𝒑𝒈)
′
𝑛𝑔
𝑖=1
            (3.1) 
3.2.3 Multinomial Probability Estimation 
 The objective of the estimation is the distribution of outcomes; and for an ordinal 
outcome, cumulative probabilities are usually considered. Without loss of generality, assume 
lower values of the ordinal outcome are more favorable, i.e., 𝑘 = 1 is the most favorable 
outcome. Under MCAR, the cumulative favorable proportion of the first 𝑙 categories for visit 𝑗 is 
expressed in (3.2).  
∑ 𝑞𝑔𝑗𝑘 =
∑ 𝑝𝑔𝑗𝑘
𝑙
𝑘=1
∑ 𝑝𝑔𝑗𝑘
𝐾
𝑘=1
=
𝑙
𝑘=1
∑ 𝑝𝑔𝑗𝑘
𝑙
𝑘=1
+
∑ 𝑝𝑔𝑗𝑘
𝑙
𝑘=1
∑ 𝑝𝑔𝑗𝑘
𝐾
𝑘=1
 𝑝𝑔𝑗(𝐾+1)       (3.2) 
 As MCAR, (3.2) implies that the probability of each outcome category in the patients 
with missing responses is the same for those with responses observed.  
3.2.4 Sensitivity Analysis 
 For the subsequent discussion, we omit the notation for group 𝑔 for simplicity of 
presentation. Now let 𝑛𝑗1,⋯, 𝑛𝑗𝐾, and 𝑛𝑗(𝐾+1) represent the counts of the 𝐾 ordinal outcome 
categories and the missing responses at visit 𝑗, and 𝑛𝑗1 + ⋯+ 𝑛𝑗𝐾 + 𝑛𝑗(𝐾+1) = 𝑛𝑗. We further 
divide the missing counts 𝑛𝑗(𝐾+1) into the counts of the 𝐾 outcome categories 
𝑛𝑗(𝐾+1)1, ⋯ , 𝑛𝑗(𝐾+1)𝐾, and they represent the counts among the patients with missing status for 
the 𝐾 outcome categories respectively if their missing status did not occur, and so we have the 
data structure as Table 3.2.  
 
47 
  
Table 3.2 Data Structure for Missing Counts Redistribution 
Visit 1 ⋯ 𝐾 Missing Total 
𝑗 𝑛𝑗1 ⋯ 𝑛𝑗𝐾 𝑛𝑗(𝐾+1) = 𝑛𝑗(𝐾+1)1 + ⋯+ 𝑛𝑗(𝐾+1)𝐾 𝑛𝑗  
 The odds ratio comparing the first 𝑙 categories to the last (𝐾 − 𝑙) categories in the 
patients with missing responses versus those with observed responses as shown in (3.3), which 
implies (3.4) for the redistribution to the first l categories combined. 
𝜃𝑗𝑙 =
∑ 𝑛𝑗(𝐾+1)𝑘
𝑙
𝑘=1
∑ 𝑛𝑗(𝐾+1)𝑘
𝐾
𝑘=𝑙+1
  /   
∑ 𝑛𝑗𝑘
𝑙
𝑘=1
∑ 𝑛𝑗𝑘
𝐾
𝑘=𝑙+1
, 𝑙 = 1,⋯ , (𝐾 − 1).         (3.3) 
∑ 𝑛𝑗(𝐾+1)𝑘 =
𝑙
𝑘=1
 
𝜃𝑗𝑙 ∑ 𝑛𝑗𝑘
𝑙
𝑘=1
𝜃𝑗𝑙 ∑ 𝑛𝑗𝑘
𝑙
𝑘=1 + ∑ 𝑛𝑗𝑘
𝐾
𝑘=𝑙+1
 𝑛𝑗(𝐾+1)       (3.4) 
 If 𝜃𝑗𝑙 = 1 for all 𝑙 = 1,⋯ , (𝐾 − 1), an MCAR-like structure applies; if 𝜃𝑗𝑙 > 1, the 
patients with missing status are assumed to be more likely to have better outcome than those 
observed; if 𝜃𝑗𝑙 < 1, the patients with missing status are assumed to be more likely to have worse 
outcome  Furthermore, if 𝜃𝑗1 = ⋯ = 𝜃𝑗(𝐾−1), 𝐾 ≥ 2, a proportional odds assumption is imposed. 
 Through adjusting for different 𝜃, different specifications of the possible outcomes in the 
missing observations could be attained, and thus we call 𝜃 the sensitivity parameter for 
missingness. The adjusted cumulative proportion estimator could be expressed in terms of the 
unadjusted proportions 𝒑 and 𝜃𝑗𝑙  as shown in (3.5).  
∑ 𝑞𝑗𝑘𝜃
𝑙
𝑘=1
=
∑ 𝑛𝑗𝑘
𝑙
𝑘=1 + ∑ 𝑛𝑗(𝐾+1)𝑘
𝑙
𝑘=1
𝑛𝑗
=
1
𝑛𝑗
(∑ 𝑛𝑗𝑘
𝑙
𝑘=1
+
𝜃𝑗𝑙 ∑ 𝑛𝑗𝑘
𝑙
𝑘=1
𝜃𝑗𝑙 ∑ 𝑛𝑗𝑘
𝑙
𝑘=1 + ∑ 𝑛𝑗𝑘
𝐾
𝑘=𝑙+1
 𝑛𝑗(𝐾+1) ) 
= ∑ 𝑝𝑗𝑘
𝑙
𝑘=1
+
𝜃𝑗𝑙 ∑ 𝑝𝑗𝑘
𝑙
𝑘=1
𝜃𝑗𝑙 ∑ 𝑝𝑗𝑘
𝑙
𝑘=1 + ∑ 𝑝𝑗𝑘
𝐾
𝑘=𝑙+1
 𝑝𝑗(𝐾+1),      𝑙 = 1,⋯ , (𝐾 − 1)        (3.5) 
𝑞𝑗𝐾𝜃 = 1 − ∑ 𝑞𝑗𝑘𝜃
(𝐾−1)
𝑘=1
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 Now we consider group 𝑔, and we express the adjusted cumulative proportion vector 
𝒒𝒈𝜽 = (𝒒𝒈𝟏𝜽
′ , … , 𝒒𝒈𝑱𝜽
′ )
′
 with 𝒒𝒈𝒋𝜽 = (𝑞𝑔𝑗1𝜃, … , 𝑞𝑔𝑗𝐾𝜃)
′
in the form of compound functions of the 
unadjusted proportion vector 𝒑𝒈 and sensitivity parameters 𝜽 as shown in (3.6) in order to use  
𝒒𝒈𝜽 = 𝑨𝟒𝑨𝟑𝒆𝒙𝒑[𝑨𝟐 𝒍𝒐𝒈(𝑨𝟏𝒈𝜽𝒑𝒈)] + 𝒄                                  (3.6) 
linear Taylor series methods to produce a consistent estimator for the corresponding matrix. For 
(3.6), matrices 𝑨𝟏𝒈𝜽, 𝑨𝟐, 𝑨𝟑, and 𝑨𝟒, and (𝐽𝐾 × 1) vector 𝒄 are shown in (3.7) and (3.8).  
𝑨𝟏𝒈𝜽 = 𝒃𝒅𝒊𝒂𝒈𝑱(𝑨𝟏𝒈𝒋𝜽)                           
𝑨𝟏𝒈𝒋𝜽 = 
[
 
 
 
𝑨𝟏𝒈𝒋𝟏𝜽
𝑨𝟏𝒈𝒋𝟐𝜽
⋮
𝑨𝟏𝒈𝒋(𝑲−𝟏)𝜽]
 
 
 
3(𝐾−1)×(𝐾+1)
                    (3.7) 
𝑨𝟏𝒈𝒋𝒌𝜽 = (
𝟏𝒌
′  𝟎𝑲−𝒌
′ 0 
 𝜽𝒈𝒋𝒌𝟏𝒌
′  𝟏𝑲−𝒌
′ 0
𝟎𝒌
′ 𝟎𝑲−𝒌
′  𝜃𝑔𝑗𝑘
)
3×(𝐾+1)
, 𝑘 = 1,⋯ , (𝐾 − 1). 
 
𝑨2 = 𝒃𝒅𝒊𝒂𝒈𝑱 {𝒃𝒅𝒊𝒂𝒈(𝑲−𝟏) (
1 0 0
1 − 1 1
) }                      (3.8) 
𝑨3 = 𝒃𝒅𝒊𝒂𝒈𝑱{𝒃𝒅𝒊𝒂𝒈(𝑲−𝟏)(1 1) }  
𝑨𝟒 = 𝒃𝒅𝒊𝒂𝒈𝑱
(
  
 
10 00 00
−11 00 00
0 − 1 10 00
⋮ ⋯ ⋯⋯ ⋯ ⋮
00 00 − 11
00 00 0 − 1)
  
 
𝐾×(𝐾−1)
    
𝒄 = (0, 0, … , 0, 1, … ,… ,… , 0, 0, … , 0, 1)(𝐽𝐾×1)
′  
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 By applying linear Taylor series, we can obtain a consistent estimator for the covariance 
matrix of 𝒒𝒈𝜽 as shown in (3.9) and (3.10) where 𝑩1𝑔𝜃 is the elementwise first partial derivative 
𝑽𝒒𝒈𝜽 = 𝑩1𝑔𝜃𝑽𝒑𝒈𝑩1𝑔𝜃
′          (3.9) 
𝑩𝟏𝒈𝜽 =
𝝏𝒒𝒈𝜽
𝝏𝒑𝒈
=
𝝏𝒒𝒈𝜽
𝝏𝒂𝟑𝜽
 
𝝏𝒂𝟑𝜽
𝝏𝒂𝟐𝜽
  
𝝏𝒂𝟐𝜽
𝝏𝒂𝟏𝜽
 
𝝏𝒂𝟏𝜽
𝝏𝒑𝒈
= 𝑨𝟒𝑨𝟑𝑫𝒂𝟑𝜽𝑨𝟐𝑫𝒂𝟏𝜽
−𝟏 𝑨𝟏𝒈𝜽   (3.10) 
of vector 𝒒𝒈𝜽 with respect to vector 𝒑𝒈 and is obtained by the chain rule, with 𝒂𝟏𝐠𝜽 = 𝑨𝟏𝐠𝜽𝒑𝒈, 
𝒂𝟐𝐠𝜽 = 𝐥𝐨𝐠 (𝒂𝟏𝐠𝜽), 𝒂𝟑𝐠𝜽 = 𝐞𝐱𝐩 [𝑨𝟐𝒂𝟐𝐠𝜽], and 𝒒𝒈𝜽 = (𝑨𝟒𝑨𝟑𝒂𝟑𝐠𝜽 + 𝒄), and 𝑫𝒂𝟏𝐠𝜽
−𝟏   is a diagonal 
matrix with the reciprocals of the elements of the vector 𝒂1g𝜃 on the main diagonal and 𝑫𝒂𝟑𝐠𝜽  is 
the diagonal matrix with the elements of the vector 𝒂𝟑𝐠𝜽 on the main diagonal. 
 Typically, if we assume 𝜃𝑔𝑗𝑘 are the same for all categories 𝑘, i.e., 𝜃𝑔𝑗𝑘 = 𝜃𝑔𝑗, and they 
could vary at different visits 𝑗 and 𝑗′, and so a proportional odds assumption is made. In addition, 
one often could expect missing responses for patients in the placebo group to have a similar 
outcome distribution as the observed patients, which means 𝜃2𝑗𝑘 = 1 for any visit 𝑗 in the 
placebo group could be specified. 
3.2.5 Treatment Comparison 
Mann-Whitney Probability for Treatment Difference  
 A Mann-Whitney probability estimator (MW estimator) can be used for the treatment 
comparison for a strictly ordinal outcome. Comparing the outcome of test treatment to placebo, 
the Mann-Whitney probability estimates the probability that a randomly selected patient with the 
test treatment has better outcome than a randomly selected patient with placebo. If the two 
treatments are equally effective, the chance of having a better response for the test treatment 
would be 0.5.  
50 
  
 Denote the Mann-Whitney probability as 𝜉𝑗 for visit 𝑗. The null hypothesis for comparing 
the test treatment with the placebo is 𝐻0𝑗: 𝜉𝑗 < 0.5 versus 𝐻𝐴𝑗: 𝜉𝑗 ≥ 0.5, , 𝑗 = 1,⋯ , 𝐽. 
Denote 𝑇𝑔𝑗 as the outcome for a subject in group 𝑔 at visit 𝑗. If a smaller value of the 
outcome is better, the probability 𝜉𝑗 of test treatment being better than placebo at visit 𝑗 is 
expressed in (3.11). 
Denote 𝑇𝑔𝑗 as the outcome for a subject in group 𝑔 at visit 𝑗. If a smaller value of the 
outcome is better, the probability 𝜉𝑗 of test treatment being better than placebo at visit 𝑗 is 
expressed in (3.11). 
𝜉𝑗 = 𝑃(𝑇1𝑗 ≤ 𝑇2𝑗) = ∑ 𝑃(𝑇1𝑗
𝐾
𝑘=1
= 𝑘) [𝑃(𝑇2𝑗 ≥ 𝑘) −
1
2
𝑃(𝑇2𝑗 = 𝑘)]   (3.11) 
Then the Mann-Whitney probability estimator  𝑟𝑗𝜃 of 𝜉𝑗 at visit 𝑗, for the sensitivity 
analysis is expressed as shown in (3.12).  
𝑟𝑗𝜃 = ∑ 𝑞1𝑗𝑘𝜃(∑𝑞2𝑗𝑘𝜃 −
1
2
𝑞2𝑗𝑘𝜃) 
𝐾
𝑙=𝑘
𝐾
𝑘=1
   (3.12) 
Letting 𝒓𝜽 = (𝑟1𝜃, ⋯ , 𝑟𝐽𝜃)
′
, the Mann-Whitney probability estimator could be expressed 
as the compound function of the proportions 𝒒𝜽 = (𝒒𝟏𝜽
′ , 𝒒𝟐𝜽
′ )′ as shown in (3.13) where matrices 
𝑨𝟓, 𝑨𝟔, and 𝑨𝟕 are defined in (3.14) where 𝑇𝐾 is a 𝐾 × 𝐾 upper triangular matrix with all  
𝒓𝜽 = 𝑨𝟕 𝐞𝐱𝐩[𝑨𝟔 𝒍𝒐𝒈(𝑨𝟓𝒒𝜽)]   (3.13) 
𝑨𝟓 = (
𝑰𝑱𝑲 𝟎𝑱𝑲,𝑱𝑲
𝟎𝑱𝑲,𝑱𝑲 𝒃𝒅𝒊𝒂𝒈𝑱(𝑻𝑲 − 0.5𝑰𝑲)
)
2𝐾𝐽×2𝐾𝐽
, 𝑨𝟔 = (𝑰𝑱𝑲, 𝑰𝑱𝑲)𝐾𝐽×2𝐾𝐽, 𝑨𝟕
= 𝒃𝒅𝒊𝒂𝒈𝑱(𝟏𝑲
′  )𝐽×𝐾𝐽   (3.14) 
elements on or below the diagonal equal to 1. 
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We apply the chain rule again in (3.15) to obtain the first partial derivative matrix of  𝜉  
𝑩𝟐𝜽 =
𝝏𝒓𝜽
𝝏𝒒𝜽
= 
𝝏𝒓
𝝏𝒂𝟔
𝝏𝒂𝟔
𝝏𝒂𝟓
𝝏𝒂𝟓
𝝏𝒂𝟒
𝝏𝒂𝟒
𝝏𝒒𝜽
= 𝑨𝟕𝑫𝒂𝟔𝑨𝟔 𝑫𝒂𝟒
−𝟏𝑨𝟓           (3.15) 
with respect to 𝒒𝜽 with 𝒂𝟒𝜽 = 𝑨𝟓𝒒𝜽, 𝒂𝟓𝜽 = 𝐥𝐨𝐠(𝒂𝟒𝜽),𝒂𝟔𝜽 = 𝐞𝐱𝐩[𝑨𝟔𝒂𝟓𝜽], and  𝒓𝜽 = 𝑨𝟕𝒂𝟔𝜽. 
Thus, a consistent estimator for the covariance matrix 𝑽𝒓𝜽 of 𝒓𝜽  is obtained on the basis 
of linear Taylor series approximations, and it is expressed in (3.16) where 𝑽𝒒𝜽 =
𝒃𝒅𝒊𝒂𝒈(𝑽𝒒𝟏𝜽 , 𝑽𝒒𝟐𝜽). 
𝑽𝒓𝜽 = 𝑩𝟐𝜽𝑽𝒒𝜽𝑩𝟐𝜽
′                  (3.16) 
Adjusted Treatment Difference via Randomization-Based ANCOVA 
 In a randomized clinical trial, baseline covariables are expected to have the same 
distributions in the randomized groups. Baseline covariables could include the baseline 
measurements of the outcome, demographic variables, or other variables to be taken into 
account. However, random imbalances in the baseline covariables could occur as each treatment 
group is a finite sample of the randomized population.  
 Covariance adjustment can provide variance reduction in estimation for treatment 
comparisons, together with correction for random imbalances between treatments (Koch et al., 
1998b; Tangen and Koch, 2001; LaVange et al., 2005). The motivation behind the variance 
reduction is that the parameter estimator that is associated with the imbalance is corrected to 
offset the imbalance in covariables. 
 The estimation is through nonparametric ANCOVA, which is an approach that applies 
weighted least squares methods to evaluate comparisons between treatment group with respect to 
outcome variables and covariables simultaneously (Koch et al., 1998b).  
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 Here, we introduce some notation for the covariables. 
 Suppose each subject has 𝑀 baseline covariables 𝒙𝒈𝒊, 𝒙𝒈𝒉𝒊 = (𝑥𝑔𝑖1, … , 𝑥𝑔𝑖𝑀)
′
, and ?̅?𝒈 =
1
𝑛𝑔ℎ
∑ 𝒙𝒈𝒊
𝑛𝑔ℎ
𝑖=1  is the mean vector of the prespecified covariables. 
 We define 𝒇𝒈𝒊 = (𝒀𝒈𝒊∗∗
′ , 𝒙𝒈𝒊
′ )
′
 as a ((𝐾 + 1) × 𝐽 + 𝑀) dimensional response-covariable 
vector, and  ?̅?𝒈 =
1
𝑛𝑔ℎ
∑ 𝒇𝒈𝒊
𝑛𝑔ℎ
𝑖=1 = (𝒑𝒈
′ , ?̅?𝒈
′ )
′
 is the mean of the responses-covariables.  
 We define a (𝐽 + 𝑀) dimensional vector 𝑮𝜽 = (𝒓𝜽
′ , 𝒖′)′ to include both the treatment 
comparisons 𝒓𝒈𝜽 and the covariable differences 𝒖 = ?̅?𝟏 − ?̅?𝟐. 
 The consistent covariance matrix estimator 𝑽?̅?𝒈 of ?̅?𝒈 can be obtained nonparametrically 
as shown in (3.17). 
 For ?̅? = (𝒑𝟏
′ , ?̅?𝟏, 𝒑𝟐
′ , ?̅?𝟐)
′, we have 𝑽?̅? = 𝒃𝒅𝒊𝒂𝒈(𝑽?̅?𝟏 , 𝑽?̅?𝟐). Also, we let  ?̃? =
(𝒑𝟏
′ , 𝒑𝟐
′ , ?̅?𝟏
′ , 𝒙𝟐
′ )′, and so  ?̃? = 𝑩𝒇?̅? with (3.18), the covariance matrix estimator 𝑽𝑮𝜽 of 𝑮𝜽 can be 
obtained as (3.19) where 𝑩𝟏𝜽 = 𝒃𝒅𝒊𝒂𝒈(𝑩𝟏𝟏𝜽, 𝑩𝟏𝟐𝜽) and 𝑽?̃? = 𝑩𝒇𝑽?̅?𝑩𝒇
′ . 
𝑩𝒇 =
(
 
 
𝑰𝑱(𝑲+𝟏) 𝟎𝑱(𝑲+𝟏),𝑴   𝑶𝑱(𝑲+𝟏),𝑱(𝑲+𝟏) 𝟎𝑱(𝑲+𝟏),𝑴
𝑶𝑱(𝑲+𝟏),𝑱(𝑲+𝟏) 𝟎𝑱(𝑲+𝟏),𝑴 𝑰𝑱(𝑲+𝟏) 𝟎𝑱(𝑲+𝟏),𝑴
𝟎𝑴,𝑱(𝑲+𝟏) 𝑰𝑴 𝟎𝑴,𝑱(𝑲+𝟏) 𝑶𝑴,𝑴
𝟎𝑴,𝑱(𝑲+𝟏) 𝑶𝑴,𝑴 𝟎𝑴,𝑱(𝑲+𝟏) 𝑰𝑴 )
 
 
𝟐((𝑲+𝟏)𝑱+𝑴)×𝟐((𝑲+𝟏)𝑱+𝑴)
     (3.18) 
𝑽𝑮𝜽 = [
𝑩𝟐𝜽 𝑩𝟏𝜽 𝟎𝑱,𝑴 𝟎𝑱,𝑴
 𝟎𝟐𝑱,𝑴 𝑰𝑴 −𝑰𝑴
]𝑽?̅? [
𝑩𝟐𝜽𝑩𝟏𝜽 𝟎𝑱,𝑴 𝟎𝑱,𝑴
 𝟎𝟐𝑱,𝑴 𝑰𝑴 −𝑰𝑴
]
′
                         (3.19) 
 Weighted least squares regression can be applied to 𝑮𝜽 so as to account for the 
constraints for the expected differences of means for covariables between the two treatment 
groups to be zero on the basis of randomization of patients to the two treatments; such 
constraints are expressed in (3.20). 
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𝑬(𝒖) = 𝟎𝑴      (3.20) 
 Randomization-based covariable adjustment for the treatment comparison estimator 𝒓𝜽 
with respect to 𝒖 can be invoked by fitting the linear model in (3.21) by weighted least squares 
𝐸(𝑮𝜽) ≜ [
𝑰𝑱
𝟎𝑴,𝑱
] 𝒃 = 𝒁𝒃 =
(
 
 
 
𝒃1
⋮
 𝒃𝐽
0
⋮
0 )
 
 
 
             (3.21) 
regression with weights based from 𝑽𝑮𝜽
−𝟏 in (3.19) and with “≜” meaning “is estimated by.” 
The weighted least squares regression yields the estimator 𝒃𝜽 in (3.22) for the  
𝒃𝜽 = (𝒁
′𝑽𝑮𝜽
−𝟏𝒁)
−𝟏
𝒁′𝑽𝑮𝜽
−𝟏𝑮𝜽               (3.22) 
covariable-adjusted treatment comparisons, and the consistent estimator for the covariance 
matrix of 𝒃𝜽 is 𝑽𝒃𝜽 in (3.23). 
𝑽𝒃𝜽 = (𝒁
′𝑽𝑮𝜽
−𝟏𝒁)
−𝟏
                   (3.23) 
Hypothesis Testing 
 For the hypothesis 𝐻0: 𝑪𝛏 = 𝟎, we have the test statistic in (3.24) where ?̂? is the  
𝑄𝑪𝛏 = ?̂?
′𝑪′(𝑪𝑽?̂?𝑪
′)
−𝟏
𝑪?̂?    (3.24) 
corresponding treatment comparison estimator  𝒓𝜽 or covariable-adjusted estimator 𝒃𝜽 of the 
Mann Whitney criteria 𝝃, and  𝑪 is the specified contrast matrix. Under 𝐻0,  𝑄𝑪𝛏~𝜒𝑟𝑎𝑛𝑘(𝑪)
2  when 
the sample size is sufficiently large, where 𝜒𝑟𝑎𝑛𝑘(𝑪)
2 is the central Chi-square distribution with 
𝑟𝑎𝑛𝑘(𝑪) degrees of freedom, and 𝑟𝑎𝑛𝑘(𝑪) is the rank of the full rank contrast matrix 𝑪.  
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 Example 
 The proposed method is illustrated with an example based on an adaptation of data in 
Stanish et al [1978]. The clinical trial was to evaluate the efficacy of a new drug relative to 
placebo for skin conditions. 
 One of the endpoints for this skin condition study is disease condition improvement from 
baseline at visit 3. The study participants were followed for 3 visits and the ordinal outcome is 
1=Rapidly Improving, 2=Slowly Improving, 3=Stable, 4=Slowly Worsening, 5=Rapidly 
worsening. 
 The study had three visits. Sample sizes were 88 (test) and 84 (placebo) respectively. The 
missing data count in each visit is shown in Table 3.3. 
Table 3.3 Missing Counts of Assessment Visits 
             Visit 
Group 
1 2 3 
Test 2 9 15 
Placebo 1 7 15 
 The question of interest is whether patients in the test treatment improved more than 
those in the placebo treatment. If the loss to follow-up cannot be assumed to be ignorable, the 
robustness of the results to challening by a sequence of sensitivity parameters 𝜃 is of interest.  
The hypotheses are 𝐻0𝑗: 𝑰𝒋,𝟑𝛏 ≤ 0.5 versus 𝐻𝐴𝑗: 𝑰𝒋,𝟑𝛏 > 0.5 for 𝑗 = 1, 2, 3 of the 3 visits, 
where 𝑰𝒋,𝟑 denotes the 𝑗
𝑡ℎ row of the identity matrix 𝑰𝟑, and it will be addressed with the direct 
treatment comparison estimator and the covariable adjusted treatment comparison estimator 
respectively. For sequential testing, the primary assessment Visit 3 for 𝐻03 would be addressed 
as a first step with two-sided 𝛼 = 0.05, and if significant, 𝐻02 would be addressed, etc. 
              The methodology can accommodate different sensitivity parameters for different visits 
and treatment groups and different specifications for the odds among the ordinal categories. But 
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for convenience of illustration, we only consider different sensitivity parameters for the test and 
placebo treatment with the proportional odds assumption, and specify 𝜃𝑔ℎ𝑗 = 𝜃𝑔 for 𝑔 = 1,2 for 
test and placebo groups and 𝑗 = 1, 2, 3 for visits 1 to 3. For the placebo group, one would 
typically use 𝜃2 = 1, which could be a realistic assumption if patients with missing outcomes 
would usually experience similar results as if they remained in the placebo group. The values of 
𝜃1 ≤ 1 for the test group could address the specifications that the post-withdrawal experience of 
a test drug patient was less favorable than patients with observed outcomes.  
               As a tipping point analysis, we use a sequence of 𝜃1 values to see under what 
specifications the result of rejection of the null hypothesis would remain unchanged (at the two 
sided significance level of 0.05). The estimates for unadjusted and adjusted treatment 
comparisons, and their standard errors (SE), and the chi-square values and corresponding p 
values of the testing for the hypothesis 𝐻0 above are listed in Table 3.4. 
When the loss to follow-up is MCAR in either the test group or the placebo group with 
𝜃1 = 𝜃2 = 1, the conclusion that the test treatment is better than the placebo treatment is well 
supported at the primary assessment visit (Visit 3), but not so significant at Visits 2 and 1. As we 
place more stringent penalties on the missing data for the test treatment while keeping the 
placebo missingness as MCAR, the estimator for the treatment comparison becomes closer to 
0.5. At Visit 3, when the specification is made that the odds for missing outcomes is only (1/3) as 
good as for observed outcomes for the test treatment, the probability for test being better than 
placebo is 0.589 with a standard error at about 0.047, and the conclusion that the test treatment is 
better than the placebo no longer holds. 
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The results of the estimates for the unadjusted comparisons 𝒓𝜽 and the covariable 
adjusted comparisons 𝒃𝜽 are similar. And the standard errors of the adjusted comparison 𝒃𝜽 are 
only slightly smaller than those of the unadjusted 𝒓𝜽. 
Table 3.4 Results of Sensitivity Analyses 
Sensitivity 
parameter 
𝜃 
Visit 
Unadjusted Adjusted 
𝑟 SE 
Chi-
Sq 
p 
value 
𝑏 SE 
Chi-
Sq 
p 
value 
𝜃1 = 1 1 0.565 0.0429 2.294 0.130 0.562 0.0426 2.121 0.145 
 2 0.581 0.0449 3.294 0.070 0.580 0.0448 3.171 0.075 
 3 0.614 0.0457 6.249 0.012 0.615 0.0457 6.272 0.012 
𝜃1 = 0.5 1 0.563 0.0429 2.128 0.145 0.560 0.0427 1.960 0.162 
 2 0.570 0.0452 2.409 0.121 0.568 0.0451 2.276 0.131 
 3 0.598 0.0464 4.490 0.034 0.598 0.0464 4.473 0.034 
𝜃1 = 1/3 1 0.561 0.0429 2.038 0.153 0.558 0.0427 1.872 0.171 
 2 0.563 0.0453 1.952 0.162 0.561 0.0452 1.818 0.178 
 3 0.589 0.0467 3.597 0.058 0.588 0.0467 3.564 0.059 
Note: 𝜃2 = 1 
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 CHAPTER 4: RANDOMIZATION-BASED ANCOVA FOR HYPOTHESES TESTING IN 
THE SEQUENTIAL PARALLEL COMPARISON DESIGN (SPCD) 
 Introduction 
 Crossover designs have been utilized in addition to the gold standard randomized 
parallel-group placebo-controlled trial for the assessment of efficacy for drugs intended for 
regulatory submission. There are many possible designs of crossover studies, depending on the 
number of treatments to compare, the number of periods of each treatment, and the aim of the 
trials (Jones and Kenward, 2014b). 
There are several benefits of crossover designs compared to the traditional parallel-group 
trial. One of them is that the power of the treatment comparison is improved at a fixed sample 
size, mainly because every subject provides multiple response measurements of the outcome in 
the multiple periods. Another feature is that its use could reduce the dropout rates, at least for the 
first period, because the subjects in the placebo group could expect a treatment no worse than the 
first period if they continue (Koch, Davis and Anderson, 1998a). For example, Pincus et al. 
(2001) performed a randomized crossover trial of the experimental drug versus active control in 
ambulatory patients with osteoarthritis of the hip or knee and achieved a low dropout rate for the 
first period. Of the 227 enrolled patients, 218 (96.0%) patients provided data for the first 
treatment period and 181 (79.7%) provided data for both treatment periods.   
With a two-period design comparing test treatment (T) to placebo treatment (P), four 
sequence groups P:P, P:T, T:P, and T:T could be of interest. Designs with some combination of 
those sequence groups have useful features for studies of different patient populations. Also,
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other extensions of crossover designs with this structure could be achieved with other added 
design features such as enrichment. Designs with a crossover structure are in the general class of 
re-randomization designs, for which subjects could be re-randomized at the start of the second 
period. Alternatively, rather than re-randomization at the beginning of the second period, 
randomization before the first period could be performed to produce the multiple randomized 
sequences.  
One of the popular crossover designs with the enriched feature is the randomized 
withdrawal design with the T:P and T:T sequence groups, and it focuses on only the patients who 
respond to the drug in the first period and continue to the second period. This design is helpful 
when there is heterogeneity in the patient population itself to respond to a treatment (Dunger-
Baldauf et al., 2006; Dunger-Baldauf, 2007).  
The P:P and P:T design, usually known as the placebo lead-in design, has the other two 
sequence groups in contrast to the randomized withdrawal design. In this design, only the 
patients who do not respond to placebo in the first period continue to the second period in the 
study. This design is practical in studies to treat disorders in the central nerve system, where 
there are many placebo responders (Fava et al., 2003). The placebo response rate in 
antidepressant and antipsychotic trials has been reported to increase over time in meta analyses 
of trials between 1985 and 2000 (Khan et al., 2005). With only the placebo nonresponders 
identified in the first period continuing in the second period to receive either experimental 
treatment or placebo, the treatment effect is maximized since patients who do not respond to the 
first period are not expected to become placebo-responders in the second period (Fava et al., 
2003). 
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The design of interest for this paper is the one with three sequence groups, P:P, P:T, and 
T:T, and it is sometimes known as the sequential parallel comparison design (SPCD) (Fava et al., 
2003).  Another popular design that has these three sequence groups is the randomized delayed-
start design (RDSD), which is useful to evaluate treatments for disease with long term 
progression by distinguishing the symptomatic improvement from the true disease modifying 
effect (Dunger-Baldauf et al., 2006). The SPCD, with the P:P, P:T, and T:T sequences, serves 
similar purposes as the two-sequence placebo lead-in design in psychiatric clinical trials with 
high placebo response, except that it has an additional T:T sequence, which can be useful for 
masking the treatment in the first period, reducing the dropout rate during the first period, and 
enabling a treatment comparison during the first period.  
The original paper by Fava et al. (2003) focused on a dichotomized outcome for a study; 
and other methods have been proposed for the analysis of dichotomous outcomes in the context 
of SPCD designs by Huang and Tamura (2010, 2011), and Huang, Tamura, and Boos (2011). 
Recent uses of the SPCD design have extensions to continuous or ordinal outcomes as they arise 
more naturally than the binary outcomes with dichotomization of a continuous measurement. 
Huang and Tamura (2010) considered seemingly unrelated regression (SUR) to account for the 
correlation between subjects in the two periods of the trial. Chen et al (2011) proposed an 
ordinary least squares approach, and Doros et al. (2013) proposed a repeated measures model 
that more extensively includes the outcome data collected in the trial. 
In this paper, we consider sources of information for the comparison between a test 
treatment and placebo that are provided in the traditional SPCD design, i.e., the first period 
treatment difference in the overall population and the second period treatment difference in the 
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placebo non-responders; and we also evaluate the potential role of other sources of information 
that are available in this design and that could be of potential interest.  
For the analysis of the SPCD design with scope for outcomes in both placebo non-
responders and responders, we propose in Section 4.2 a hypothesis testing method based on the 
randomization distribution of the observed population using the randomization-based mean and 
variance estimates under the null hypothesis to control Type I error. Further, with this method, 
adjustment is possible for covariables at baseline for all patients and at the beginning of the 
second period for patients in the P:P and P:T groups so as to produce variance reduction and to 
eliminate random imbalances for the covariables. In this regard, we introduce a randomization-
based ANCOVA as opposed to a traditional model-based ANCOVA (Koch et al. 1998). In 
Section 4.3, we report results from simulation studies for the statistical properties of the proposed 
methods, and we compare their performance with applicable counterparts from the repeated 
measures model of Doros et al. (2013). A hypothetical study with the three SPCD sequence 
groups is provided to illustrate the use of the method. 
 Methods 
 For a randomized clinical trial to compare a test treatment T to placebo P during two 
periods for patients with a chronic (or recurrent) disorder, such as osteoarthritis (or migraine 
headache), let 𝑖 = 1, 2, 3 index P:P, P:T, T:T as the sequence groups for the two treatments in the 
two periods; and let 𝑘 = 1, 2, … , 𝑛 index the population of patients who are eligible for inclusion 
in the clinical trial and who are randomly assigned to the three sequence groups. In this regard, 
let 𝑈𝑖𝑘 denote a random variable which has the value 1 for the assignment of the k-th patient to 
the i-th group and the value 0 otherwise. The specification for the {𝑈𝑖𝑘} has 𝑛𝑖 patients randomly 
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assigned to the i-th group according to simple random sampling without replacement. Thus, the 
{𝑈𝑖𝑘} have the expected values and covariance structure shown in (4.1).  
𝐸{𝑈𝑖𝑘} = 𝑃𝑟{𝑈𝑖𝑘 = 1} = (𝑛𝑖 𝑛⁄ ) for all 𝑖, 𝑘 
𝑉𝑎𝑟{𝑈𝑖𝑘} = 𝑛𝑖(𝑛 − 𝑛𝑖) 𝑛
2⁄  for all 𝑖, 𝑘 
𝐶𝑜𝑣{𝑈𝑖𝑘, 𝑈𝑖′𝑘′} = {[𝑃𝑟(𝑈𝑖𝑘 = 𝑈𝑖′𝑘′ = 1)] − Pr(𝑈𝑖𝑘 = 1)Pr(𝑈𝑖′𝑘′ = 1)}                    (4.1) 
= 0 −
𝑛𝑖𝑛𝑖′
𝑛2
= −
𝑛𝑖𝑛𝑖′
𝑛2
 for 𝑖 ≠ 𝑖′and 𝑘 = 𝑘′ 
=
𝑛𝑖(𝑛𝑖 − 1)
𝑛(𝑛 − 1)
−
𝑛𝑖
2
𝑛2
= −
𝑛𝑖(𝑛 − 𝑛𝑖)
𝑛2(𝑛 − 1)
 for 𝑖 = 𝑖′with 𝑘 ≠ 𝑘′  
=
𝑛𝑖𝑛𝑖′
𝑛(𝑛 − 1)
−
𝑛𝑖𝑛𝑖′
𝑛2
=
𝑛𝑖𝑛𝑖′
𝑛2(𝑛 − 1)
 for 𝑖 ≠ 𝑖′and 𝑘 ≠ 𝑘′ 
Let 𝑼∗𝑘 = (𝑈1𝑘, 𝑈2𝑘, 𝑈3𝑘)′ and let 𝒏 = (𝑛1, 𝑛2, 𝑛3)′. From (4.1), it then follows that the 
𝑼∗𝑘 have the expected values and covariance structure shown in (4.2) where 𝑫𝒏 is a diagonal 
𝑬{𝑼∗𝑘} = (𝒏 𝑛⁄ ) 
𝑽𝒂𝒓{𝑼∗𝑘} = (𝑛𝑫𝒏 − 𝒏𝒏′) 𝑛
2⁄ = 𝑽𝑼   for all 𝑘                   (4.2)   
𝑪𝒐𝒗{𝑼∗𝑘 , 𝑼∗𝑘′} = −
𝑽𝑼
𝑛 − 1
for all 𝑘 ≠ 𝑘′ 
matrix with diagonal elements 𝒏. 
 Let 𝑗 = 0, 1, 2 index the baseline, period 1, and period 2. Let 𝑦𝑖𝑗𝑘 denote the constant that 
corresponds to the observed response for the k-th patient during the j-th period according to a 
non-negative numeric (or ordinal) scale if their random assignment is to the i-th sequence group. 
Also, 𝑦∗𝑗𝑘 = ∑ 𝑈i𝑘
3
𝑖=1 𝑦𝑖𝑗𝑘 represents the random response of the k-th patient during the j-th 
period with the 𝑈i𝑘 being the basis of its randomness. In this regard, 𝑦10𝑘 = 𝑦20𝑘 = 𝑦30𝑘 = 𝑦∗0𝑘 
since the baseline response for the k-th patient is the same regardless of their randomly assigned 
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group; moreover, 𝑦11𝑘 = 𝑦21𝑘 since the k-th patient receives placebo in period 1 if randomly 
assigned to either the P:P group or the P:T group. Let 𝒚𝑖𝑘 = (𝑦𝑖0𝑘, 𝑦𝑖1𝑘, 𝑦𝑖2𝑘)′ with no missing 
data being assumed for all patients. Under the global null hypothesis 𝐻0 that each patient has the 
same responses for the three periods regardless of their randomly assigned sequence group (and 
thereby their randomly assigned treatment), the specification 𝒚1𝑘 = 𝒚2𝑘 = 𝒚3𝑘 = 𝒚∗𝑘 applies.  
 Let 𝑧𝑖𝑘 be a dichotomous responder variable for period 1 such that 𝑧𝑖𝑘 = 1 if the k-th 
patient has favorable response during period 1 in the sense that (𝑦𝑖1𝑘 ≤ 𝐿) if their random 
assignment is to the i-th group with its corresponding treatment for period 1 versus 𝑧𝑖𝑘 = 0 if 
(𝑦𝑖1𝑘 > 𝐿); alternatively the {𝑧𝑖𝑘} could be based on change (or percent change) from baseline. 
Let 𝑓𝑖𝑗𝑘 = 𝑧𝑖𝑘𝑦𝑖𝑗𝑘 so as to equal 𝑦𝑖𝑗𝑘 for period 𝑗 = 1, 2 for responders in period 1 and be equal 
to 0 for non-responders in period 1; and let 𝑔𝑖𝑘 = (𝑦𝑖2𝑘 − 𝑓𝑖2𝑘) = (1 − 𝑧𝑖𝑘)𝑦𝑖2𝑘 so as to equal 
𝑦𝑖2𝑘 for period 2 for period 1 non-responders and to equal 0 for period 1 responders. Let 𝑭𝑖𝑘 =
(𝑦𝑖0𝑘, 𝑦𝑖1𝑘, 𝑧𝑖𝑘, 𝑓𝑖1𝑘 , 𝑦𝑖2𝑘, 𝑓𝑖2𝑘)
′ with the assumption of no missing data for its components. Under 
𝐻0, 𝑭1𝑘 = 𝑭2𝑘 = 𝑭3𝑘 = 𝑭∗𝑘 applies as a consequence of the 𝒚1𝑘 = 𝒚2𝑘 = 𝒚3𝑘 = 𝒚∗𝑘. Also, 𝑭𝑖𝑘 
could be expanded to include one or more other covariables 𝒙∗0𝑘 at baseline, such as age (in 
addition to 𝑦∗0𝑘); but the presentation is more straightforward and sufficient without this 
extension because the same considerations apply to both 𝑦∗0𝑘 and 𝒙∗0𝑘.  
 Let ?̅?𝑖 = (∑ 𝑈𝑖𝑘𝑭𝑖𝑘 𝑛𝑖⁄
𝑛
𝑘=1 ) = (?̅?𝑖0, ?̅?𝑖1, 𝑧?̅? , 𝑓?̅?1, ?̅?𝑖2, 𝑓?̅?2)′ denote the vector of the means for 
the i-th sequence group. From (4.2), it follows that the randomization distributions of the ?̅?𝑖 have 
expected values and covariance structure as shown in (4.3).  
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𝑬{?̅?𝑖} = (∑ 𝑭𝑖𝑘𝑛𝑖 𝑛𝑖⁄
𝑛
𝑘=1
𝑛) = 𝝁𝑖 
𝑽𝒂𝒓{?̅?𝑖} =
1
𝑛𝑖
2 [∑
𝑛𝑖(𝑛 − 𝑛𝑖)
𝑛2
𝑛
𝑘=1
𝑭𝑖𝑘𝑭𝑖𝑘
′ − ∑
𝑛𝑖(𝑛 − 𝑛𝑖)
𝑛2(𝑛 − 1)
𝑘≠𝑘′
𝑭𝑖𝑘𝑭𝑖𝑘′
′ ] 
=
(𝑛 − 𝑛𝑖)
𝑛𝑖𝑛(𝑛 − 1)
[∑(𝑭𝑖𝑘 − 𝝁𝑖)
𝑛
𝑘=1
(𝑭𝑖𝑘 − 𝝁𝑖)
′]                   
=
(𝑛 − 𝑛𝑖)
𝑛𝑖𝑛
𝑽𝑭𝑖 = (
1
𝑛𝑖
−
1
𝑛
)𝑽𝑭𝑖                                   (4.3) 
𝑪𝒐𝒗{?̅?𝑖, ?̅?𝑖′} =
1
𝑛𝑖𝑛𝑖′
[∑
−𝑛𝑖𝑛𝑖′
𝑛2
𝑛
𝑘=1
𝑭𝑖𝑘𝑭𝑖′𝑘
′ + ∑
𝑛𝑖𝑛𝑖′
𝑛2(𝑛 − 1)
𝑭𝑖𝑘𝑭𝑖′𝑘′ 
′
𝑘≠𝑘′
] 
=
−1
𝑛(𝑛 − 1)
[∑(𝑭𝑖𝑘 − 𝝁𝑖)(𝑭𝑖′𝑘 − 𝝁𝑖′)
𝑛
𝑘=1
] = −
1
𝑛
𝑽𝑭𝑖,𝑭𝑖′  
In (4.3), 𝝁𝑖 is the mean vector for the 𝑭𝑖𝑘 in the finite population of the 𝑛 randomized 
patients and 𝑽𝑭𝑖 is the corresponding finite population covariance matrix. Since 𝑭1𝑘 = 𝑭2𝑘 =
𝑭3𝑘 = 𝑭∗𝑘 = (𝑦∗0𝑘, 𝑦∗1𝑘, 𝑧∗𝑘, 𝑓∗1𝑘, 𝑦∗2𝑘, 𝑓∗2𝑘)
′ under 𝐻0, it follows that (4.3) simplifies to (4.4) 
under 𝐻0.  
𝑬{?̅?𝑖 | 𝐻0} = (∑ 𝑭∗𝑘𝑛𝑖 𝑛𝑖𝑛⁄
𝑛
𝑘=1
) = 𝝁∗0 = (𝜇0, 𝜇10, 𝜇𝑧0 , 𝜇𝑓10 , 𝜇20, 𝜇𝑓20)
′
, 
𝑽𝒂𝒓{?̅?𝑖 | 𝐻0} = (
1
𝑛𝑖
−
1
𝑛
) [∑(𝑭∗𝑘 − 𝝁∗0)(𝑭∗𝑘 − 𝝁∗0)
′
𝑛
𝑘=1
] = (
1
𝑛𝑖
−
1
𝑛
)𝑽𝐹,0,         (4.4) 
𝑪𝒐𝒗{?̅?𝑖, ?̅?𝑖′ | 𝐻0} = −
1
𝑛
𝑽𝐹,0. 
Thus, for ?̅? = (?̅?1
′ , ?̅?2
′ , ?̅?3
′ )′ it follows that 𝑬{?̅? | 𝐻0} = 𝟏3⨂ 𝝁∗0 where 𝟏3 is the (3 x 1) 
vector of 1’s and ⨂ denotes the right Kronecker product for the multiplication of each element of 
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the vector on the left by the vector on the right; and the covariance structure of ?̅? under 𝐻0 is as 
shown in (4.5).  
𝑽?̅?,0 =  𝑽𝒂𝒓{?̅? | 𝐻0} =
[
 
 
 
 
 
 (
1
𝑛1
−
1
𝑛
) −
1
𝑛
−
1
𝑛
−
1
𝑛
(
1
𝑛2
−
1
𝑛
) −
1
𝑛
−
1
𝑛
−
1
𝑛
(
1
𝑛3
−
1
𝑛
)
]
 
 
 
 
 
 
 ⨂ 𝑽𝑭,0           (4.5) 
= [𝑫𝒏
−1 − (𝟏3𝟏3
′ 𝑛)⁄ ] ⨂ 𝑽𝑭,0. 
In this regard, 𝑬{?̅? | 𝐻0} and 𝑽𝒂𝒓{?̅? | 𝐻0} pertain to the randomization distribution of ?̅? 
under 𝐻0 for re-randomizations of the finite population of the 𝑛 randomized patients. Since 𝑽?̅?,0 
is singular through ∑ 𝑛𝑖?̅?𝑖 𝑛⁄
3
𝑖=1 = 𝝁∗0 (or (𝒏
′⨂ 𝑰6) 𝑽?̅? (𝒏 ⨂ 𝑰6) = 𝟎6,6 with 𝟎6,6 being a 
matrix of 0’s), assessment of 𝐻0 with ?̅? is through 𝒂 = 𝑨?̅? as shown in (4.6), and the 
𝒂 = 𝑨?̅? = [
−𝑰6 𝑰6 𝟎6,6
−𝑰6 𝟎6,6 𝑰6
] ?̅? = [
(?̅?2 − ?̅?1)
(?̅?3 − ?̅?1)
]            (4.6). 
corresponding covariance structure of 𝒂 under 𝐻0 is shown in (4.7).  
𝑽𝒂,0 = 𝑉𝑎𝑟{𝒂 | 𝐻0} = 𝑨𝑽?̅?,𝟎𝑨′ =
[
 
 
 (
1
𝑛1
+
1
𝑛2
)
1
𝑛1
1
𝑛1
(
1
𝑛1
+
1
𝑛3
)
]
 
 
 
⨂ 𝑽𝑭,0            (4.7) 
For the assessment of 𝐻0 without adjustment for 𝑦10𝑘 = 𝑦20𝑘 = 𝑦30𝑘, 𝑦11𝑘 = 𝑦21𝑘, 
𝑧1𝑘 = 𝑧2𝑘, and 𝑓11𝑘 = 𝑓21𝑘, the potential comparisons of interest are shown in (4.8), and they are 
linear functions 𝒄 = 𝑪𝒂 = 𝑪𝑨?̅? of 𝒂 with 𝑪 shown in (4.9); also, 𝜇𝑧0 = (∑ 𝑧∗𝑘 𝑛⁄
𝑛
𝑘=1 ), 𝜇𝑓20 =
(∑ 𝑓∗2𝑘 𝑛⁄
𝑛
𝑘=1 ), and 𝜇20 = (∑ 𝑦∗2𝑘 𝑛⁄
𝑛
𝑘=1 ). The rationale for 𝑐3 is that (𝜇𝑧0𝑓?̅?2 − 𝜇𝑓20𝑧?̅?) 𝜇𝑧0
2⁄  for 
𝑖 = 1, 2 is the mean of deviations (𝜇𝑧0𝑓𝑖2𝑘 − 𝜇𝑓20𝑧𝑖𝑘) 𝜇𝑧0
2⁄  which equal 0 when 𝑧𝑖𝑘 = 0, and so 
its behavior is through the (𝑦𝑖2𝑘 − (𝜇𝑓20/𝜇𝑧0)) 𝜇𝑧0⁄  when 𝑧𝑖𝑘 = 1; also, (𝜇𝑧0𝑓?̅?2 − 𝜇𝑓20𝑧?̅?) 𝜇𝑧0
2⁄ =
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(𝑧?̅? 𝜇𝑧0⁄ )[(𝑓?̅?2 𝑧?̅?⁄ ) − (𝜇𝑓20 𝜇𝑧0⁄ )], and so 𝑐3 addresses the difference between the means of period 
2 responders and their population counterparts (𝜇𝑓20 𝜇𝑧0⁄ ) under 𝐻0 in a rescaled linearized way. 
Similar considerations pertain to 𝑐4.  
𝑐1 = {?̅?31 −
𝑛1?̅?11 + 𝑛2?̅?21
(𝑛1 + 𝑛2)
}                                
𝑐2 = (?̅?32 − ?̅?12)                                                                                                          (4.8), 
𝑐3 = {(𝑓2̅2 − 𝑓1̅2) 𝜇𝑧0⁄ } − {𝜇𝑓20(𝑧2̅ − 𝑧1̅) 𝜇𝑧0
2⁄ } 
𝑐4 = {(?̅?22 − 𝑓2̅2 − ?̅?12 + 𝑓1̅2) (1 − 𝜇𝑧0)⁄ } − {(𝜇20 − 𝜇𝑓20)(𝑧1̅ − 𝑧2̅) (1 − 𝜇𝑧0)
2
⁄ } 
𝐶 =
[
 
 
 
 
 
0    −
𝑛2
(𝑛1+𝑛2)
        0         0           0            0               0     1    0     0     0    0
0           0            0            0           0            0              0      0     0     0      1    0
0         0         −
𝜇𝑓20
𝜇𝑧0
2           0           0           
1
𝜇𝑧0
           0     0     0      0       0     0
0        0      
(𝜇20−𝜇𝑓20)
(1−𝜇𝑧0)
2     0    
1
(1−𝜇𝑧0)
    −
1
(1−𝜇𝑧0)
   0     0     0     0    0     0
]
 
 
 
 
 
           (4.9) 
Under 𝐻0, 𝑬{𝒄 | 𝐻0} = 𝟎4; and the covariance structure for 𝒄 under 𝐻0 is 𝑽𝒄,0 = 𝑪𝑽𝒂,0𝑪
′. 
For 𝒄 = (𝑐1, 𝑐2, 𝑐3, 𝑐4)
′, the comparison 𝑐1 pertains to T versus P in period 1; the comparison 𝑐2 
pertains to T:T versus P:P in period 2; the comparison 𝑐3 pertains to P:T versus P:P in period 2 
for responders to placebo in period 1; 𝑐4 pertains to P:T versus P:P in period 2 for non-
responders to placebo in period 1; and both 𝑐3 and 𝑐4 have linearized adjustments for the 
corresponding influences of differences in responder proportions for the P:P and P:T groups. 
Univariate test statistics for 𝐻0, and thereby for the comparison between T and P, can be based 
on weighted linear combinations 𝑐𝑤 = ∑ 𝑤ℎ𝑐ℎ
4
ℎ=1  where 𝒘 = (𝑤1, 𝑤2, 𝑤3, 𝑤4)
′ is a vector of 
weights such that all 𝑤ℎ ≥ 0 and ∑ 𝑤ℎ
4
ℎ=1 = 1. In this regard, all 𝑤ℎ = 0.25 corresponds to 
equal weights and 𝒘𝑖𝑛𝑣 = (𝟏′𝑽𝒄,0
−1𝟏)
−1
𝟏′𝑽𝒄,0
−1 corresponds to inverse covariance matrix weights, 
with the latter being optimal in the sense of minimum variance and potentially statistical power 
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under the alternatives to 𝐻0 whereby the 𝑐ℎ express similar non-null differences between T and 
P. With the weights 𝒘, the test statistic for the global null hypothesis 𝐻0 at the one-sided 
significance level 𝛼 is 𝑇𝑤,𝒄 = 𝒘′𝒄 (𝒘′𝑽𝒄,0𝒘)
0.5
⁄ . Under 𝐻0, 𝑇𝑤,𝒄 approximately has a standard 
normal distribution with mean 0 and variance 1. If the one-sided p-value for 𝑇𝑤,𝒄 significantly 
contradicts 𝐻0 in the sense that p < 𝛼 for some specified type 1 error level, such as 𝛼 = 0.025, 
then the closed testing methods of Lehmacher et al. (1991) can be used to test 𝐻0 for subsets of 
the 𝑐ℎ through counterparts of 𝑇𝑤,𝒄 for weighted averages of subsets of the 𝑐ℎ. In this regard, if 
p < 𝛼 for such test statistics for all subsets that include 𝑐ℎ, then statistical significance applies to 
𝑐ℎ in its own right for contradicting 𝐻0 with strong control of type 1 error for the corresponding 
scope of multiple comparisons. Also, in some situations, a subset of the 𝑐ℎ is of more interest for 
the assessment of 𝐻0 than all components of  𝒄, and so it can be assessed directly in its own right 
with particular cases of interest being 𝑐1 and 𝑐4 for the SPCD design, and perhaps 𝑐1, 𝑐2, and 𝑐4 
for other versions of the crossover design with P:P, P:T, and T:T sequence groups.  
 The constraints 𝒄0 = 𝑪0𝒂 = 𝑪0𝑨?̅? for 𝒂 with null expected values regardless of whether 
𝐻0 applies are shown in (4.10) with 𝑪0 in (4.11).  
𝒄0 =
[
 
 
 
 
 
 
(?̅?20 − ?̅?10)
(?̅?30 − ?̅?10)
(?̅?21 − ?̅?11)
(𝑧2̅ − 𝑧1̅)
{
(𝑓2̅1 − 𝑓1̅1)
𝜇𝑧0
} − {
𝜇𝑓10(𝑧2̅ − 𝑧1̅)
𝜇𝑧0
2
}
]
 
 
 
 
 
 
                    (4.10) 
𝑪0 =
[
 
 
 
 
 
1   0     0       0     0     0     0    0    0   0   0   0
0   0      0        0     0    0   1    0   0    0   0   0
0   1     0        0    0     0    0   0   0   0   0   0
0   0      1        0     0    0   0   0   0   0   0   0
0   0   −
𝜇𝑓10
𝜇𝑧0
2     
1
𝜇𝑧0
   0   0   0   0   0   0   0   0
]
 
 
 
 
 
        (4.11) 
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Let 𝒄+ = [𝒄
′, 𝒄0
′ ]′ = [𝑪′, 𝑪0
′ ]′𝒂 = 𝑪+𝒂 denote the combined set of comparisons 𝒄 
pertaining to 𝐻0 and constraints 𝒄0. Under 𝐻0, the covariance structure for 𝒄+ is 𝑽𝒄+,0 =
𝑪+𝑽𝒂,0𝑪+
′ . Since 𝑬{𝒄0} = 𝟎5 regardless of whether 𝐻0 applies, randomization-based covariance 
adjustment for 𝒄 with respect to the constraints 𝒄0 is invoked by fitting the linear model shown in 
(4.12) by weighted least squares with weights based on 𝑽𝒄+,0
−1 , and with “≜” meaning  
𝑬{𝒄+} ≜ [
𝑰4
𝟎5,4
] 𝒃0 = 𝑿𝒃0                   (4.12) 
“is estimated by.” To account for other covariables 𝒙∗0𝑘 at baseline, 𝒄0 in (4.10) is expanded to 
include (?̅?20 − 𝒙10) and (?̅?30 − ?̅?10) where ?̅?𝑖0 =
1
𝑛𝑖
∑ 𝑈𝑖𝑘𝒙∗0𝑘
𝑛
𝑘=1 . 
 For the model in (4.12), 𝒃0 = (𝑏01, 𝑏02, 𝑏03, 𝑏04)
′ are covariance adjusted counterparts of 
𝒄, and 𝒃𝟎 = (𝑿
′𝑽𝒄+,0
−1 𝑿)
−1
𝑿′𝑽𝒄+,0
−1 𝒄+; also, the covariance matrix for 𝒃𝟎 is 𝑽b0 = (𝑿
′𝑽𝒄+,0
−1 𝑿)
−1
. 
As a consequence of the structure of 𝑿 in (4.12), 𝒃𝟎 and 𝑽𝒃0 can be expressed as shown in (4.13)  
𝒃𝟎 = 𝒄 − (𝑪𝑽𝑎,0𝑪0
′ )(𝑪0𝑽𝑎,0𝑪0
′ )
−1
𝒄0 
𝑽𝒃𝟎 = 𝑽𝒄,0 − (𝑪𝑽𝑎,0𝑪0
′ )(𝑪0𝑽𝑎,0𝑪0
′ )
−1
(𝑪0𝑽𝑎,0𝑪
′)            (4.13) 
= 𝑪 [𝑽𝑎,0 − 𝑽𝑎,0𝑪0
′ (𝑪0𝑽𝑎,0𝑪0
′ )
−1
𝑪0𝑽𝑎,0] 𝑪
′ 
so as to show the nature of randomization-based covariance adjustment. Covariance adjusted test 
statistics for 𝐻0 can be based on weighted linear combinations 𝒃𝒘,𝟎 = ∑ 𝑤ℎ𝒃𝒉,𝟎
4
ℎ=1  in ways 
similar to those discussed for 𝒄. In this regard, 𝑇𝑤,𝒃𝟎 = 𝒘
′𝒃𝟎/(𝒘
′𝑽𝒃𝟎𝒘)
0.5
 approximately has 
the normal distribution with mean 0 and variance 1 under 𝐻0. Finally, the unadjusted test 
statistics based on 𝒄 and their randomization-based covariance adjusted counterparts with respect 
to 𝐛𝟎 are applicable to transformations of the elements of the 𝒚∗𝑘 that apply under 𝐻0 such as 
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ranks across subjects in the pooled groups or to dichotomous indicators with the value 1 if some 
criterion, such as (𝑦∗𝑗𝑘 < 𝐿
∗ < 𝐿), is satisfied for 𝑗 = 1, 2 and the value 0 if otherwise. 
 Simulation Study 
4.3.1 Simulation Setup 
 The Type I errors and powers of the methods discussed in this chapter were evaluated 
with simulation studies. The responses 𝑌𝑖𝑗 of patients in the i-th group for the j-th period, where 
𝑖 = P:P, P:T, T:T were randomly generated in the manner shown in (4.14) for which 𝑍𝑖1 is an  
[
 𝑌𝑖0 
 𝑌𝑖1 
 𝑌𝑖2 
] = [
 𝑒𝑖0 
 𝑒𝑖1 
 𝑒𝑖2 
] + [
𝜉0
𝜉𝑖1
𝑍𝑖1𝜉𝑖2 + (1 − 𝑍𝑖1)𝜉𝑖3
]                (4.14) 
indicator for a period 1 responder in the i-th group with 𝑍𝑖1 = 1 if  𝑌𝑖1 ≤ 𝐿, 𝑍𝑖1 = 0 if  𝑌𝑖1 > 𝐿 
for 𝐿 as the specified criterion for a responder or not. In (4.14), the 𝒆𝑖 = (𝑒𝑖0, 𝑒𝑖1, 𝑒𝑖2) are 
independently generated, random errors from the trivariate normal distribution with 𝟎3 as the 
common mean for all three groups, and with ∧ in (4.15) as the common covariance matrix for all 
∧ = 𝜎2 [
1 𝜌01 𝜌02
𝜌01 1 𝜌12
𝜌02 𝜌12 1
]              (4.15) 
three groups where 𝜎2 is the common variance for all three periods and 𝜌𝑗𝑗′ is the correlation for 
periods 𝑗 and 𝑗′.  Additionally, 𝜉0 is the common mean at baseline for all three groups; 𝜉𝑖1 is the 
mean for period 1 for the i-th group; 𝜉𝑖2 is an i-th group shift parameter that applies to period 2 
for period 1 responders; and 𝜉𝑖3 is an i-th group shift parameter that applies to period 2 for period 
1 non-responders. 
 For all simulation studies, the specified covariance matrix ∧ had 𝜎2 = 36, with the scope 
of correlations being 𝜌12 = 𝜌13 = 𝜌23 = 0.3, 0.5 as exchangeable structures and 𝜌12 = 𝜌23 =
𝜌13
0.5 = 0.5, 0.7 as autoregressive structures. The specifications for the assessments of type 1 error 
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were 𝜉0 = 40, 𝜉P:P,1 = 𝜉P:T,1 = 𝜉T:T,1 = 35, 𝜉P:P,2 = 𝜉P:T,2 = 𝜉T:T,2 = 32, and 𝜉P:P,3 = 𝜉P:T,3 =
𝜉T:T,3 = 35, with  𝑌𝑖1 ≤ 𝐿 = 33 being the criterion for a period 1 responder in the i-th group. 
Also, with 𝜋𝑖 = 𝐸{𝑍𝑖1} as the probability of responder status for group i, it follows from  
𝜉P:P,1 = 𝜉P:T,1 = 𝜉T:T,1 = 35 that 𝜋P:P = 𝜋P:T = 𝜋T:T = 0.37 for the assessments of type 1 error 
under the global null hypothesis 𝐻0 as specified in Section 4.2. 
 The specifications of the 𝜉𝑖1, 𝜉𝑖2, and 𝜉𝑖3 for the assessments of statistical power are 
shown in Table 4.1. Also, 𝜉0 = 40 and 𝜋P:P = 𝜋P:T = 0.37, but 𝜋T:T = 0.47 so that the 
difference in period 1 responder rates for the T:T group versus the P:P and P:T groups is about 
0.10. From Table 4.1, it follows that ∆1= (𝜉T:T,1 − 𝜉P:P,1) = −1.5, ∆3= (𝜉P:T,2 − 𝜉P:P,2) =
−1.0, and ∆4= (𝜉P:T,3 − 𝜉P:P,3) = −2.0. Since 𝐸{𝑌𝑖2} = {𝜋𝑖𝜉𝑖2 + (1 − 𝜋𝑖)𝜉𝑖3} = 𝜂𝑖, it follows 
that ∆2= (𝜂T:T − 𝜂P:P) = (32.1 − 33.9) = −1.8. Thus, (Δ1, Δ2, Δ3, Δ4) = (−1.5, −1.8, −1,−2) 
is the specification that corresponds to the assessments of statistical power with respect to 
(𝑐1, 𝑐2, 𝑐3, 𝑐4) and (𝑏10, 𝑏20, 𝑏30, 𝑏40); and (Δ1, Δ2, Δ3, Δ4) = (0, 0, 0, 0) corresponds to the 
assessments of type 1 error. 
Table 4.1 Specifications for Assessments of Statistical Power 
Group Period 1 
Period 2 for 
Period 1 Responder 
Period 2 for 
Period 1 Non-
Responder 
P:P 𝜉P:P,1 = 35 𝜉P:P,2 = 32 𝜉P:P,3 = 35 
P:T 𝜉P:T,1 = 35 𝜉P:T,2 = 31 𝜉P:T,3 = 33 
T:T 𝜉T:T,1 = 33.5 𝜉T:T,2 = 30.5 𝜉T:T,3 = 33.5 
 
 The simulations were performed with equal sample sizes 𝑛∗ = 40, 80, 160 patients per 
group, with the total sample sizes respectively being 3𝑛∗ = 120, 240, 480. For each simulation, 
the responses of the baseline, period 1, and period 2 are generated via (4.14) with the previously 
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noted specifications. For testing the hypothesis 𝐻0: Δ𝑤 = 0 𝑣𝑒𝑟𝑠𝑢𝑠 𝐻𝐴: Δ𝑤 ≠ 0 in 
correspondence to 𝑐𝑤 or 𝑏0,𝑤, the determination of p value for the test statistic 𝑇𝑤,𝑐 or 𝑇𝑤𝑏0 is 
based on reference of its squared value to the chi-square value 𝜒1,1−𝛼
2  where 𝛼 is the specified 
significance level and we chose 𝛼 to be 0.05. The simulation results are based on 50,000 
replicates for the specifications previously stated. The results of Type I error and power from the 
simulations are means of indicator variables for whether 𝑝 ≤ 𝛼 applies for testing 𝐻0, and the 
empirical standard deviation (ESD) is taken as the square root of the variance of the estimated 𝑐𝑤 
or 𝑏𝑤,0  across all simulations, and the average of the estimated standard error (ASE) of 𝑐𝑤 or 
𝑏𝑤,0  in the simulations is provided. 
4.3.2 Simulation Results 
The results that only address Δ1 and Δ4, as is usually the case of interest in the SPCD 
design under the null hypothesis, are displayed in Table 4.2. As shown there, under the null 
hypothesis, the unadjusted and adjusted methods provide unbiased point estimates and 
reasonable estimates of the standard errors of the estimators, as the ASE and ESD are similar. 
Type I errors under all scenarios are well-controlled at the nominal 0.05 level regardless of the 
sample sizes using the unadjusted 𝒄 or covariable adjusted 𝒃𝟎. The MMRM approach of Doros et 
al. (2013) also had its type 1 error evaluated with the simulation studies, and it provided good 
control when the sample size per group is 80 and 160; but it had an elevated type one error when 
the sample size is 40 per group, under each of the different correlation specifications.  
Additionally, the covariable adjusted method 𝒃𝟎 provides variance reduction of 10% to 45%, 
depending on the correlation levels and sample sizes, as shown in the efficiency column.  
Under 𝐻0 for no treatment differences, results that additionally address Δ2, the treatment 
difference between P:P and T:T sequences, in addition to the usual Δ1 and Δ4 for the SPCD 
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design, are shown in Table 4.3. These results also show good control of the Type I error. For 
utilizing all available information from a study, a weighted statistic can address all Δ1 to Δ4, with 
equal weighting or inverse variance weighting, and Table 4.4 shows that it controls the type I 
error well at the 0.05 significance level. 
Under the alternative parameter specification in Table 4.1, the powers with the three 
methods are presented in Table 4.5. The covariable adjusted method 𝒃𝟎 and MMRM approach of 
Doros et al. (2013) for addressing Δ1 and Δ4 have similar power, with both having higher power 
than the unadjusted method 𝒄. Under the specification of Δ2 for Table 4.1, when taking Δ2 into 
account in addition to Δ1 and Δ4, the powers are slightly better than without addressing Δ2. 
When considering all the available sources of information with equal weights, the power 
decreases due to smaller Δ3 compared to ∆1, ∆2, ∆4. But when inverse variance weighting is 
used, the power is similar to that when Δ3 is not addressed, mainly because the weight 
corresponding to ∆3 is smaller than those corresponding to ∆1, ∆2, ∆4.
 
 
 
  
  
7
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Table 4.2 Results from 50, 000 replicate simulations for the test statistics of 𝐻0: 𝛥1 = 𝛥4 = 0 under 𝛥1 = 𝛥2 = 𝛥3 = 𝛥4 = 0 
𝜌 𝑛𝑖 Weight 
Unadjusted  Adjusted MMRM Efficiency 
Bias ASE ESD 
Type I 
error 
Bias ASE ESD 
Type I 
error 
Bias ASE ESD 
Type I 
error 
a/u a/m 
0.3 (EX) 
40 Equal -0.0031 1.005 1.009 0.0491 -0.0013 0.956 0.956 0.0490 -0.0014 0.973 0.977 0.0520 0.90 0.96 
 InvVar -0.0030 0.944 0.950 0.0499 -0.0009 0.898 0.899 0.0490 0.0085 0.908 0.919 0.0526 0.90 0.96 
80 Equal -0.0045 0.712 0.716 0.0500 -0.0042 0.680 0.683 0.0505 -0.0042 0.684 0.688 0.0513 0.91 0.98 
 InvVar -0.0029 0.670 0.671 0.0500 -0.0029 0.639 0.640 0.0492 0.0020 0.641 0.645 0.0515 0.91 0.99 
160 Equal 0.0037 0.504 0.503 0.0488 0.0025 0.482 0.482 0.0497 0.0027 0.483 0.482 0.0494 0.92 1.00 
 InvVar 0.0030 0.474 0.473 0.0494 0.0019 0.454 0.453 0.0500 0.0042 0.453 0.454 0.0506 0.92 1.00 
0.5 (AR) 
40 Equal -0.0027 0.974 0.980 0.0493 -0.0038 0.878 0.883 0.0500 -0.0037 0.912 0.928 0.0542 0.81 0.91 
 InvVar -0.0038 0.929 0.937 0.0495 -0.0052 0.820 0.824 0.0506 0.0021 0.838 0.854 0.0552 0.77 0.93 
80 Equal -0.0026 0.689 0.693 0.0499 -0.0031 0.624 0.627 0.0516 -0.0021 0.642 0.648 0.0540 0.82 0.93 
 InvVar -0.0015 0.659 0.661 0.0504 -0.0029 0.583 0.583 0.0509 0.0016 0.592 0.597 0.0528 0.78 0.96 
160 Equal 0.0029 0.488 0.486 0.0488 0.0032 0.443 0.442 0.0497 0.0026 0.453 0.454 0.0509 0.83 0.95 
 InvVar 0.0029 0.466 0.465 0.0495 0.0037 0.413 0.413 0.0499 0.0052 0.419 0.420 0.0519 0.79 0.97 
0.5 (EX) 
40 Equal -0.0032 0.974 0.980 0.0519 -0.0014 0.857 0.864 0.0514 -0.0022 0.865 0.873 0.0538 0.78 0.98 
 InvVar -0.0026 0.929 0.936 0.0510 -0.0012 0.810 0.816 0.0515 0.0061 0.816 0.829 0.0561 0.76 0.97 
80 Equal 0.0011 0.689 0.692 0.0504 0.0008 0.609 0.613 0.0508 0.0016 0.609 0.612 0.0509 0.78 1.00 
 InvVar 0.0019 0.659 0.660 0.0504 0.0006 0.576 0.578 0.0502 0.0050 0.576 0.580 0.0519 0.77 0.99 
160 Equal 0.0010 0.488 0.484 0.0476 -0.0002 0.432 0.430 0.0486 0.0001 0.429 0.427 0.0489 0.79 1.02 
 InvVar 0.0006 0.466 0.464 0.0474 0.0000 0.409 0.407 0.0488 0.0020 0.407 0.406 0.0496 0.77 1.00 
0.7 (AR) 
40 Equal 0.0003 0.923 0.928 0.0512 0.0011 0.724 0.725 0.0492 0.0001 0.752 0.758 0.0533 0.61 0.91 
 InvVar -0.0011 0.909 0.917 0.0523 0.0005 0.678 0.679 0.0502 0.0052 0.690 0.700 0.0536 0.55 0.94 
80 Equal -0.0017 0.654 0.655 0.0486 -0.0016 0.515 0.516 0.0501 -0.0010 0.529 0.533 0.0519 0.62 0.94 
 InvVar -0.0003 0.645 0.644 0.0483 -0.0009 0.482 0.481 0.0491 0.0018 0.488 0.490 0.0508 0.56 0.96 
160 Equal 0.0046 0.462 0.460 0.0483 0.0025 0.365 0.364 0.0501 -0.0009 0.373 0.376 0.0518 0.63 0.94 
 InvVar 0.0037 0.457 0.454 0.0486 0.0018 0.342 0.341 0.0498 0.0005 0.345 0.346 0.0516 0.56 0.97 
Note: Bias = mean of (estimate-true value); Type I error = rejection rate of null hypothesis (when 𝑍𝑤
2 > 𝜒0.95
2 ); ASE=average standard error; 
ESD=empirical standard deviation. a/u=(adjusted variance) / (unadjusted variance); a/m = (adjusted variance) / (MMRM variance) 
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Table 4.3 Results from 50, 000 simulations for the test statistics of 𝐻0: 𝛥1 = 𝛥3 = 𝛥4 = 0 under 𝛥1 = 𝛥2 = 𝛥3 = 𝛥4 = 0 
𝜌 𝑛𝑖  Weight 
Unadjusted Adjusted Efficiency 
Bias ASE ESD 
Type I 
error 
Bias ASE ESD 
Type I 
error 
a/u 
0.3 
(EX) 
40 Equal -0.0013 1.009 1.015 0.0504 0.0009 0.940 0.942 0.0494 0.86 
 InvVar -0.0030 0.931 0.937 0.0503 -0.0006 0.875 0.877 0.0503 0.88 
80 Equal -0.0016 0.714 0.716 0.0506 -0.0014 0.668 0.670 0.0496 0.87 
 InvVar -0.0019 0.661 0.663 0.0500 -0.0014 0.623 0.624 0.0491 0.89 
160 Equal 0.0022 0.505 0.505 0.0496 0.0009 0.474 0.474 0.0492 0.88 
 InvVar 0.0024 0.468 0.467 0.0502 0.0009 0.443 0.443 0.0496 0.90 
0.5 
(AR) 
40 Equal -0.0053 1.023 1.030 0.0506 -0.0061 0.919 0.922 0.0497 0.80 
 InvVar -0.0035 0.926 0.933 0.0500 -0.0049 0.816 0.821 0.0500 0.77 
80 Equal -0.0013 0.724 0.725 0.0504 -0.0024 0.653 0.654 0.0490 0.81 
 InvVar -0.0016 0.657 0.660 0.0504 -0.0030 0.582 0.583 0.0510 0.78 
160 Equal 0.0034 0.512 0.510 0.0497 0.0037 0.463 0.462 0.0493 0.82 
 InvVar 0.0029 0.466 0.465 0.0495 0.0037 0.413 0.413 0.0496 0.79 
0.5 
(EX) 
40 Equal -0.0051 1.023 1.031 0.0512 -0.0039 0.859 0.865 0.0513 0.70 
 InvVar -0.0030 0.926 0.933 0.0513 -0.0029 0.799 0.805 0.0518 0.74 
80 Equal 0.0010 0.724 0.726 0.0500 -0.0001 0.610 0.613 0.0500 0.71 
 InvVar 0.0018 0.657 0.659 0.0496 0.0002 0.569 0.571 0.0508 0.75 
160 Equal 0.0023 0.512 0.508 0.0477 0.0014 0.433 0.430 0.0470 0.71 
 InvVar 0.0006 0.466 0.463 0.0476 0.0006 0.404 0.402 0.0489 0.75 
0.7 
(AR) 
  
40 Equal 0.0007 1.026 1.033 0.0505 0.0028 0.794 0.795 0.0496 0.59 
 InvVar -0.0014 0.884 0.890 0.0515 -0.0005 0.665 0.667 0.0496 0.56 
80 Equal 0.0002 0.726 0.726 0.0495 -0.0001 0.564 0.563 0.0488 0.60 
 InvVar -0.0016 0.628 0.628 0.0492 -0.0015 0.474 0.474 0.0500 0.57 
160 Equal 0.0030 0.514 0.512 0.0494 0.0009 0.400 0.400 0.0500 0.61 
 InvVar 0.0046 0.445 0.442 0.0489 0.0024 0.337 0.335 0.0491 0.57 
Note: Bias = mean of (estimate-true value); Type I error = rejection rate of null hypothesis (when 𝑍𝑤
2 > 𝜒0.95
2 ); ASE=average standard error; 
ESD=empirical standard deviation. a/u=(adjusted variance) / (unadjusted variance). 
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Table 4.4 Results from 50, 000 replicate simulations for the test statistics of 𝐻0: 𝛥1 = 𝛥3 = 𝛥3 = 𝛥4 = 0 under 𝛥1 = 𝛥2 = 𝛥3 = 𝛥4 = 0 
𝜌 𝑛𝑖 Weight 
Unadjusted Adjusted Efficiency 
Bias ASE ESD Type I 
error 
Bias ASE ESD Type I 
error 
a/u 
0.3 
(EX) 
40 Equal -0.0006 0.980 0.985 0.0505 0.0004 0.917 0.920 0.0496 0.87 
 InvVar -0.0026 0.857 0.862 0.0511 -0.0012 0.809 0.811 0.0504 0.89 
80 Equal -0.0018 0.694 0.694 0.0477 -0.0007 0.653 0.653 0.0491 0.88 
 InvVar -0.0026 0.610 0.610 0.0500 -0.0017 0.578 0.578 0.0493 0.90 
160 Equal 0.0022 0.491 0.490 0.0489 0.0013 0.464 0.464 0.0488 0.89 
 InvVar 0.0028 0.432 0.431 0.0499 0.0017 0.411 0.411 0.0497 0.91 
0.5 
(AR) 
40 Equal -0.0084 0.965 0.968 0.0496 -0.0100 0.881 0.883 0.0505 0.83 
 InvVar -0.0050 0.827 0.833 0.0514 -0.0067 0.738 0.743 0.0517 0.79 
80 Equal -0.0014 0.683 0.682 0.0491 -0.0014 0.627 0.627 0.0480 0.84 
 InvVar -0.0021 0.588 0.590 0.0509 -0.0025 0.527 0.527 0.0501 0.80 
160 Equal 0.0030 0.483 0.481 0.0482 0.0037 0.445 0.443 0.0489 0.85 
 InvVar 0.0025 0.417 0.416 0.0500 0.0036 0.375 0.374 0.0493 0.81 
0.5 
(EX) 
40 Equal -0.0060 0.964 0.970 0.0501 -0.0050 0.824 0.829 0.0499 0.73 
 InvVar -0.0036 0.827 0.831 0.0505 -0.0033 0.725 0.729 0.0509 0.77 
80 Equal 0.0005 0.683 0.685 0.0509 0.0002 0.587 0.590 0.0501 0.74 
 InvVar 0.0014 0.588 0.592 0.0508 0.0006 0.518 0.522 0.0511 0.78 
160 Equal 0.0021 0.483 0.481 0.0492 0.0013 0.416 0.415 0.0494 0.74 
 InvVar 0.0004 0.417 0.416 0.0510 0.0001 0.369 0.367 0.0489 0.78 
0.7 
(AR) 
  
40 Equal 0.0023 0.929 0.935 0.0498 0.0027 0.748 0.750 0.0491 0.64 
 InvVar 0.0006 0.761 0.764 0.0513 -0.0002 0.591 0.592 0.0508 0.60 
80 Equal -0.0020 0.658 0.658 0.0491 -0.0015 0.532 0.532 0.0498 0.65 
 InvVar -0.0035 0.541 0.541 0.0500 -0.0026 0.422 0.422 0.0489 0.61 
160 Equal 0.0018 0.466 0.465 0.0495 0.0006 0.378 0.378 0.0493 0.66 
  InvVar 0.0036 0.384 0.383 0.0503 0.0022 0.300 0.300 0.0497 0.61 
Note: Bias = mean of (estimate-true value); Type I error = rejection rate of null hypothesis (when 𝑍𝑤
2 > 𝜒0.95
2 ); ASE=average 
standard error; ESD=empirical standard deviation. a/u=(adjusted variance) / (unadjusted variance).
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Table 4.5 Results from 50,000 replicate simulations for power of test statistics under the alternative specified in Table 4.1 
𝜌 𝑛𝑖  Weight 
Δ1 and Δ4 Δ1, Δ2, and Δ4 Δ1, Δ2, Δ3, and  Δ4 
Unadjusted Adjusted MMRM Unadjusted Adjusted Unadjusted Adjusted 
0.3 
(EX) 
40 Equal 0.418 0.438 0.443 0.426 0.460 0.368 0.396 
 InvVar 0.426 0.448 0.451 0.434 0.464 0.427 0.459 
80 Equal 0.688 0.721 0.723 0.698 0.745 0.631 0.673 
 InvVar 0.699 0.736 0.733 0.712 0.757 0.712 0.755 
160 Equal 0.931 0.948 0.950 0.936 0.959 0.900 0.927 
 InvVar 0.938 0.955 0.954 0.943 0.963 0.945 0.964 
0.5 
(AR) 
40 Equal 0.441 0.501 0.491 0.418 0.477 0.379 0.424 
 InvVar 0.435 0.510 0.506 0.435 0.506 0.436 0.511 
80 Equal 0.716 0.791 0.775 0.689 0.765 0.644 0.708 
 InvVar 0.711 0.801 0.793 0.714 0.801 0.723 0.807 
160 Equal 0.946 0.974 0.969 0.932 0.966 0.909 0.944 
 InvVar 0.943 0.977 0.976 0.946 0.977 0.951 0.980 
0.5 
(EX) 
40 Equal 0.443 0.519 0.529 0.416 0.527 0.376 0.472 
 InvVar 0.434 0.525 0.535 0.436 0.535 0.437 0.539 
80 Equal 0.716 0.805 0.815 0.686 0.815 0.642 0.763 
 InvVar 0.711 0.816 0.820 0.714 0.825 0.722 0.829 
160 Equal 0.948 0.980 0.982 0.933 0.983 0.908 0.968 
 InvVar 0.945 0.982 0.983 0.947 0.984 0.952 0.986 
0.7 
(AR) 
40 Equal 0.478 0.655 0.643 0.414 0.588 0.398 0.541 
 InvVar 0.445 0.656 0.663 0.462 0.662 0.478 0.680 
80 Equal 0.763 0.917 0.907 0.686 0.873 0.676 0.839 
 InvVar 0.727 0.920 0.919 0.750 0.923 0.778 0.935 
160 Equal 0.964 0.997 0.997 0.932 0.992 0.926 0.987 
 InvVar 0.950 0.997 0.997 0.960 0.997 0.970 0.998 
Note: Power = rejection rate of null hypothesis (when 𝑍𝑤
2 > 𝜒0.95
2 ). 
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 Example 
 A hypothetical placebo-controlled pre-randomized two-period study that makes use of the 
P:P, P:T, and T:T sequence groups is created to illustrate an application of the proposed methods 
and to compare them to those from the MMRM method proposed by Doros et al. (2013). The 
example has 240 subjects which are equally assigned to the three sequence groups. Assessments 
of responses occur at the baseline, end of period 1 and period 2, with a lower outcome score 
being more beneficial. At period 1, a score less than 33 is considered as a responder to the 
treatment. The means and standard deviations of the responses are provided in Table 4.6. The 
means of responses at baseline are similar across the three sequence groups, with a slightly larger 
mean in the T:T group. There are 31%, 34%, and 39% of responders in the three groups 
respectively, as shown in the ?̅? row, with only 6% more responders in the test treatment group 
than the placebo group at Period 1. And as the trial continues to the second period, the mean 
responses there for the P:T and T:T groups are almost the same, and the P:P group is slightly 
worse. 
Table 4.6 Mean and Standard Deviation of Outcome 
 Statistics P:P P:T T:T 
?̅?0 40.54 40.45 40.80 
SD 5.36 5.57 6.91 
?̅?1 35.15 34.92 34.24 
SD 6.17 5.72 6.48 
𝑧̅ 0.31 0.34 0.39 
?̅?2 33.98 32.44 32.39 
SD 5.69 5.04 6.13 
 
The estimates using the proposed unadjusted and adjusted methods as well as the 
MMRM method are shown in Table 4.7. The standard errors of the estimates increase as the 
sample sizes decrease, as those pertaining to ∆1 have  the smallest standard errors and  those 
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pertaining to ∆3 have the largest standard errors (since only 30% to 40% of patients are 
responders in period 1). The covariable-adjusted method and the MMRM method provide similar 
estimates for ∆1, the treatment difference at the end of the first period with a value of 0.95, 
whereas the unadjusted estimate is somewhat closer to the null. For the period 1 treatment 
difference only, the p values of 0.289, 0.111, and 0.130 for the unadjusted method, the adjusted 
method, and the MMRM method, respectively, similarly fail to contradict the null hypothesis. 
Table 4.7 Estimates of Δ1 to Δ4 
Method Statistics Δ1 Δ2 Δ3 Δ4 (
Δ1
𝑆𝐸
)
2
 p value 
Unadjusted Etimate -0.791 -1.591 -0.666 -1.731 1.126 0.289 
 SE 0.745 1.033 1.440 1.091   
Adjusted Estimate -0.960 -1.600 -0.467 -1.838 2.535 0.111 
 SE 0.603 0.951 1.385 1.035   
MMRM Estimate -0.951 NA -0.111 -1.909 2.488 0.130 
 SE 0.603 NA 1.546 1.051   
Equal: equal weights; InvVar: Inverse variance weighting. 
 
Importantly, the estimate pertaining to ∆4 for the treatment difference at the end of the 
second period for the placebo non-responders in period 1 is twice as large as that pertaining to ∆1 
and at least three times bigger than that pertaining to ∆3 as the difference for the placebo 
responders; and this indicates that the placebo non-responders, when given the test treatment, are 
more informative than the placebo responders. The comparison that addresses ∆2 for the 
difference between the T:T group and the P:P group also show better improvement than that for 
the first period, and this consideration could possibly contribute to the overall treatment 
comparison if taken into account. 
As shown in Table 4.8, all of the statistics provided by the unadjusted method, except for 
the one accounting for ∆2 with equal weight, fail to contradict the null hypothesis at the 0.05 
 79 
  
level, mainly due to  somewhat larger variance; but the adjusted method, with any specification 
for ∆’s, and the MMRM method considering Δ1 and Δ4, similarly show significant results at the 
0.05 level. 
Table 4.8 Estimates of Weighted Statistics 
 
Method Statistics Δ1 and Δ4 Δ1, Δ2 and Δ4 Δ1, Δ2 Δ3 and Δ4 
  Equal InvVar Equal InvVar Equal InvVar 
Unadjusted 
Weighted 
estimate 
-1.261 -1.090 -1.371 -1.082 -1.195 -0.967 
 SE 0.661 0.615 0.696 0.615 0.669 0.560 
 P value 0.056 0.077 0.049 0.079 0.074 0.084 
Adjusted 
Weighted 
estimate 
-1.399 -1.199 -1.466 -1.167 -1.216 -1.041 
 SE 0.599 0.521 0.631 0.520 0.620 0.480 
 P value 0.020 0.022 0.020 0.025 0.050 0.030 
MMRM 
Weighted 
estimate 
-1.430 -1.188     
 SE 0.606 0.523     
 P value 0.025 0.031     
Equal: equal weights; InvVar: Inverse variance weighting. 
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 CHAPTER 5: RANDOMIZATION-BASED ANCOVA FOR POINT AND CONFIDENCE 
INTERVAL ESTIMATION IN SEQUENTIAL PARALLEL COMPARISON DESIGN 
(SPCD) 
 Introduction 
 When the global null hypothesis 𝐻0 for the SPCD design is contradicted by test statistics 
in Chapter 4 such as 𝑇𝒘,𝒄 or 𝑇𝒘,𝑏0, or is not expected to apply, randomization-based covariance 
adjustment can proceed for confidence interval estimation for comparisons between T and P 
through the expansion of the population for inference to an almost infinitely large population of 
𝑁 patients so that the 𝑛 randomized patients included in the trial are conceptually representative 
of this large population in a simple random sampling sense (Koch et al., 1998).  
 Methods 
 In the above setting, the randomization process is comparable to the random assignment 
of 𝑛𝑖 patients to the i-th sequence group for 𝑖 = 1, 2, 3 and (𝑁 − 𝑛) patients to a group without 
random selection for inclusion in the clinical trial. Accordingly, 𝝁𝑖 and 𝑽𝑭𝑖 in (4.3) become the 
population mean vector and population covariance matrix for the population of 𝑁 patients which 
the 𝑛𝑖 patients in the i-th group are assumed to represent if all 𝑁 patients received the  i-th 
sequence of treatments. Also, with 𝑛 replaced by 𝑁 in (4.1), (4.2), and (4.3), 𝝁𝑖 and 𝑽𝑭𝑖 have the 
structure shown in (5.1). 
𝝁𝑖 =
1
𝑁
∑ 𝑭𝑖𝑘
𝑁
𝑘=1
,   𝑽𝑭𝑖 =
1
(𝑁 − 1)
∑(𝑭𝑖𝑘 − 𝝁𝑖)(𝑭𝑖𝑘 − 𝝁𝑖′)
′
𝑁
𝑘=1
          (5.1) 
 Also, the sample mean estimator for the i-th group ?̅?𝑖 = (∑ 𝑈𝑖𝑘𝑭𝑖𝑘 𝑛𝑖⁄
𝑁
𝑘=1 ) applies, 
although the summation only includes the 𝑛𝑖 patients randomized to the i-th group.
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As 𝑁 → ∞, the covariance matrix of the sample mean simplifies to (5.2).  
𝑽𝒂𝒓(?̅?𝑖) = (𝑽𝑭𝑖 𝑛𝑖⁄ )                        (5.2) 
𝑪𝒐𝒗(?̅?𝑖, ?̅?𝑖′) = 0. 
 An unbiased estimator for 𝑽𝒂𝒓(?̅?𝑖) is ?̂??̅?𝑖 is as shown in (5.3), since 𝑬{?̂??̅?𝑖} =  𝑽𝒂𝒓(?̅?𝑖) 
?̂??̅?𝑖 = ∑ 𝑈𝑖𝑘(𝑭𝑖𝑘 − ?̅?𝑖)(𝑭𝑖𝑘 − ?̅?𝑖)
′ 𝑛𝑖(𝑛𝑖 − 1)⁄
𝑁
𝑘=1
                                                   (5.3) 
=
1
𝑛𝑖(𝑛𝑖 − 1)
{∑[𝑈𝑖𝑘(𝑭𝑖𝑘 − 𝝁𝑖)(𝑭𝑖𝑘 − 𝝁𝑖)
′] − [𝑛𝑖(?̅?𝑖 − 𝝁𝑖)(?̅?𝑖 − 𝝁𝑖)
′]
𝑁
𝑘=1
}           
can be derived in (5.4), regardless of the large population size 𝑁. 
𝑬{?̂??̅?𝑖} = {[∑ (𝑭𝑖𝑘 − 𝝁𝑖)(𝑭𝑖𝑘 − 𝝁𝑖)
′ 𝑁(𝑛𝑖 − 1)⁄
𝑁
𝑘=1
] − [
(𝑁 − 𝑛𝑖)𝑽𝑭,𝑖
𝑁𝑛𝑖(𝑛𝑖 − 1)
]}          (5.4) 
=
𝑽𝑭,𝑖
𝑁(𝑛𝑖 − 1)
[(𝑁 − 1) −
(𝑁 − 𝑛𝑖)
𝑛𝑖
] = (𝑽𝑭,𝑖 𝑛𝑖⁄ ) = 𝑉𝑎𝑟(?̅?𝑖) 
 Thus, ?̂??̅? = 𝑫𝒊𝒂𝒈(?̂??̅?1 , ?̂??̅?2 , ?̂??̅?3) is the block diagonal estimated covariance matrix for ?̅? 
with the {?̂??̅?,𝑖} as its diagonal blocks. 
 Let ?̃?𝑖 denote the transformation of ?̅?𝑖 whereby the 𝑓?̅?𝑗 for 𝑗 = 1, 2 are replaced by 𝑓𝑖𝑗 =
(𝑓?̅?𝑗 𝑧?̅?⁄ ), and ?̃?𝑖2 = (?̅?𝑖2 − 𝑓?̅?2) (1 − 𝑧?̅?)⁄  is also included, as shown in (5.5), with matrices 𝑹1, 𝒓,  
?̃?𝑖 = (?̅?𝑖0, ?̅?𝑖1, 𝑧?̅? , 𝑓𝑖1, ?̅?𝑖2, 𝑓𝑖2, ?̃?𝑖2)
′
         (5.5) 
= 𝐞𝐱𝐩[𝑹2 𝒍𝒐𝒈(𝑹1?̅?𝑖 + 𝒓)],                    
and 𝑹2 as shown in (5.6). 
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𝑹1 =
[
 
 
 
 
 
 
 
 
1
0
0
0
0
0
0
0
  
0
1
0
0
0
0
0
0
  
0
0
1
−1
0
0
0
0
  
0
0
0
0
1
0
0
0
  
0
0
0
0
0
1
0
1
  
0
0
0
0
0
0
1
−1
 
]
 
 
 
 
 
 
 
, 𝒓 =
[
 
 
 
 
 
 
 
 
0
0
0
1
0
0
0
0
 
]
 
 
 
 
 
 
 
, 𝑹2 =
[
 
 
 
 
 
 
 
1
0
0
0
0
0
0
  
0
1
0
0
0
0
0
  
0
0
1
−1
0
−1
0
  
0
0
0
0
0
0
−1
  
0
0
0
1
0
0
0
  
0
0
0
0
1
0
0
  
0
0
0
0
0
1
0
  
0
0
0
0
0
0
1
 
]
 
 
 
 
 
 
      (5.6) 
 By linear Taylor series methods as discussed in Koch et al. (1977), a consistent estimate 
for the covariance matrix of ?̃?𝑖 is ?̂??̃?𝑖 = 𝑳𝑖?̂??̅?𝑖𝑳𝑖
′ for which 𝑳𝑖 = 𝑫?̃?𝑖𝑹2𝑫(𝑹1?̅?𝑖+𝒓)
−1 𝑹1 and 
(𝑹1?̅?𝑖 + 𝒓) = (?̅?𝑖0, ?̅?𝑖1, 𝑧?̅?, (1 − 𝑧?̅?), 𝑓?̅?1, ?̅?𝑖2, 𝑓?̅?2, (?̅?𝑖2 − 𝑓?̅?2)
′
). 
 Let ?̃? = (?̃?1
′ , ?̃?2
′ , ?̃?3
′ )
′
. A consistent estimate for the covariance matrix of ?̃? is the block 
diagonal matrix ?̂??̃? = 𝑫𝒊𝒂𝒈(?̂??̃?1 , ?̂??̃?2 , ?̂??̃?3) with the ?̂??̃?𝑖 as its diagonal blocks. 
 The difference between sequence groups ?̃?  =  [(?̃?2 − ?̃?1)
′
, (?̃?3 − ?̃?1)
′
]
′
= 𝑨?̃? is 
constructed as shown in (5.7), and a consistent estimate for the covariance matrix of ?̃?  
?̃? = 𝑨?̃? = [
−𝑰6 𝑰6 𝟎66
−𝑰6 𝟎66 𝑰6
] ?̃?               (5.7) 
is ?̂??̃? = 𝑨?̂??̃?𝑨
′ as shown in (5.8).  
?̂??̃? = [
?̂??̃?1 + ?̂??̃?2 ?̂??̃?1
?̂??̃?1 ?̂??̃?1 + ?̂??̃?3
]                      (5.8) 
 For the assessment of 𝐻0 without adjustment for 𝑦10𝑘 = 𝑦20𝑘 = 𝑦30𝑘, 𝑦11𝑘 = 𝑦21𝑘, 
𝑧1𝑘 = 𝑧2𝑘, and 𝑓11𝑘 = 𝑓21𝑘, the potential comparisons of interest for this crossover design are 
shown in (5.9), and they are linear functions ?̃? = ?̃??̃? = ?̃?𝑨?̃? of ?̃? with matrix ?̃? as shown in 
(5.10).  
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?̃?1 = {?̅?31 −
(𝑛1?̅?11 + 𝑛2?̅?21)
(𝑛1 + 𝑛2)
} 
?̃?2 = (?̅?32 − ?̅?12)                            
?̃?3 = (𝑓22 − 𝑓21)                   (5.9) 
?̃?4 = (?̃?22 − ?̃?21)                            
?̃? = [ 
0
0
0
0
  
−
𝑛2
(𝑛1+𝑛2)
0
0
0
    
0
0
0
0
     
0 0
0 0
0 0
0 0
    
0 0
0 0
1 0
0 1
    
0 1
0 0
0 0
0 0
    
0 0
0 0
0 0
0 0
    
0 0
1 0
0 0
0 0
    
0
0
0
0
 ]        (5.10) 
 A consistent estimate for the covariance matrix of ?̃? is ?̂??̃? = ?̃??̂??̃??̃?
′. Also, under 𝐻0, 
𝑬𝐴{?̃? | 𝐻0} = 𝟎4 where 𝑬𝐴{   } denotes asymptotic expected value with respect to the distribution 
of ?̃? through the assumed random sampling of patients and the invoked randomization for 
sufficiently large sample size to support its statistical behavior through its linear Taylor series 
approximation. 
Similarly to the previous chapter, for ?̃? = (?̃?1, ?̃?2, ?̃?3, ?̃?4)
′, the comparison ?̃?1 pertains to T 
versus P in period 1; the comparison  ?̃?2 pertains to T:T versus P:P in period 2; the 
comparison  ?̃?3 pertains to P:T versus P:P in period 2 for responders to placebo in period 1; ?̃?4 
pertains to P:T versus P:P in period 2 for non-responders to placebo in period 1. Univariate test 
statistics for 𝐻0 and thereby for the comparison between T and P can be based on weighted linear 
combinations ?̃?𝑤 = ∑ 𝑤ℎ?̃?ℎ
4
ℎ=1  where 𝒘 = (𝑤1, 𝑤2, 𝑤3, 𝑤4)
′ is a vector of weights such that all 
𝑤ℎ ≥ 0 and ∑ 𝑤ℎ
4
ℎ=1 = 1. With the weights 𝒘, the test statistic for the global null hypothesis 𝐻0 
at the two-sided significance level 𝛼 is ?̃?𝑤,?̃? = 𝑤′?̃? (𝒘′𝑽?̃?𝒘)
0.5⁄ . Under 𝐻0, ?̃?𝑤,?̃? approximately 
has a standard normal distribution with mean 0 and variance 1. A confidence interval based 
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on  ?̃?𝑤 can be constructed as [?̃?w − 𝑍𝛼
2
√𝑉𝑐w̃ , ?̃?w + 𝑍𝛼
2
√𝑉𝑐w̃], where 𝑍𝛼
2
 is the (1 −
𝛼
2
)th 
percentile of the standard normal distribution and 𝑽𝑐?̃? = 𝒘
′𝑽𝑐?̃?𝒘. 
 The constraints ?̃?0 = ?̃?0?̃? = ?̃?0𝑨?̃? for ?̃? with 𝑬𝐴{?̃?0} = 0 regardless of whether 𝐻0 
applies are shown in (5.11). 
?̃?0 =
[
 
 
 
 
 
(?̅?20 − ?̅?10)
(?̅?30 − ?̅?10)
(?̅?21 − ?̅?11)
(𝑧2̅ − 𝑧1̅)
(𝑓21 − 𝑓11)]
 
 
 
 
 
=
[
 
 
 
 
1 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 1 0
0 1 0
0 0 1
0 0 0
0 0 0
0 0 0
1 0 0
0 0 0
0 0 0
0 0 0
    
0 0 0
0 0 0
0 0 0
0 0
0 0
0 0
0 0 0
0 0 0
0 0
0 0]
 
 
 
 
?̃? 
= ?̃?0?̃?                                                                                                                                   (5.11) 
 Let ?̃?+ = [?̃?
′, ?̃?0
′ ]′ = [?̃?′, ?̃?0
′ ]
′
?̃? = ?̃?+?̃? denote the combined set of comparisons ?̃? 
pertaining to 𝐻0 and constraints ?̃?0. The estimated covariance structure for ?̃?+ is ?̂??̃?+ = ?̃?+?̂??̃??̃?+
′ . 
Since 𝑬{?̃?0} = 𝟎5 regardless of whether 𝐻0 applies, randomization-based covariance adjustment 
for ?̃? with respect to the constraints ?̃?0 is invoked by fitting the linear model shown in (5.12) by  
𝑬{?̃?+} ≜ [
𝑰4
𝟎5,4
] ?̃? = 𝑿?̃?                             (5.12) 
weighted least squares with weights based on ?̂??̃?+
−1 and with “≜” meaning “is estimated by”; and 
?̃? = (?̃?1, ?̃?2, ?̃?3, ?̃?4)′ are covariance adjusted counterparts of ?̃?, and ?̃? = (𝑿
′?̂??̃?+
−1𝑿)
−1
𝑿′?̂??̃?+
−1?̃?+; 
also, the covariance matrix for ?̃? is ?̂??̃? = (𝑿
′?̂??̃?+
−1𝑿)
−1
. Covariance adjusted test statistics for 𝐻0 
can be based on weighted linear combinations ?̃?w = ∑ 𝑤ℎ?̃?ℎ
4
ℎ=1  in ways similar to those 
discussed for ?̃?. 
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 Simulation Study 
5.3.1 Simulation Setup 
 The Type I errors and powers of the methods discussed in this chapter were evaluated 
with simulation studies. The responses 𝑌𝑖𝑗 of patients in the i-th group for the j-th period, where 
𝑖 = P:P, P:T, T:T, were randomly generated in the manner shown in (5.13) for which 𝑍𝑖1 is an  
[
 𝑌𝑖0 
 𝑌𝑖1 
 𝑌𝑖2 
] = [
 𝑒𝑖0 
 𝑒𝑖1 
 𝑒𝑖2 
] + [
𝜉0
𝜉𝑖1
𝑍𝑖1𝜉𝑖2 + (1 − 𝑍𝑖1)𝜉𝑖3
]                (5.13) 
 
indicator for a period 1 responder in the i-th group with 𝑍𝑖1 = 1 if  𝑌𝑖1 ≤ 𝐿, 𝑍𝑖1 = 0 if  𝑌𝑖1 > 𝐿 
for 𝐿 as the specified criterion for a responder or not. In (5.13), the 𝒆𝑖 = (𝑒𝑖0, 𝑒𝑖1, 𝑒𝑖2) are 
independently generated, random errors from the trivariate normal distribution with 𝟎3 as the 
common mean for all three groups, and with ∧ in (5.14) as the common covariance matrix for all 
∧ = 𝜎2 [
1 𝜌01 𝜌02
𝜌01 1 𝜌12
𝜌02 𝜌12 1
]                        (5.14) 
three groups where 𝜎2 is the common variance for all three periods and 𝜌𝑗𝑗′ is the correlation for 
periods 𝑗 and 𝑗′.  Additionally, 𝜉0 is the common mean at baseline for all three groups; 𝜉𝑖1 is the 
mean for period 1 for the i-th group; 𝜉𝑖2 is an i-th group shift parameter that applies to period 2 
for period 1 responders; and 𝜉𝑖3 is an i-th group shift parameter that applies to period 2 for period 
1 non-responders.  
 For all simulation studies, the specified covariance matrix ∧ had 𝜎2 = 36, with the scope 
of correlations being 𝜌12 = 𝜌13 = 𝜌23 = 0.3, 0.5 as exchangeable structures and 𝜌12 = 𝜌23 =
𝜌13
0.5 = 0.5, 0.7  as autoregressive structures. The specifications for the assessments of type 1 
error were 𝜉0 = 40, 𝜉P:P,1 = 𝜉P:T,1 = 𝜉T:T,1 = 35, 𝜉P:P,2 = 𝜉P:T,2 = 𝜉T:T,2 = 32, and 𝜉P:P,3 =
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𝜉P:T,3 = 𝜉T:T,3 = 35, with  𝑌𝑖1 ≤ 𝐿 = 33 being the criterion for a period 1 responder in the i-th 
group. Also, with 𝜋𝑖 = 𝐸{𝑍𝑖1} as the probability of responder status for group i, it follows from  
𝜉P:P,1 = 𝜉P:T,1 = 𝜉T:T,1 = 35 that 𝜋P:P = 𝜋P:T = 𝜋T:T = 0.37 for the assessments of type 1 error 
under the global null hypothesis 𝐻0 as specified in Section 4.2. 
 The specifications of the 𝜉𝑖1, 𝜉𝑖2, and 𝜉𝑖3 for the assessments of statistical power are 
shown in Table 5.1. Also, 𝜉0 = 40 and 𝜋P:P = 𝜋P:T = 0.37, but 𝜋T:T = 0.47 so that the 
difference in period 1 responder rates for the T:T group versus the P:P and P:T groups is about 
0.10. From Table 5.1, it follows that ∆1= (𝜉T:T,1 − 𝜉P:P,1) = −1.5, ∆3= (𝜉P:T,2 − 𝜉P:P,2) =
−1.0, and ∆4= (𝜉P:T,3 − 𝜉P:P,3) = −2.0. Since 𝐸{𝑌𝑖2} = {𝜋𝑖𝜉𝑖2 + (1 − 𝜋𝑖)𝜉𝑖3} = 𝜂𝑖, it follows 
that ∆2= (𝜂T:T − 𝜂P:P) = (32.1 − 33.9) = −1.8. Thus, (Δ1, Δ2, Δ3, Δ4) = (−1.5, −1.8, −1,−2) 
is the specification that corresponds to the assessments of statistical power with respect to 
(𝑐1, 𝑐2, 𝑐3, 𝑐4) and (𝑏1, 𝑏2, 𝑏3, 𝑏4); and (Δ1, Δ2, Δ3, Δ4) = (0, 0, 0, 0) corresponds to the 
assessments of Type 1 error.  
Table 5.1 Specifications for Assessments of Statistical Power 
Group Period 1 
Period 2 for  
Period 1 Responder 
Period 2 for  
Period 1 Non-
Responder 
P:P 𝜉P:P,1 = 35 𝜉P:P,2 = 32 𝜉P:P,3 = 35 
P:T 𝜉P:T,1 = 35 𝜉P:T,2 = 31 𝜉P:T,3 = 33 
T:T 𝜉T:T,1 = 33.5 𝜉T:T,2 = 30.5 𝜉T:T,3 = 33.5 
 The simulations were performed with equal sample sizes 𝑛∗ = 40, 80, 160 patients per 
group, with the total sample sizes respectively being 3𝑛∗ = 120, 240, 480. For each simulation, 
the responses of the baseline, period 1, and period 2 are generated via (5.13) with the previously 
noted specifications. For testing the hypothesis 𝐻0: Δ𝑤 = 0 𝑣𝑒𝑟𝑠𝑢𝑠 𝐻𝐴: Δ𝑤 ≠ 0 in 
correspondence to 𝑐𝑤 or 𝑏0,𝑤, the determination of p value for the test statistic 𝑇𝑤,𝑐 or 𝑇𝑤𝑏0 is 
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based on reference of its squared value to the chi-square value 𝜒1,1−𝛼
2  where 𝛼 is the specified 
significance level and we chose 𝛼 to be 0.05. The simulation results are based on 50,000 
replicates for the specifications previously stated. The results of Type I error and power from the 
simulations are means of indicator variables for whether 𝑝 ≤ 𝛼 applies for testing 𝐻0, and the 
empirical standard deviation (ESD) is taken as the square root of the variance of the estimated 𝑐𝑤 
or 𝑏𝑤,0  across all simulations, and the average of the estimated standard error (ASE) of 𝑐𝑤 or 
𝑏𝑤,0  in the simulations is provided.  
5.3.2 Simulation Results 
 The results that address Δ1  and Δ4 only, which is usually the case of interest in the SPCD 
design, under the null hypothesis, are displayed in Table 5.2 with equal weighting and inverse 
variance weighting; and the results under the null that address Δ1, Δ2 and Δ4, and all Δ1 to Δ4, 
are as shown in Tables 5.3 and 5.4 respectively.  
 For closer to nominal control of Type 1 error at the two-sided 0.05 level and closer to 
nominal coverage for the two-sided 0.95 confidence interval, the estimator ?̂??̃?+ for the variance 
of  ?̃?+ has multiplication by 
𝑁−3  
𝑁−𝑚
, where the subtraction of 𝑚 corresponds to the number of 
sample means estimated from the 3 sequence groups combined; for example, 𝑚 = 7 and 𝑚 = 12 
for the unadjusted approach and covariate-adjusted approach when the test statistic is based on a 
weighted mean to address Δ1 and Δ4 with (𝑚 = 9, 14 for addressing Δ1, Δ2, Δ4 and 𝑚 = 11, 16 
for addressing all Δ1 to Δ4). Accordingly, an approximate F distribution with d.f.=(1, 𝑁 − 𝑚) for 
the p value of hypothesis testing and t-distribution with d. f. = (𝑁 − 𝑛) for confidence interval 
determination is used.  
 As shown in Table 5.2, under the null hypothesis, all three methods provide unbiased 
point estimates and reasonably accurate corresponding standard errors, as the ASE and ESD are 
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similar. When equal weights are used, Type I errors range from 0.0467 to 0.0501 for the 
unadjusted approach, and from 0.0485 to 0.0533 for the covariate adjusted approach, and 0.0489 
to 0.0542 for the MMRM approach of Doros et al. (2013), with the larger Type I errors occurring 
at the 𝑛 = 40 per group and the somewhat smaller than nominal Type I errors at n=160 per 
group for all three approaches. Similar results are observed in the inverse variance weighting to 
the parameters. As shown in the efficiency column, the covariate adjusted and MMRM methods 
have similar variances for estimation, with these being smaller than that for the unadjusted 
method; and thus there is better precision and narrower confidence interval estimation. As shown 
in Table 5.2 vertically, as correlation among the outcomes increases, the variance for the 
estimation decreases in all three approaches of estimation, with a bigger impact in the covariate-
adjusted and MMRM estimators than the unadjusted.  
 Under 𝐻0 for no treatment differences, results that address Δ2, the treatment difference 
between P:P and T:T sequences (in addition to the traditional SPCD design that addresses only 
Δ1 and Δ4) are shown in Table 5.3. Results with inclusion of Δ2 also have good control of the 
Type I error. For utilizing all available information from the study, a weighted statistic that 
addresses all Δ1 to Δ4, with equal weighting or inverse variance weighting, is also considered, 
and there is control for the type I errors at the 0.05 significance level, as shown in Table 5.4.  
 Under the alternative parameter specification in Table 5.1, the nominal coverage of 95% 
confidence interval and the power with the three methods, under scenarios of different sample 
sizes and correlations among outcomes, are presented in Table 5.5. The coverage with equal 
weighting for addressing Δ1 and Δ4 by the unadjusted, adjusted, and MMRM each range from 
0.949 to 0.953, and 0.947 to 0.952, and 0.946 to 0.951, respectively, and they all indicate good 
coverage of the target parameter.  
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Table 5.2 Results from 50, 000 replicate simulations for the test statistics of 𝐻0: 𝛥1 = 𝛥4 = 0 under 𝛥1 = 𝛥2 = 𝛥3 = 𝛥4 = 0 
𝜌  𝑛𝑖  Weight 
Unadjusted  Adjusted MMRM Efficiency 
Bias ASE ESD Type I Bias ASE ESD Type I  Bias ASE ESD Type I a/u a/m 
0.3 
(EX) 
n=40 Equal -0.0030 1.021 1.014 0.0479 0.0034 0.985 0.992 0.0515 -0.0014 0.973 0.977 0.0520 0.96 1.03 
 InvVar 0.0105 0.958 0.961 0.0495 0.0175 0.921 0.941 0.0543 0.0085 0.908 0.919 0.0526 0.96 1.05 
n=80 Equal -0.0047 0.717 0.718 0.0493 -0.0017 0.690 0.696 0.0523 -0.0042 0.684 0.688 0.0513 0.94 1.02 
 InvVar 0.0040 0.674 0.675 0.0501 0.0065 0.647 0.654 0.0518 0.0020 0.641 0.645 0.0515 0.94 1.03 
n=160 Equal 0.0038 0.506 0.503 0.0486 0.0037 0.486 0.487 0.0502 0.0027 0.483 0.482 0.0494 0.93 1.02 
 InvVar 0.0065 0.476 0.475 0.0492 0.0063 0.456 0.458 0.0507 0.0042 0.453 0.454 0.0506 0.93 1.02 
0.5 
(AR) 
n=40 Equal -0.0026 0.989 0.985 0.0478 -0.0007 0.905 0.915 0.0512 -0.0037 0.912 0.928 0.0542 0.86 0.97 
 InvVar 0.0096 0.942 0.946 0.0489 0.0088 0.841 0.858 0.0539 0.0021 0.838 0.854 0.0552 0.82 1.01 
n=80 Equal -0.0026 0.695 0.694 0.0494 -0.0012 0.634 0.637 0.0517 -0.0021 0.642 0.648 0.0540 0.84 0.97 
 InvVar 0.0052 0.663 0.664 0.0500 0.0046 0.590 0.595 0.0525 0.0016 0.592 0.597 0.0528 0.80 0.99 
n=160 Equal 0.0029 0.490 0.487 0.0482 0.0038 0.446 0.446 0.0502 0.0026 0.453 0.454 0.0509 0.84 0.97 
 InvVar 0.0062 0.468 0.467 0.0490 0.0070 0.416 0.418 0.0513 0.0052 0.419 0.420 0.0519 0.80 0.99 
0.5 
(EX) 
n=40 Equal -0.0031 0.989 0.985 0.0501 0.0019 0.884 0.897 0.0533 -0.0022 0.865 0.873 0.0538 0.83 1.06 
 InvVar 0.0106 0.942 0.945 0.0504 0.0139 0.831 0.851 0.0555 0.0061 0.816 0.829 0.0561 0.81 1.05 
n=80 Equal 0.0010 0.695 0.694 0.0490 0.0028 0.619 0.623 0.0517 0.0016 0.609 0.612 0.0509 0.81 1.04 
 InvVar 0.0086 0.663 0.663 0.0498 0.0085 0.583 0.590 0.0523 0.0050 0.576 0.580 0.0519 0.79 1.03 
n=160 Equal 0.0009 0.489 0.485 0.0467 0.0005 0.435 0.433 0.0485 0.0001 0.429 0.427 0.0489 0.80 1.03 
 InvVar 0.0040 0.468 0.465 0.0477 0.0036 0.411 0.411 0.0489 0.0020 0.407 0.406 0.0496 0.78 1.02 
0.7 
(AR) 
n=40 Equal 0.0002 0.938 0.933 0.0489 0.0036 0.748 0.751 0.0507 0.0001 0.752 0.758 0.0533 0.65 0.98 
 InvVar 0.0113 0.922 0.924 0.0515 0.0104 0.697 0.706 0.0527 0.0052 0.690 0.700 0.0536 0.58 1.02 
n=80 Equal -0.0017 0.659 0.656 0.0473 0.0002 0.524 0.524 0.0505 -0.0010 0.529 0.533 0.0519 0.64 0.97 
 InvVar 0.0061 0.650 0.647 0.0477 0.0046 0.488 0.489 0.0504 0.0018 0.488 0.490 0.0508 0.57 1.00 
n=160 Equal 0.0046 0.464 0.461 0.0482 0.0032 0.368 0.367 0.0503 -0.0009 0.373 0.376 0.0518 0.64 0.96 
 InvVar 0.0069 0.458 0.455 0.0486 0.0043 0.344 0.344 0.0499 0.0005 0.345 0.346 0.0516 0.57 0.98 
Note: Bias = mean of (estimate-true value); Type I error = rejection rate of null hypothesis (when 𝑍𝑤
2 > 𝜒0.95
2 );  ASE=average standard error; 
ESD=empirical standard deviation. a/u=(adjusted variance) / (unadjusted variance); a/m = (adjusted variance) / (MMRM variance). 
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Table 5.3 Results from 50, 000 replicate simulations for the test statistics of 𝐻0: 𝛥1 = 𝛥3 = 𝛥4 = 0 under 𝛥1 = 𝛥2 = 𝛥3 = 𝛥4 = 0 
𝜌  𝑛𝑖  Weight 
Unadjusted  Adjusted Efficiency  
Bias ASE ESD Type I 
error 
Bias ASE ESD Type I 
error 
a/u 
0.3 
(EX) 
n=40 Equal -0.0012 1.033 1.018 0.0466 0.0065 0.976 0.974 0.0491 0.92 
 InvVar -0.0077 0.948 0.958 0.0516 0.0023 0.902 0.926 0.0563 0.94 
n=80 Equal -0.0017 0.723 0.717 0.0485 0.0016 0.680 0.681 0.0498 0.90 
 InvVar -0.0035 0.667 0.670 0.0507 0.0008 0.633 0.641 0.0518 0.92 
n=160 Equal 0.0023 0.508 0.505 0.0488 0.0022 0.478 0.479 0.0487 0.90 
 InvVar 0.0015 0.471 0.469 0.0501 0.0017 0.446 0.448 0.0511 0.91 
0.5 
(AR) 
n=40 Equal -0.0052 1.048 1.032 0.0468 -0.0017 0.955 0.953 0.0490 0.85 
 InvVar -0.0004 0.943 0.954 0.0511 0.0031 0.842 0.867 0.0562 0.83 
n=80 Equal -0.0014 0.733 0.726 0.0478 0.0004 0.665 0.664 0.0487 0.84 
 InvVar -0.0003 0.663 0.667 0.0509 0.0016 0.591 0.598 0.0531 0.80 
n=160 Equal 0.0034 0.515 0.510 0.0486 0.0047 0.467 0.466 0.0491 0.83 
 InvVar 0.0035 0.468 0.467 0.0495 0.0055 0.416 0.419 0.0523 0.80 
0.5 
(EX) 
n=40 Equal -0.0050 1.048 1.034 0.0474 0.0006 0.892 0.896 0.0502 0.75 
 InvVar -0.0004 0.943 0.953 0.0526 0.0012 0.824 0.850 0.0571 0.80 
n=80 Equal 0.0009 0.733 0.727 0.0485 0.0026 0.622 0.622 0.0496 0.73 
 InvVar 0.0029 0.664 0.666 0.0502 0.0026 0.578 0.586 0.0528 0.77 
n=160 Equal 0.0022 0.515 0.508 0.0467 0.0023 0.437 0.433 0.0473 0.73 
 InvVar 0.0012 0.468 0.466 0.0481 0.0015 0.407 0.407 0.0499 0.76 
0.7 
(AR) 
  
n=40 Equal 0.0007 1.051 1.036 0.0467 0.0075 0.825 0.821 0.0486 0.63 
 InvVar 0.0068 0.901 0.909 0.0520 0.0075 0.688 0.703 0.0553 0.60 
n=80 Equal 0.0002 0.735 0.727 0.0476 0.0025 0.575 0.571 0.0487 0.62 
 InvVar 0.0030 0.634 0.635 0.0495 0.0032 0.482 0.486 0.0516 0.59 
n=160 Equal 0.0030 0.517 0.513 0.0485 0.0022 0.403 0.403 0.0504 0.62 
  InvVar 0.0067 0.447 0.444 0.0487 0.0044 0.339 0.339 0.0499 0.58 
Note: Bias = mean of (estimate-true value); Type I error = rejection rate of null hypothesis (when 𝑍𝑤
2 > 𝜒0.95
2 ); 
ASE=average standard error; ESD=empirical standard deviation. a/u=(adjusted variance) / (unadjusted variance). 
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Table 5.4 Results from 50, 000 replicate simulations for the test statistics of 𝐻0: 𝛥1 = 𝛥3 = 𝛥3 = 𝛥4 = 0 under 𝛥1 = 𝛥2 = 𝛥3 = 𝛥4 = 0 
𝜌  𝑛𝑖  Weight 
Unadjusted  Adjusted  Efficiency  
Bias ASE ESD Type I 
error 
Bias ASE ESD Type I 
error 
a/u 
0.3 
(EX) 
n=40 Equal -0.0011 1.011 0.994 0.0468 0.0036 0.958 0.965 0.0518 0.94 
 InvVar -0.0050 0.878 0.892 0.0532 0.0036 0.839 0.870 0.0586 0.95 
n=80 Equal -0.0020 0.705 0.698 0.0465 0.0018 0.667 0.668 0.0491 0.92 
 InvVar -0.0030 0.617 0.621 0.0508 0.0017 0.589 0.598 0.0534 0.93 
n=160 Equal 0.0022 0.495 0.492 0.0476 0.0024 0.468 0.469 0.0495 0.91 
 InvVar 0.0024 0.435 0.435 0.0499 0.0030 0.415 0.417 0.0511 0.92 
0.5 
(AR) 
n=40 Equal -0.0088 0.995 0.977 0.0457 -0.0072 0.920 0.926 0.0514 0.90 
 InvVar -0.0080 0.848 0.863 0.0529 -0.0037 0.765 0.796 0.0589 0.85 
n=80 Equal -0.0011 0.693 0.685 0.0469 0.0009 0.641 0.641 0.0492 0.88 
 InvVar -0.0030 0.596 0.600 0.0514 -0.0001 0.537 0.545 0.0534 0.82 
n=160 Equal 0.0029 0.487 0.482 0.0468 0.0044 0.450 0.448 0.0490 0.87 
 InvVar 0.0020 0.420 0.420 0.0498 0.0044 0.378 0.380 0.0515 0.82 
0.5 
(EX) 
n=40 Equal -0.0062 0.995 0.979 0.0461 -0.0018 0.861 0.871 0.0510 0.79 
 InvVar -0.0061 0.848 0.860 0.0527 0.0005 0.752 0.782 0.0582 0.83 
n=80 Equal 0.0002 0.694 0.689 0.0488 0.0022 0.600 0.603 0.0503 0.77 
 InvVar -0.0001 0.596 0.602 0.0514 0.0026 0.528 0.539 0.0549 0.80 
n=160 Equal 0.0020 0.487 0.482 0.0484 0.0019 0.421 0.419 0.0496 0.76 
 InvVar -0.0002 0.420 0.420 0.0513 0.0010 0.372 0.373 0.0506 0.79 
0.7 
(AR) 
  
n=40 Equal 0.0021 0.959 0.941 0.0456 0.0062 0.782 0.784 0.0497 0.69 
 InvVar -0.0027 0.780 0.790 0.0527 0.0015 0.614 0.633 0.0582 0.64 
n=80 Equal -0.0021 0.669 0.660 0.0461 0.0002 0.544 0.544 0.0497 0.68 
 InvVar -0.0049 0.548 0.550 0.0499 -0.0013 0.430 0.435 0.0517 0.63 
n=160 Equal 0.0019 0.469 0.466 0.0483 0.0015 0.382 0.382 0.0492 0.67 
  InvVar 0.0027 0.386 0.387 0.0506 0.0026 0.303 0.304 0.0514 0.62 
Note: Bias = mean of (estimate-true value); Type I error = rejection rate of null hypothesis (when 𝑍𝑤
2 > 𝜒0.95
2 ); 
ASE=average standard error; ESD=empirical standard deviation. a/u=(adjusted variance) / (unadjusted variance). 
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Table 5.5 Results from 50,000 replicate simulations for the coverage of confidence intervals and  power of test statistics under the 
alternative specified in Table 5.1 
𝜌 𝑛𝑖 Weight 
Δ1 and Δ4 Δ1, Δ2, and Δ4 Δ1, Δ2, Δ3, and  Δ4 
Unadjusted Adjusted MMRM Unadjusted Adjusted Unadjusted Adjusted 
CR Power CR Power CR Power CR Power CR Power CR Power CR Power 
0.3 
(EX) 
n=40 Equal 0.952 0.403 0.948 0.425 0.948 0.443 0.954 0.395 0.951 0.431 0.953 0.334 0.948 0.368 
 InvVar 0.950 0.410 0.945 0.435 0.946 0.451 0.948 0.426 0.943 0.457 0.944 0.423 0.939 0.454 
n=80 Equal 0.951 0.679 0.948 0.710 0.949 0.723 0.952 0.681 0.950 0.729 0.953 0.605 0.951 0.647 
 InvVar 0.950 0.691 0.948 0.724 0.947 0.733 0.949 0.706 0.947 0.748 0.947 0.707 0.945 0.747 
n=160 Equal 0.951 0.929 0.950 0.945 0.951 0.950 0.951 0.933 0.951 0.956 0.952 0.887 0.951 0.916 
 InvVar 0.950 0.936 0.949 0.952 0.948 0.954 0.950 0.943 0.949 0.961 0.948 0.943 0.947 0.962 
0.5 
(AR) 
n=40 Equal 0.952 0.422 0.949 0.486 0.946 0.491 0.953 0.385 0.951 0.450 0.954 0.343 0.948 0.395 
 InvVar 0.951 0.419 0.946 0.495 0.944 0.506 0.948 0.425 0.943 0.498 0.945 0.433 0.939 0.506 
n=80 Equal 0.951 0.707 0.948 0.782 0.946 0.775 0.952 0.670 0.951 0.750 0.953 0.618 0.951 0.683 
 InvVar 0.950 0.702 0.947 0.793 0.946 0.793 0.949 0.708 0.947 0.794 0.947 0.721 0.943 0.803 
n=160 Equal 0.952 0.945 0.950 0.972 0.948 0.969 0.952 0.928 0.951 0.963 0.953 0.899 0.951 0.935 
 InvVar 0.950 0.941 0.948 0.975 0.948 0.976 0.950 0.945 0.948 0.976 0.948 0.950 0.947 0.980 
0.5 
(EX) 
n=40 Equal 0.950 0.424 0.947 0.505 0.946 0.529 0.953 0.384 0.950 0.499 0.954 0.342 0.949 0.437 
 InvVar 0.949 0.417 0.943 0.510 0.943 0.535 0.947 0.426 0.942 0.526 0.945 0.434 0.940 0.530 
n=80 Equal 0.951 0.708 0.948 0.797 0.949 0.815 0.951 0.667 0.950 0.802 0.951 0.615 0.950 0.737 
 InvVar 0.950 0.702 0.947 0.807 0.947 0.820 0.949 0.708 0.947 0.819 0.946 0.721 0.942 0.825 
n=160 Equal 0.951 0.946 0.952 0.979 0.951 0.982 0.951 0.928 0.952 0.981 0.952 0.898 0.951 0.962 
 InvVar 0.950 0.944 0.950 0.981 0.949 0.983 0.950 0.946 0.950 0.983 0.948 0.952 0.947 0.985 
0.7 
(AR) 
 
n=40 Equal 0.951 0.456 0.949 0.637 0.947 0.643 0.953 0.380 0.952 0.558 0.955 0.364 0.950 0.507 
 InvVar 0.949 0.427 0.946 0.639 0.946 0.663 0.948 0.449 0.944 0.649 0.946 0.476 0.939 0.671 
n=80 Equal 0.953 0.754 0.950 0.912 0.946 0.907 0.952 0.666 0.952 0.863 0.954 0.651 0.951 0.822 
 InvVar 0.952 0.717 0.949 0.914 0.946 0.919 0.951 0.744 0.947 0.918 0.947 0.779 0.946 0.931 
n=160 Equal 0.952 0.963 0.950 0.997 0.949 0.997 0.951 0.927 0.950 0.991 0.952 0.917 0.951 0.984 
  InvVar 0.951 0.949 0.949 0.997 0.947 0.997 0.952 0.959 0.950 0.997 0.948 0.971 0.946 0.998 
Note: CR = 2 sided coverage rate of the nominal 95% confidence interval; Power = rejection rate of null hypothesis (when 𝑍𝑤
2 > 𝜒0.95
2 ). 
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5.4 Example 
 A hypothetical placebo-controlled pre-randomized two-period study that makes use of the 
P:P, P:T, and T:T sequence groups is created to illustrate an application of the proposed methods 
and to compare them to counterparts from the MMRM method proposed by Doros et al. (2013). 
The example has 240 subjects which are equally assigned to the three sequence groups.  The 
means and standard deviations of the outcomes are provided in Table 5.6. Assessments of 
outcomes occur at the baseline, end of period 1 and period 2, with a smaller outcome score being 
more beneficial. At period 1, a score less than 33 is considered as a responder to the treatment. 
The means of measurements at baseline ?̅?0 are similar across the three sequence groups, with a 
slightly larger mean in the T:T group. There are 31%, 34%, and 39% of responders in the three 
groups respectively, as shown in the 𝑧̅ row, with only 6% more responders in the test treatment 
group than the placebo group. And as the trial continues to the second period, the mean 
measurements at the end of this period for the P:T and T:T groups are almost the same, and the 
P:P group is slightly worse than the P:T or T:T group overall.  
Table 5.6 Mean and Standard Deviation of Outcome 
  Statistics P:P P:T T:T 
?̅?0 40.54 40.45 40.80 
SD 5.36 5.57 6.91 
?̅?1 35.15 34.92 34.24 
SD 6.17 5.72 6.48 
𝑧̅ 0.31 0.34 0.39 
?̅?2 33.98 32.44 32.39 
SD 5.69 5.04 6.13 
 
 The estimates using the proposed unadjusted and adjusted methods as well as the 
MMRM method are shown in Table 5.7. The standard errors of the estimates increase as the 
sample sizes decrease, as Δ̂1 has the smallest standard error and  Δ̂3 has the largest standard error 
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(as it only uses about 30% (i.e., the placebo responders) of the sample size in the P:P and P:T 
groups). The covariable-adjusted method provides similar estimates for Δ̂1, the treatment 
difference at the end of the first period, with a value of 0.95, whereas the unadjusted difference is 
slightly smaller because it does not correct for the slight random imbalance of the measurement 
at baseline. For the period 1 treatment difference only, the p values are 0.271 for the unadjusted 
method, 0.098 for the adjusted method, and 0.115 for the MMRM method, and they fail to 
contradict the null hypothesis of no treatment difference.  
Table 5.7 Estimates of ∆1 to ∆4 
Method Statistics Δ1 Δ2 Δ3 Δ4 (
Δ1
𝑆𝐸
)
2
 p value 
Unadjusted Etimate -0.791 -1.591 -0.677 -1.664 1.211 0.271 
 SE 0.719 1.033 1.504 1.074   
Adjusted Estimate -0.955 -1.585 -0.530 -1.749 2.732 0.098 
 SE 0.578 0.937 1.468 1.022   
MMRM Estimate -0.951 NA -0.111 -1.909 2.488 0.115 
 SE 0.603 NA 1.546 1.051   
 
Importantly, estimates for addressing Δ4 for the difference at the end of the second period 
for the placebo non-responders in period 1 are twice as large as those addressing Δ1, and at least 
three times bigger than  those addressing Δ3, the difference for the placebo responders; and these 
considerations show that the placebo non-responders, when given the test treatment, are more 
informative than the placebo responders. The comparisons between the T:T and P:P sequences at 
the second period, which corresponds to Δ2, also show better improvement than that at the first 
period, and this could possibly contribute to the overall treatment comparison if taken into 
consideration.  
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 As shown in Table 5.8, none of the statistics provided by the unadjusted method succeed 
in contradicting the null hypothesis at the 0.05 level, due to a smaller weighted statistic or a 
slightly larger variance; but the adjusted method, except for the one also accounting for Δ3 with 
equal weight, shows significant results at the 0.05 level, and the MMRM method accounting for 
Δ1 and Δ4 also shows significant p-values.  
Table 5.8 Estimates of Weighted Statistics 
Method 
  
Statistics 
  
Δ1 and Δ4 Δ1, Δ2 and Δ4 Δ1, Δ2 Δ3 and Δ4 
Equal InvVar Equal InvVar Equal InvVar 
Unadjusted Weighted 
estimate 
-1.227 -1.054 -1.349 -1.063 -1.181 -0.944 
 SE/F 0.657 0.607 0.691 0.610 0.697 0.566 
  P value 0.063 0.084 0.052 0.083 0.091 0.096 
Adjusted Weighted 
estimate 
-1.352 -1.150 -1.430 -1.132 -1.205 -1.016 
 SE/F 0.611 0.524 0.636 0.526 0.662 0.495 
  P value 0.028 0.029 0.026 0.032 0.070 0.041 
MMRM Weighted 
estimate 
-1.430 -1.188     
 SE 0.606 0.523     
  P value 0.025 0.031         
SE/F: estimated standard error inflated by the F distribution factor 
 
  
 98 
  
REFERENCES 
Doros, G., Pencina, M., Rybin, D., Meisner, A. and Fava, M. (2013) A repeated measures model 
for analysis of continuous outcomes in sequential parallel comparison design studies. 
Statistics in Medicine, 32, 2767–2789. 
Huang, X. and Tamura, R.N. (2010) Comparison of Test Statistics for the Sequential Parallel 
Design. Statistics in Biopharmaceutical Research, 2, 42–50. 
Jones, B. and Kenward, M.G. (2014) Design and Analysis of Cross-Over Trials, Third Edition. 
CRC Press. 
Kawaguchi, A., Koch, G.G. and Ramaswamy, R. (2009) Applications of extensions of bivariate 
rank sum statistics to the crossover design to compare two treatments through four 
sequence groups. Biometrics, 65, 979–988. 
Koch, G.G., Landis, J.R., Freeman, J.L., Freeman, D.H., Jr., and Lehnen, R.G. (1977). A general 
methodology for the analysis of experiments with repeated measurements of categorical 
data. Biometrics, 33, 133-158. 
Koch, G.G., Tangen, C.M., Jung, J.G. and Amara, I.A. (1998) Issues for covariance analysis of 
dichotomous and ordered categorical data from randomized clinical trials and non-
parametric strategies for addressing them. Statistics in Medicine, 17, 1863–1892. 
Lehmacher, W. (1991) Analysis of the crossover design in the presence of residual effects. 
Statistics in Medicine, 10, 891–899. 
Tamura, R.N. and Huang, X. (2007) An examination of the efficiency of the sequential parallel 
design in psychiatric clinical trials. Clinical Trials (London, England), 4, 309–317. 
 
 
 
 99 
  
 CHAPTER 6: RANDOMIZATION-BASED ANCOVA FOR INFERENCE IN TWO-WAY 
ENRICHMENT DESIGN 
 Introduction 
 This chapter presents extensions of the methods in Chapter 5 to the two-way enrichment 
design (TED) discussed by Ivanova and Tamura (2011). For this purpose, let 𝑖 = 1, 2, 3, 4 index 
P:P, P:T, T:P, T:T as the sequence groups for test treatment T and placebo P in the two periods. 
For this design, treatment comparisons between T and P during the second period are of 
particular interest for placebo non-responders during the first period (i.e., P:T vs. P:P) and test 
treatment responders during the first period (i.e., T:T vs. T:P).  
 Methods 
 Among 𝑛 patients who are eligible for inclusion in the clinical trial, let 𝑛𝑖 denote the 
number of such patients who are randomly assigned to the 𝑖-th sequence group. Also, the 𝑛 =
∑ 𝑛𝑖
4
𝑖=1  patients in the clinical trial are assumed to represent an essentially infinite target 
population in a sense that is conceptually comparable to a simple random sample with 
replacement. Let 𝑗 = 0, 1, 2 index the baseline, period 1, and period 2 for the clinical trial; and let 
𝑌𝑖𝑗𝑘 denote the observed random response during the 𝑗-th period for the 𝑘-th patient in the 𝑖-th 
sequence group according to a non-negative numeric scale. Let 𝑍𝑖𝑘 be a dichotomous responder 
variable for period 1 such that 𝑍𝑖𝑘 = 1 if the 𝑘-th patient in the 𝑖-th group has favorable response 
during the first period in the sense that (0 ≤ 𝑌𝑖1𝑘 ≤ 𝐿) versus 𝑍𝑖𝑘 = 0 if (𝑌𝑖1𝑘 > 𝐿); 
alternatively, the {𝑍𝑖𝑘} could be based on change (or percent change) from baseline. Let 𝐹𝑖𝑗𝑘 =
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𝑍𝑖𝑘𝑌𝑖𝑗𝑘 so as to equal 𝑌𝑖𝑗𝑘 for 𝑗 = 1, 2 for responders in period 1 and to equal 0 for non-
responders in period 1, and let 𝐺𝑖𝑘 = (𝑌𝑖2𝑘 − 𝐹𝑖2𝑘) = (1 − 𝑍𝑖𝑘)𝑌𝑖2𝑘 so as to equal 𝑌𝑖2𝑘 for period 
2 for period 1 non-responders and to equal 0 for period 1 responders. Let 𝑭𝑖𝑘 =
(𝑌𝑖0𝑘, 𝑌𝑖1𝑘, 𝑍𝑖𝑘 , 𝐹𝑖1𝑘, 𝑌𝑖2𝑘, 𝐹𝑖2𝑘)
′ with the assumption of no missing values for its components. 
Also, the 𝑭𝑖𝑘 could be expanded to include one or more other covariables 𝑿𝑖0𝑘 at baseline, such 
as age (in addition to 𝑌𝑖0𝑘); but the presentation is more straightforward without this extension 
because the same considerations apply to both 𝑌𝑖0𝑘 and 𝑿𝑖0𝑘. 
 Let ?̅?𝑖 = (∑ 𝑭𝑖𝑘 𝑛𝑖⁄
𝑛𝑖
𝑘=1 ) = (?̅?𝑖0, ?̅?𝑖1, ?̅?𝑖, ?̅?𝑖1, ?̅?𝑖2, ?̅?𝑖2)
′ denote the vector of the means of the 
𝑭𝑖𝑘 for the 𝑖-th group; and let ?̂??̅?𝑖 denote the unbiased estimate for its covariance matrix in (6.1). 
?̂??̅?𝑖 = ∑ (𝑭𝑖𝑘 − ?̅?𝑖)(𝑭𝑖𝑘 − ?̅?𝑖)
′ 𝑛𝑖(𝑛𝑖 − 1)⁄
𝑛𝑖
𝑘=1
               (6.1) 
Let ?̅? = (?̅?1
′ , ?̅?2
′ , ?̅?3
′ , ?̅?4
′ )′ and let ?̂??̅? = 𝑫𝒊𝒂𝒈(?̂??̅?𝑖 , ?̂??̅?2 , ?̂??̅?3 , ?̂??̅?4) denote its block diagonal 
covariance matrix so as to account for the statistical independence of the {?̅?𝑖} and their 
corresponding estimated covariance matrices ?̂??̅?𝑖. 
6.2.1 Estimates for Treatment Comparisons 
 Let ?̃?𝑖 denote the transformation in (6.2) whereby the ?̅?𝑖𝑗 for 𝑗 = 1, 2 are replaced by 
?̃?𝑖 = (?̅?𝑖0, ?̅?𝑖1, ?̅?𝑖, ?̃?𝑖1, ?̅?𝑖2, ?̃?𝑖2, ?̃?𝑖2)
′
                   (6.2) 
 ?̃?𝑖𝑗 = (?̅?𝑖𝑗 ?̅?𝑖⁄ ) and ?̃?𝑖2 = (?̅?𝑖2 − ?̅?𝑖2) (1 − ?̅?𝑖)⁄  is also included. In order to apply the linear 
Taylor series methods discussed in Koch et al. (1977) to produce a consistent estimator ?̂??̃?𝑖 for 
the covariance matrix of ?̃?𝑖, the transformation of ?̅?𝑖 to ?̃?𝑖 is expressed as in (6.3) with 𝑹1, 𝒓, 
?̃?𝑖 = 𝒆𝒙𝒑[𝑹2 𝒍𝒐𝒈(𝑹1?̅?𝑖 + 𝒓)]                         (6.3) 
and 𝑹2 as shown in (6.4) and with 𝒍𝒐𝒈 (and 𝒆𝒙𝒑) being the operation that transforms a vector to  
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𝑹1 =
[
 
 
 
 
 
 
1  0     0    0  0     0
0  1     0    0  0     0
0  0     1    0  0     0
0  0  − 1  0  0     0
0  0     0    1  0     0
0  0     0    0  1     0
0  0     0    0  1 − 1]
 
 
 
 
 
 
, 𝒓 =
[
 
 
 
 
 
 
0
0
0
1
0
0
0]
 
 
 
 
 
 
, 𝑹2 =
[
 
 
 
 
 
 
1  0     0      0  0  0  0  0
0  1     0      0  0  0  0  0
0  0     1      0  0  0  0  0
0  0 − 1     0  1  0  0  0
0  0     0      0  0  1  0  0
0  0 − 1     0  0  0  1  0
0  0     0 − 1  0  0  0  1]
 
 
 
 
 
 
       (6.4) 
the corresponding vector of natural logarithms (and exponentiated values).  
 It then follows from Koch et al. (1977) that ?̂??̃?𝑖 = 𝑳𝑖?̂??̅?𝑖𝑳𝑖
′ for which 𝑳𝑖 =
𝑫?̃?𝑖𝑹2𝑫(𝑹1?̅?1+𝒓)
−1 𝑹1 and (𝑹1?̅?1 + 𝒓) = (?̅?𝑖0, ?̅?𝑖1, ?̅?𝑖, (1 − ?̅?𝑖), ?̅?𝑖1, ?̅?𝑖2, ?̅?𝑖2, (?̅?𝑖2 − ?̅?𝑖2))
′
 is a 
consistent estimator for the covariance matrix of ?̃?𝑖. Accordingly, for ?̃? = (?̃?1
′ , ?̃?2
′ , ?̃?3
′ , ?̃?4
′ )
′
, the 
block diagonal matrix ?̂??̃? = 𝑫𝒊𝒂𝒈(?̂??̃?1 , ?̂??̃?2 , ?̂??̃?3 , ?̂??̃?4) is a consistent estimator for the 
corresponding covariance matrix.  
 For treatment comparisons between T and P, the estimators of interest are shown in (6.5), 
𝑐1 = {
𝑛3?̅?31 + 𝑛4?̅?41
(𝑛3 + 𝑛4)
−
𝑛1?̅?11 + 𝑛2?̅?21
(𝑛1 + 𝑛2)
} 
𝑐2 = (?̅?42 − ?̅?12)                                           
𝑐3 = (?̃?22 − ?̃?21)                                   (6.5) 
𝑐4 = (?̃?22 − ?̃?21)                                         
𝑐5 = (?̃?42 − ?̃?32)                                          
𝑐6 = (?̃?42 − ?̃?32)                                         
and they are linear functions 𝒄 = 𝑪?̃? of ?̃? with the matrix 𝑪 as shown in (6.6) for which 𝜹7,𝑢 is a 
𝑪 =
[
 
 
 
 
 
 
−𝑝1𝜹7,2
′
−𝜹7,5
′
−𝜹7,6
′
−𝜹7,7
′
𝟎7
′
𝟎7
′
   
−𝑝2𝜹7,2
′
𝟎7
′
𝜹7,6
′
𝜹7,7
′
𝟎7
′
𝟎7
′
   
𝑝3𝜹7,2
′
𝟎7
′
𝟎7
′
𝟎7
′
−𝜹7,6
′
−𝜹7,7
′
   
𝑝4𝜹7,2
′
𝜹7,5
′
𝟎7
′
𝟎7
′
𝜹7,6
′
𝜹7,7
′ ]
 
 
 
 
 
 
               (6.6) 
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(7 × 1) vector with 1 in the 𝑢-th position and 𝑝1 = 𝑛1 (𝑛1 + 𝑛2)⁄ , 𝑝2 = (1 − 𝑝1), 𝑝3 =
𝑛3 (𝑛3 + 𝑛4)⁄ , 𝑝4 = (1 − 𝑝3). A consistent estimator for the covariance matrix of 𝒄 is ?̂?𝒄 =
𝑪𝑽?̃?𝑪
′. For 𝒄 = (𝑐1, 𝑐2, 𝑐3, 𝑐4, 𝑐5, 𝑐6)
′, the comparison 𝑐1 pertains to T versus P in the first 
period; the comparison 𝑐2 pertains to T:T versus P:P in period 2; the comparison 𝑐3 pertains to 
P:T versus P:P in period 2 for responders to placebo in period 1; 𝑐4 pertains to P:T versus P:P in 
period 2 for non-responders to placebo in period 1; the comparison 𝑐5 pertains to T:T versus T:P 
in period 2 for responders to T in period 1; and the comparison 𝑐6 pertains to T:T versus T:P for 
non-responders to T in period 1. Univariate test statistics for the overall comparison between T 
and P can be based on weighted linear combinations 𝑐𝑊 = ∑ 𝑤ℎ𝑐ℎ
6
ℎ=1  where 𝒘 =
(𝑤1, 𝑤2, 𝑤3, 𝑤4, 𝑤5, 𝑤6)
′ is a vector of weights such at all 𝑤ℎ ≥ 0 and ∑ 𝑤ℎ
6
ℎ=1 = 1. With the 
weights 𝒘, the test statistic for the overall null hypothesis 𝐻0𝒄 for 𝑬𝑨{𝒄} = 0, where 𝑬𝑨{  } 
denotes asymptotic expected value, is 𝑇𝑤,𝒄 = 𝒘
′𝒄 (𝒘′?̂?𝒄𝒘)
0.5
⁄ . Under 𝐻0𝒄, 𝑇𝑤,𝒄 approximately 
has the normal distribution with mean 0 and variance 1. A (1 − 𝛼) two-sided confidence interval 
based on 𝑐𝑤 can be constructed as [𝑐𝑤 − 𝑍𝛼 2⁄ √𝑣𝑐𝑤 , 𝑐𝑤 + 𝑍𝛼 2⁄ √𝑣𝑐𝑤  ] where 𝑍𝛼 2⁄  is the 
(1 − 𝛼 2⁄ ) percentile of the standard normal distribution and 𝑣𝑐𝑤 = 𝒘
′?̂?𝑐𝒘. Since the 
comparisons of principal interest for the two-way enrichment design are 𝑐1, 𝑐4, and 𝑐5, a 
specification of equal weight for them and 0 weight for 𝑐2, 𝑐3, and 𝑐6 is 𝒘3 = ( (1/3), 0,
0, (1/3), (1/3), 0). Alternatively, the use of other weights for other subsets for 𝒄 is passible, 
with the scope including both equal weights and inverse covariance matrix weights.  
6.2.2 Randomization-Based Covariance Adjusted Estimators 
 The constraints 𝒄0 = 𝑪0?̃? with 𝑬𝑨{𝒄0} = 𝟎 regardless of whether the previously noted 
overall null hypothesis 𝐻0 applies are shown in (6.7) with the matrix 𝑪0 shown in (6.8).  
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𝒄0 =
[
 
 
 
 
 
 
 
 
 
 
(?̅?20 − ?̅?10)
(?̅?30 − ?̅?10)
(?̅?40 − ?̅?10)
(?̅?21 − ?̅?11)
(?̅?41 − ?̅?31)
(?̅?2 − ?̅?1)
(?̅?4 − ?̅?3)
(?̃?21 − ?̃?11)
(?̃?41 − ?̃?31)]
 
 
 
 
 
 
 
 
 
 
                        (6.7) 
𝑪0 =
[
 
 
 
 
 
 
 
 
 
 
−𝜹7,1
′
−𝜹7,1
′
−𝜹7,1
′
−𝜹7,2
′
𝟎7
′
−𝜹7,3
′
𝟎7
′
−𝜹7,4
′
𝟎7
′
   
𝜹7,1
′
𝟎7
′
𝟎7
′
𝜹7,2
′
𝟎7
′
𝜹7,3
′
𝟎7
′
𝜹7,4
′
𝟎7
′
   
𝟎7
′
𝜹7,1
′
𝟎7
′
𝟎7
′
−𝜹7,2
′
𝟎7
′
−𝜹7,3
′
𝟎7
′
−𝜹7,4
′
   
𝟎7
′
𝟎7
′
𝜹7,1
′
𝟎7
′
𝜹7,2
′
𝟎7
′
𝜹7,3
′
𝟎7
′
𝜹7,4
′
]
 
 
 
 
 
 
 
 
 
 
     (6.8) 
 Let 𝒄+ = [𝒄
′, 𝒄0
′ ] = [𝑪′, 𝑪0
′ ]′ = 𝑪+?̃? denote the combined set of comparisons 𝒄 pertaining 
to 𝐻0 and constraints 𝒄0. The estimated covariance structure for 𝒄+ is ?̂?𝒄+ = 𝑪+?̂??̃?𝑪+. Since 
𝑬𝑨{𝒄0} = 𝟎 regardless of whether 𝐻0 applies, randomization-based covariance adjustment for 𝒄 
with respect to the constraints 𝒄0 is invoked by fitting the linear model in (6.9) by weighted least 
𝑬𝑨{𝒄+} = [
𝑰6
𝟎9,6
] 𝒃 = 𝑨𝒃                    (6.9) 
squares with weights based on ?̂?𝒄+ and with “=̂” meaning “is estimated by”. 
 Accordingly, 𝒃 = (𝑏1, 𝑏2, 𝑏3, 𝑏4, 𝑏5, 𝑏6)
′ are covariance adjusted counterparts of 𝒄. More 
specifically, 𝒃 = (𝑨′?̂?𝒄+
−1𝑨)
−1
𝑨′?̂?𝒄+
−1𝒄+. Also, a consistent estimator for the covariance matrix of 
𝒃 is ?̂?𝒃 = (𝑨
′?̂?𝒄+
−1𝑨)
−1
. Covariance adjusted test statistics for 𝐻0 can be based on weighted 
linear combinations 𝒃𝑤 = ∑ 𝑤ℎ𝑏ℎ
6
ℎ=1  in ways similar to those discussed for 𝒄 in Section 2. In 
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this regard, test statistics based on 𝒃𝑤 can have better power than those based on 𝒄𝑤 because of 
their smaller variance via the structure shown in (6.10) for ?̂?𝒃. 
?̂?𝒃 = ?̂?𝒄 − (𝑪?̂??̃?𝑪0
′ )(𝑪0?̂??̃?𝑪0
′ )
−1
(𝑪0?̂??̃?𝑪
′)          (6.10) 
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 CHAPTER 7: RANDOMIZATION-BASED ANCOVA FOR INFERENCE IN 
BILATERAL DESIGN 
 Introduction 
 This chapter presents adaptions of the methods in Chapter 6 to the bilateral design in 
clinical settings such as dermatology whereby patients receive alternative treatments on opposite 
sides of their bodies. For this purpose, let 𝑖 = 1, 2, 3, 4 index P:P, P:T, T:P, T:T as the groups for 
test treatment T and placebo P on the left and right sides. For this design, treatment comparisons 
between T and P on one side are of particular interest for placebo non-responders on the opposite 
side and for test treatment responders on the opposite side. 
 Methods 
 Among 𝑛 patients who are eligible for inclusion in the clinical trial, let 𝑛𝑖 denote the 
number of such patients who are randomly assigned to the 𝑖-th group. Also, the 𝑛 = ∑ 𝑛𝑖
4
𝑖=1  
patients in the clinical trial are assumed to represent an essentially infinite target population in a 
sense that is conceptually comparable to a simple random sample with replacement. Let 𝑗 = 1, 2 
index the left and right sides for a patient; and let 𝑌𝑖𝑗𝑘 denote the observed random response for 
the 𝑗-th side of the 𝑘-th patient in the 𝑖-th group according to a non-negative numerical scale; and 
let 𝑌𝑖𝑗𝑘0 denote the baseline counterpart of 𝑌𝑖𝑗𝑘. Let 𝑍𝑖𝑗𝑘 be a dichotomous responder variable for 
the 𝑗-th side of the 𝑘-th patient in the 𝑖-th group such that 𝑍𝑖𝑗𝑘 = 1 corresponds to favorable 
response in the sense that (0 ≤ 𝑌𝑖𝑗𝑘 ≤ 𝐿) versus 𝑍𝑖𝑗𝑘 = 0 if (𝑌𝑖𝑗𝑘 > 0); alternatively, the 𝑍𝑖𝑗𝑘 
could be based on change (or percent change) from baseline. Let 𝐹𝑖𝑗𝑘 = 𝑍𝑖𝑗′𝑘𝑌𝑖𝑗𝑘 for 𝑗
′ ≠ 𝑗 so as 
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to equal 𝑌𝑖𝑗𝑘 for responders on the 𝑗
′-th side and to equal 0 for non-responders on the 𝑗′-th side; 
and let 𝐺𝑖𝑗𝑘 = (𝑌𝑖𝑗𝑘 − 𝐹𝑖𝑗𝑘) = (1 − 𝑍𝑖𝑗′𝑘)𝑌𝑖𝑗𝑘 so as to equal 𝑌𝑖𝑗𝑘 for non-responders on the 𝑗
′-th 
side and to equal 0 for responders on the 𝑗′-th side. Let 𝑭𝑖𝑘 =
(𝑌𝑖1𝑘0, 𝑌𝑖1𝑘, 𝑍𝑖1𝑘, 𝐹𝑖1𝑘 , 𝑌𝑖2𝑘0, 𝑌𝑖2𝑘, 𝑍𝑖2𝑘, 𝐹𝑖2𝑘)
′ with the assumption of no missing values for its 
components. Also, the 𝑭𝑖𝑘 could be expanded to include one or more covariables 𝑿𝑖0𝑘 at 
baseline, such as age (in addition to 𝑌𝑖𝑗𝑘0); but the presentation is more straightforward without 
this extension because the same considerations apply to both the 𝑌𝑖𝑗𝑘0 and 𝑿𝑖0𝑘. 
 Let ?̅?𝑖 = (∑ 𝑭𝑖𝑘
𝑛𝑖
𝑘=1 ) = (?̅?𝑖1∗0, ?̅?𝑖1, ?̅?𝑖1, ?̅?𝑖1, ?̅?𝑖2∗0, ?̅?𝑖2, ?̅?𝑖2, ?̅?𝑖2)
′ denote the vector of means 
of the 𝑭𝑖𝑘 for the 𝑖-th group; and let ?̂??̅?𝑖 denote the unbiased estimator for its covariance matrix 
in (7.1).  
?̂??̅?𝑖 = ∑ (𝑭𝑖𝑘 − ?̅?𝑖)(𝑭𝑖𝑘 − ?̅?𝑖)
′ 𝑛𝑖(𝑛𝑖 − 1)⁄
𝑛𝑖
𝑘=1
           (7.1) 
 Let ?̅? = (?̅?1
′ , ?̅?2
′ , ?̅?3
′ , ?̅?4
′ )′ and let ?̂??̅? = 𝑫𝒊𝒂𝒈(?̂??̅?1 , ?̂??̅?2 , ?̂??̅?3 , ?̂??̅?4) denote its block 
diagonal estimated covariance matrix so as to account for the statistical independence of the {?̅?𝑖} 
and their corresponding estimated covariance matrices ?̂??̅?𝑖. 
7.2.1 Estimates for Treatment Comparisons 
 Let ?̃?𝑖 denote the transformation in (7.2) whereby the ?̅?𝑖𝑗 are replaced by 
?̃?𝑖 = (?̅?𝑖1∗0, ?̅?𝑖1, ?̅?𝑖1, ?̃?𝑖1, ?̃?𝑖1,?̅?𝑖2∗0, ?̅?𝑖2, ?̅?𝑖2, ?̃?𝑖2, ?̃?𝑖2)
′
                   (7.2) 
?̃?𝑖𝑗 = (?̅?𝑖𝑗 ?̅?𝑖𝑗′⁄ ) and the ?̃?𝑖𝑗 = (?̅?𝑖𝑗 − ?̅?𝑖𝑗) (1 − ?̅?𝑖𝑗′)⁄  are also included. In order to apply the 
linear Taylor series methods discussed in Koch et al. (1977) to produce a consistent estimator 
?̂??̃?𝑖 for the covariance matrix of ?̃?𝑖, the transformation of ?̅?𝑖 to ?̃?𝑖 is expressed as in (7.3) with 
?̃?𝑖 = 𝒆𝒙𝒑[𝑹2 𝒍𝒐𝒈(𝑹1?̅?𝑖 + 𝒓)]                              (7.3) 
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𝑹1, 𝒓, and 𝑹2 as shown in (7.4) and with 𝒍𝒐𝒈 (and 𝒆𝒙𝒑) being the operation that transforms a  
𝑹1 =
[
 
 
 
 
 
 
 
 
 
 
 
1
0
0
0
0
0
0
0
0
0
0
0
  
0
1
0
0
0
1
0
0
0
0
0
0
  
0
0
1
−1
0
0
0
0
0
0
0
0
 
0
0
0
0
1
−1
0
0
0
0
0
0
  
0
0
0
0
0
0
1
0
0
0
0
0
   
0
0
0
0
0
0
0
1
0
0
0
1
  
0
0
0
0
0
0
0
0
1
−1
0
0
 
0
0
0
0
0
0
0
0
0
0
1
−1]
 
 
 
 
 
 
 
 
 
 
 
, 𝒓 =
[
 
 
 
 
 
 
 
 
 
 
 
 
0
0
0
1
0
0
0
0
0
1
0
0
 
]
 
 
 
 
 
 
 
 
 
 
 
, 𝑹2 =
[
 
 
 
 
 
 
 
 
 
1
0
0
0
0
0
0
0
0
0
  
0
1
0
0
0
0
0
0
0
0
  
0
0
1
0
0
0
0
0
−1
0
 
0
0
0
0
0
0
0
0
0
−1
  
0
0
0
1
0
0
0
0
0
0
   
0
0
0
0
1
0
0
0
0
0
  
0
0
0
0
0
1
0
0
0
0
  
0
0
0
0
0
0
1
0
0
0
  
0
0
0
−1
0
0
0
1
0
0
  
0
0
0
0
−1
0
0
0
0
0
  
0
0
0
0
0
0
0
0
1
0
  
0
0
0
0
0
0
0
0
0
1]
 
 
 
 
 
 
 
 
 
   (7.4) 
vector to the corresponding vector of natural logarithms (and exponentiated values). It then 
follows that from Koch et al. (1977) that ?̂??̃?𝑖 = 𝑳𝑖?̂??̅?𝑖𝑳𝑖
′ for which 𝑳𝑖 = 𝑫?̃?𝑖𝑹2𝑫(𝑹1?̅?1+𝒓)
−1 𝑹1 and 
(𝑹1?̅?1 + 𝒓) = ( ?̅?𝑖1∗0,  ?̅?𝑖1, ?̅?𝑖1, (1 − ?̅?𝑖1), ?̅?𝑖1, (?̅?𝑖1 − ?̅?𝑖1), ?̅?𝑖2∗0, ?̅?𝑖2, ?̅?𝑖2, (1 − ?̅?𝑖2), ?̅?𝑖2, (?̅?𝑖2 −
?̅?𝑖2))
′
 is a consistent estimator for the covariance matrix of ?̃?𝑖. Accordingly, for ?̃? =
(?̃?1
′ , ?̃?2
′ , ?̃?3
′ , ?̃?4
′ )
′
, the block diagonal matrix ?̂??̃? = 𝑫𝒊𝒂𝒈(?̂??̃?1 , ?̂??̃?2 , ?̂??̃?3 , ?̂??̃?4) is a consistent 
estimator for the corresponding covariance matrix. 
 For treatment comparisons between T and P, the estimators of interest are shown in (7.5), 
𝒄 =
[
 
 
 
 
 
 
 
𝑐1
𝑐2
𝑐3
𝑐4
𝑐5
𝑐6
𝑐7
𝑐8]
 
 
 
 
 
 
 
=
[
 
 
 
 
 
 
 
 
 
 
(?̃?31 − ?̃?11)
(?̃?31 − ?̃?11)
(?̃?41 − ?̃?21)
(?̃?41 − ?̃?21)
(?̃?22 − ?̃?12)
(?̃?22 − ?̃?12)
(?̃?42 − ?̃?32)
(?̃?42 − ?̃?32)]
 
 
 
 
 
 
 
 
 
 
              (7.5) 
and they are linear functions 𝒄 = 𝑪?̃? of ?̃? with the matrix 𝑪 as shown in (7.6) where 𝜹10,𝑢 is a 
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𝑪 =
[
 
 
 
 
 
 
 
 
−𝜹10,4
′
−𝜹10,5
′
𝟎10
′
𝟎10
′
−𝜹10,9
′
−𝜹10,10
′
𝟎10
′
𝟎10
′
  
𝟎10
′
𝟎10
′
−𝜹10,4
′
−𝜹10,5
′
𝜹10,9
′
𝜹10,10
′
𝟎10
′
𝟎10
′
  
𝜹10,4
′
𝜹10,5
′
𝟎10
′
𝟎10
′
𝟎10
′
𝟎10
′
−𝜹10,9
′
−𝜹10,10
′
  
𝟎10
′
𝟎10
′
𝜹10,4
′
𝜹10,5
′
𝟎10
′
𝟎10
′
𝜹10,9
′
𝜹10,10
′ ]
 
 
 
 
 
 
 
 
          (7.6) 
(10 × 1) vector with a 1 in the 𝑢-th position. 
 A consistent estimate for the covariance matrix of 𝒄 is ?̂?𝒄 = 𝑪𝑽?̃?𝑪
′. For 𝒄 =
(𝑐1, 𝑐2, 𝑐3, 𝑐4, 𝑐5, 𝑐6, 𝑐7, 𝑐8)
′, the comparison 𝑐1 and 𝑐2 respectively pertain to T versus P on the 
left for responders and non-responders to P on the right; the comparisons 𝑐5 and 𝑐6 respectively 
pertain to T versus P on the right for responders and non-responders to P on the left; the 
comparisons 𝑐3 and 𝑐4 respectively pertain to T versus P on the left for responders and non-
responders to T on the right; and the comparisons 𝑐7 and 𝑐8 respectively pertain to T versus P on 
the right for responders and non-responders to T on the left. Univariate test statistics for the 
overall comparison between T and P can be based on weighted linear combinations 𝑐𝑤 =
∑ 𝑤ℎ𝑐ℎ
8
ℎ=1  where 𝒘 = (𝑤1, 𝑤2, 𝑤3, 𝑤4, 𝑤5, 𝑤6, 𝑤7, 𝑤8)
′ is a vector of weights such at all 𝑤ℎ ≥ 0 
and ∑ 𝑤ℎ
8
ℎ=1 = 1. With the weights 𝒘, the test statistic for the overall null hypothesis 𝐻0𝒄 for 
𝑬𝑨{𝒄} = 0, where 𝑬𝑨{  } denotes asymptotic expected value, is 𝑇𝑤,𝒄 = 𝒘
′𝒄 (𝒘′?̂?𝒄𝒘)
0.5
⁄ . Under 
𝐻0𝒄, 𝑇𝑤,𝒄 approximately has the normal distribution with mean 0 and variance 1. A (1 − 𝛼) two-
sided confidence interval based on 𝑐𝑤 can be constructed as [𝑐𝑤 − 𝑍𝛼 2⁄ √𝑣𝑐𝑤 , 𝑐𝑤 + 𝑍𝛼 2⁄ √𝑣𝑐𝑤  ] 
where 𝑍𝛼 2⁄  is the (1 − 𝛼 2⁄ ) percentile of the standard normal distribution and 𝑣𝑐𝑤 = 𝒘
′?̂?𝑐𝑤𝒘. 
Since the comparisons of principal interest for the bilateral design are 𝑐2, 𝑐3, 𝑐6, and 𝑐7, a 
specification of equal weight for them and 0 weight for 𝑐1, 𝑐4, 𝑐5, and 𝑐8 is 𝒘4 =
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(0, 0.25, 0.25, 0, 0, 0.25, 0.25, 0). Alternatively, the use of other weights for other subsets for 𝒄 is 
passible, with the scope including both equal weights and inverse covariance matrix weights.  
7.2.2 Randomization-Based Covariance Adjusted Estimators 
The constraints 𝒄0 = 𝑪0?̃? with 𝑬𝑨{𝒄0} = 𝟎 regardless of whether the previously noted 
overall null hypothesis 𝐻0 applies are shown in (7.7) with the matrix 𝑪0 shown in (7.8), although 
𝒄0 =
[
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(?̅?21∗0 − ?̅?11∗0)
(?̅?31∗0 − ?̅?11∗0)
(?̅?41∗0 − ?̅?11∗0)
(?̅?21 − ?̅?11)
(?̅?21 − ?̅?11)
(?̅?41 − ?̅?31)
(?̅?41 − ?̅?31)
(?̅?22∗0 − ?̅?12∗0)
(?̅?32∗0 − ?̅?12∗0)
(?̅?42∗0 − ?̅?12∗0)
(?̅?32 − ?̅?12)
(?̅?32 − ?̅?12)
(?̅?42 − ?̅?22)
(?̅?42 − ?̅?22) ]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                 (7.7) 
𝑪0 =
[
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
−𝜹10,1
′
−𝜹10,1
′
−𝜹10,1
′
−𝜹10,2
′
−𝜹10,3
′
𝟎10
′
𝟎10
′
−𝜹10,6
′
−𝜹10,6
′
−𝜹10,6
′
−𝜹10,7
′
−𝜹10,8
′
𝟎10
′
𝟎10
′
  
𝜹10,1
′
𝟎10
′
𝟎10
′
𝜹10,2
′
𝜹10,3
′
𝟎10
′
𝟎10
′
𝜹10,6
′
𝟎10
′
𝟎10
′
𝟎10
′
𝟎10
′
−𝜹10,7
′
−𝜹10,8
′
  
𝟎10
′
𝜹10,1
′
𝟎10
′
𝟎10
′
𝟎10
′
−𝜹10,2
′
−𝜹10,3
′
𝟎10
′
𝜹10,6
′
𝟎10
′
𝜹10,7
′
𝜹10,8
′
𝟎10
′
𝟎10
′
   
𝟎10
′
𝟎10
′
𝜹10,1
′
𝟎10
′
𝟎10
′
𝜹10,2
′
𝜹10,3
′
𝟎10
′
𝟎10
′
𝜹10,6
′
𝟎10
′
𝟎10
′
𝜹10,7
′
𝜹10,8
′
]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         (7.8) 
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this specification does assume that the treatment on the left side does not affect the response on 
the right side, and vice versa. Let 𝒄+ = [𝒄
′, 𝒄0
′ ] = [𝑪′, 𝑪0
′ ]′?̃? = 𝑪+?̃? denote the combined set of 
comparisons 𝒄 pertaining to 𝐻0 and constraints 𝒄0. The estimated covariance structure for 𝒄+ is 
?̂?𝒄+ = 𝑪+?̂??̃?𝑪+. Since 𝑬𝑨{𝒄0} = 𝟎, randomization-based covariance adjustment for 𝒄 with 
respect to the constraints 𝒄0 is invoked by fitting the linear model in (7.9) by weighted least 
𝑬𝑨{𝒄+} = [
𝑰8
𝟎14,8
] 𝒃 = 𝑨𝒃                    (7.9) 
squares with weights based on ?̂?𝒄+
−1 and with “=̂” meaning “is estimated by”. 
 Accordingly, 𝒃 = (𝑏1, 𝑏2, 𝑏3, 𝑏4, 𝑏5, 𝑏6, 𝑏7, 𝑏8)
′ are covariance adjusted counterparts of 𝒄. 
More specifically, 𝒃 = (𝑨′?̂?𝒄+
−1𝑨)
−1
𝑨′?̂?𝒄+
−1𝒄+. Also, a consistent estimator for the covariance 
matrix of 𝒃 is ?̂?𝒃 = (𝑨
′?̂?𝒄+
−1𝑨)
−1
. Covariance adjusted test statistics for 𝐻0 can be based on 
weighted linear combinations 𝒃𝑤 = ∑ 𝑤ℎ𝑏ℎ
8
ℎ=1  in ways similar to those discussed for 𝒄 in 
Section 7.2. In this regard, test statistics based on 𝒃𝑤 can have better power than those based on 
𝒄𝑤 because of their smaller variance via the structure shown in (7.10) for ?̂?𝒃 (Kawaguchi et al., 
2009). 
?̂?𝒃 = ?̂?𝒄 − (𝑪?̂??̃?𝑪0
′ )(𝑪0?̂??̃?𝑪0
′ )
−1
(𝑪0?̂??̃?𝑪
′)          (7.10) 
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